10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

____________________________________________________________________________

FORM 10-Q

____________________________________________________________________________

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2025

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____ to ____

Commission File Number: 001-39516

_____________________________________________

OWLET, INC.

(Exact Name of Registrant as Specified in its Charter)

_____________________________________________

Delaware	85-1615012
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
2940 West Maple Loop Drive, Suite 203 Lehi, Utah	84043
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (844) 334-5330

_____________________________________________

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Common Stock, $0.0001 par value per share	OWLT	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	o	Accelerated filer	o
Non-accelerated filer	x	Smaller reporting company	x
Emerging growth company	x

1

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 6, 2025, the registrant had 16,524,690 shares of common stock, $0.0001 par value per share, outstanding.

2

Table of Contents

		Page
PART I.
	Cautionary Note Regarding Forward-Looking Statements	1
Item 1.	Financial Statements	3
	Condensed Consolidated Balance Sheets (Unaudited)	3
	Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)	4
	Condensed Consolidated Statements of Changes in Mezzanine Equity and Stockholders’ Deficit (Unaudited)	5
	Condensed Consolidated Statements of Cash Flows (Unaudited)	6
	Notes to Condensed Consolidated Financial Statements (Unaudited)	8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	32
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	40
Item 4.	Controls and Procedures	40
PART II.
Item 1.	Legal Proceedings	43
Item 1A.	Risk Factors	43
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	43
Item 3.	Defaults Upon Senior Securities	43
Item 4.	Mine Safety Disclosures	43
Item 5.	Other Information	43
Item 6.	Exhibits	44
	Signatures	45

3

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (this “Report”) contains certain statements that are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements other than statements of historical facts contained in this Report, including statements concerning possible or assumed future actions, business strategies, events or results of operations, and any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this Report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Report and are subject to a number of risks, uncertainties and assumptions described in the sections entitled “Risk Factors” and “Management's Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this Report, our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “Form 10-K”) and Amendment No. 1 to our Annual Report on Form 10-K/A for the fiscal year ended December 31, 2024 (the “Form 10-K/A”). These forward-looking statements are subject to numerous risks, including, without limitation, the following:

•We have a limited operating history.

•We have not been profitable to date, and operating losses could continue, which could materially and adversely affect our business, financial condition and results of operations, including our ability to continue as a going concern.

•We have experienced fluctuations in the growth of our business and anticipate this will continue. If we fail to manage our growth effectively, our business could be materially and adversely affected.

•If any governmental authority or notified body were to require marketing authorization or similar certification for any product that we sell for which we have not obtained such marketing authorization or certification, we could be subject to regulatory enforcement actions and/or be required to cease selling or recall the product pending receipt of marketing authorization or similar certification from such other governmental authority or notified body, which can be a lengthy and time-consuming process, harm financial results and have long-term negative effects on our operations.

•Our products rely on mobile applications to function and we rely on Apple’s App Store and the Google Play Store for distribution of our mobile applications.

•A substantial portion of our sales comes through a limited number of retailers.

•We are required to obtain and maintain marketing authorizations or certifications from the FDA, foreign regulatory authorities or notified bodies for medical device products in the U.S. or in foreign jurisdictions, which can be a lengthy and time-consuming process, and a failure to do so on a timely basis, or at all, could severely harm our business.

•We currently rely on a single manufacturer for the assembly of our Dream Sock, Smart Sock, and BabySat products and a single manufacturer for the assembly of our Owlet Cam. We will likely rely on single manufacturers for future products we may develop. If we encounter manufacturing problems, delays, or increased costs, we may be unable to promptly transition to alternative manufacturers and our ability to generate revenue may be limited.

•Our success depends in part on our proprietary technology, and if we are unable to obtain, maintain or successfully enforce our intellectual property rights, the commercial value of our products and services will be adversely affected, our competitive position may be harmed and we may be unable to operate our business profitably.

•Our business and operations may suffer in the event of IT system failures, cyberattacks or deficiencies in our cybersecurity.

•We are involved, and may become involved in the future, in disputes and other legal or regulatory proceedings that, if adversely decided or settled, could materially and adversely affect our business, financial condition and results of operations.

•We face the risk of product liability claims and the amount of insurance coverage we hold now or in the future may not be adequate to cover all liabilities we might incur.

•Operations in international markets will expose us to additional business, political, regulatory, operational, financial and economic risks.

•Our success depends substantially on our reputation and brand.

•Some of our products and services are in development or have been recently introduced into the market and may not achieve market acceptance, which could limit our growth and adversely affect our business, financial condition and results of operations.

1

•We have identified material weaknesses in our internal control over financial reporting and we may identify additional material weaknesses in the future or otherwise fail to maintain effective internal control over financial reporting, which may result in material misstatements of our consolidated financial statements, cause us to fail to meet our periodic reporting obligations or cause our access to the capital markets to be impaired.

•We will likely need to raise additional capital in the future in order to execute our strategic plan, which may not be available on terms acceptable to us, or at all.

These risks and other important factors, including those discussed in this Report, may cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Moreover, we operate in an evolving environment. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included elsewhere in this Report are not guarantees of future performance and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements included elsewhere in this Report. In addition, even if our results of operations, financial condition and liquidity, and events in the industry in which we operate, are consistent with the forward-looking statements included elsewhere in this Report, they may not be predictive of results or developments in future periods.

Any forward-looking statement that we make in this Report speaks only as of the date of such statement. Except as required by law, we do not undertake any obligation to update or revise, or to publicly announce any update or revision to, any of the forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this Report. For all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Reform Act.

As used in this Report, unless otherwise stated or the context otherwise requires: “we,” “us,” “our,” “Owlet,” the “Company,” and similar references refer to Owlet, Inc. and its subsidiaries, “common stock” refers to our Class A common stock.

2

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

Owlet, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

(unaudited)

	March 31, 2025		December 31, 2024
Assets
Current assets:
Cash and cash equivalents	$	16,310	$	20,245
Restricted cash	300		386
Accounts receivable, net of allowance for credit losses of $811 and $653, respectively	16,525		12,136
Inventory	11,813		10,523
Prepaid expenses and other current assets	3,467		2,823
Total current assets	48,415		46,113
Property and equipment, net	99		102
Right of use assets, net	109		138
Intangible assets, net	1,049		975
Other assets	1,725		2,187
Total assets	$	51,397	$	49,515
Liabilities, Mezzanine Equity, and Stockholders’ Deficit
Current liabilities:
Accounts payable	$	12,708	$	11,281
Accrued and other expenses	16,478		16,378
Current portion of deferred revenues	1,457		1,404
Line of credit	8,498		6,263
Current portion of long-term and other debt	1,554		1,103
Total current liabilities	40,695		36,429
Long-term debt, net	3,846		4,331
Common stock warrant liabilities	18,656		25,343
Other long-term liabilities	200		226
Total liabilities	63,397		66,329
Commitments and contingencies (Note 5)
Mezzanine equity:
Series A convertible preferred stock, $0.0001 par value, 11,479 and 11,479 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively	5,651		5,151
Series B convertible preferred stock, $0.0001 par value; 9,250 and 9,250 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively	3,800		3,452
Redeemable common stock, 687,500 and 750,000 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively	4,355		4,334
Total mezzanine equity	13,806		12,937
Stockholders’ deficit:
Common stock, $0.0001 par value, 107,142,857 shares authorized as of March 31, 2025 and December 31, 2024; 15,808,849 and 15,725,783 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively	2		2
Additional paid-in capital	239,362		238,442
Accumulated deficit	(265,170)		(268,195)
Total stockholders’ deficit	(25,806)		(29,751)
Total liabilities, mezzanine equity, and stockholders' deficit	$	51,397	$	49,515

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

Owlet, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

(in thousands, except share and per share amounts)

(unaudited)

	Three Months Ended March 31,
	2025		2024
Revenues	$	21,104	$	14,750
Cost of revenues	9,778		8,203
Gross profit	11,326		6,547
Operating expenses:
General and administrative	7,092		6,050
Sales and marketing	4,002		3,896
Research and development	2,903		2,347
Total operating expenses	13,997		12,293
Operating loss	(2,671)		(5,746)
Other income (expense):
Interest expense, net	(991)		(161)
Common stock warrant liability adjustment	6,687		9,179
Other income (expense), net	12		2
Total other income (expense), net	5,708		9,020
Income before income tax provision	3,037		3,274
Income tax provision	(12)		—
Net income and comprehensive income	3,025		3,274
Accretion on convertible preferred stock	(847)		(1,328)
Allocation of net income to participating securities	(344)		(661)
Accretion on redeemable common stock	(21)		—
Allocation of net income to participating securities to redeemable common stockholders	14		—
Allocation of net income attributable to redeemable common stockholders	(79)		—
Net income attributable to redeemable common stockholders	86		—
Net income attributable to common stockholders	$	1,748	$	1,285
Net income per share attributable to common stockholders, basic	$	0.11	$	0.15
Weighted-average number of shares outstanding used to compute net income per share attributable to common stockholders, basic	15,383,287		8,740,059
Net income (loss) per share attributable to common stockholders, diluted	$	0.11	$	(0.51)
Weighted-average number of shares outstanding used to compute net income (loss) per share attributable to common stockholders, diluted	15,383,287		9,617,825
Net income per share attributable to redeemable common stockholders, basic	$	0.15	$	—
Weighted-average number of shares outstanding used to compute net income per share attributable to redeemable common stockholders, basic	562,500		—
Net income per share attributable to redeemable common stockholders, diluted	$	0.15	$	—
Weighted-average number of shares outstanding used to compute net income per share attributable to redeemable common stockholders, diluted	687,500		—

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

Owlet, Inc.

Condensed Consolidated Statements of Changes in Mezzanine Equity and Stockholders’ Deficit

(in thousands, except share and per share amounts)

(unaudited)

	Series A Convertible Preferred Stock			Series B Convertible Preferred Stock			Redeemable Common Stock			Common Stock			Additional Paid-in Capital		Accumulated Deficit		Total Stockholders' Deficit
	Shares	Amount		Shares	Amount		Shares	Amount		Shares	Amount
Balance as of December 31, 2023	28,628	$	7,855	—	$	—	—	$	—	8,797,456	$	1	$	218,127	$	(255,659)	$	(37,531)
Issuance of convertible preferred stock	—	—		9,250	2,394		—	—		—	—		—		—		—
Preferred stock issuance costs	—	—		—	(102)		—	—		—	—		—		—		—
Accretion on convertible preferred stock	—	1,212		—	116		—	—		—	—		(1,328)		—		(1,328)
Conversion of preferred stock	(1,178)	(332)		—	—		—	—		171,719	—		332		—		332
Issuance of common stock for restricted stock units vesting	—	—		—	—		—	—		22,437	—		—		—		—
Issuance of common stock for employee stock purchase plan	—	—		—	—		—	—		22,791	—		92		—		92
Stock-based compensation	—	—		—	—		—	—		—	—		2,227		—		2,227
Net income	—	—		—	—		—	—		—	—		—		3,274		3,274
Balance as of March 31, 2024	27,450	$	8,735	9,250	$	2,408	—	$	—	9,014,403	$	1	$	219,450	$	(252,385)	$	(32,934)

Balance as of December 31, 2024	11,479	$	5,151	9,250	$	3,452	750,000	$	4,334	15,725,783	$	2	$	238,442	$	(268,195)	$	(29,751)
Accretion on convertible preferred stock	—	500		—	348		—	—		—	—		(847)		—		(847)
Accretion on redeemable common stock	—	—		—	—		—	21		—	—		(21)		—		(21)
Common stock issuance costs	—	—		—	—		—	—		—	—		7		—		7
Forfeiture of redeemable common stock	—	—		—	—		(62,500)	—		—	—		—		—		—
Issuance of common stock for restricted stock units vesting	—	—		—	—		—	—		56,149	—		—		—		—
Issuance of common stock for employee stock purchase plan	—	—		—	—		—	—		26,917	—		97		—		97
Stock-based compensation	—	—		—	—		—	—		—	—		1,684		—		1,684
Net income	—	—		—	—		—	—		—	—		—		3,025		3,025
Balance as of March 31, 2025	11,479	$	5,651	9,250	$	3,800	687,500	$	4,355	15,808,849	$	2	$	239,362	$	(265,170)	$	(25,806)

.

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5

Owlet, Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

	Three Months Ended March 31,
	2025		2024
Cash flows from operating activities
Net income	$	3,025	$	3,274
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation and amortization	119		109
Stock-based compensation	1,657		2,227
Provision for credit losses	64		(388)
Common stock warrant liability adjustment	(6,687)		(9,179)
Impairment of intangible and other assets	5		9
Amortization of right of use assets	29		356
Amortization of issuance costs	659		—
Other adjustments, net	169		16
Changes in assets and liabilities:
Accounts receivable	(4,453)		2,765
Prepaid expenses and other assets	(619)		555
Inventory	(1,408)		(1,245)
Accounts payable and accrued and other expenses	1,520		(1,158)
Lease liabilities	(48)		(477)
Other liabilities	—		(201)
Deferred revenue	42		(22)
Other, net	1		3
Net cash used in operating activities	(5,925)		(3,356)
Cash flows from investing activities
Purchase of property and equipment	(4)		—
Purchase of intangible assets	—		(37)
Capitalized internal-use software development costs	(106)		—
Net cash used in investing activities	(110)		(37)
Cash flows from financing activities
Proceeds from issuance of preferred stock, net of $0 and $158 of paid transaction costs, respectively	—		9,092
Proceeds from short-term borrowings	13,424		7,253
Payments of short-term borrowings	(11,491)		(9,704)
Payments of long-term borrowings	—		(1,500)
Employee taxes paid related to the net share settlement of stock-based awards	(395)		(31)
Proceeds related to the issuance of common stock under stock plans	395		31
Issuance costs paid related to 2024 preferred stock and warrants	(16)		—
Other, net	97		92
Net cash provided by financing activities	2,014		5,233
Net change in cash, cash equivalents, and restricted cash	(4,021)		1,840
Cash, cash equivalents, and restricted cash at beginning of period	20,631		16,557
Cash, cash equivalents, and restricted cash at end of period	$	16,610	$	18,397

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

6

Owlet, Inc.

Condensed Consolidated Statements of Cash Flows (continued)

(in thousands)

(unaudited)

	Three Months Ended March 31,
	2025		2024
Supplemental disclosure of cash flow information:
Cash paid for interest	$	357	$	419
Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment included in accounts payable	$	26	$	3
Purchases of intangible assets included in accounts payable	33		13
Conversion of preferred stock	—		332
Accretion on preferred stock and redeemable common stock	869		1,328
Equity issuance costs included in accounts payable and accrued liabilities	260		235
Reclassification from long-term to current debt	753		—
Stock-based compensation for software development	27		—

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

7

Owlet, Inc.

Notes to Condensed Consolidated Financial Statements

(in thousands, except share and per share amounts)

(unaudited)

8

Note 1. Basis of Presentation

As used in these financial statements, unless otherwise stated or the context otherwise requires: “we,” “us,” “our,” “Owlet,” the “Company,” and similar references refer to Owlet, Inc. and its subsidiaries, “common stock” refers to our Class A common stock.

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and applicable rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. The condensed consolidated balance sheet as of December 31, 2024, included herein, was derived from the audited consolidated financial statements as of that date, but does not include all disclosures including certain notes required by U.S. GAAP on an annual reporting basis. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary for the fair statement of the Company’s financial position, results of operations, and cash flows for the interim periods presented. All dollar amounts, except per share amounts, in the notes are presented in thousands, unless otherwise specified.

Certain prior year amounts have been reclassified to conform to the current period presentation.

Risks and Uncertainties

In accordance with ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements included in this quarterly report on Form 10-Q are issued.

Since inception, the Company has experienced recurring operating losses and generated negative cash flows from operations, resulting in an accumulated deficit of $265,170 as of March 31, 2025. During the three months ended March 31, 2025 and 2024, the Company had negative cash flows from operations of $5,925 and $3,356, respectively. As of March 31, 2025, the Company had $16,310 of cash on hand.

As the Company continues to address these financial conditions, management has undertaken the following actions:

•As described further in Note 7, Common Stock Issuance, Redeemable Common Stock, Common Stock Warrants, and Convertible Preferred Stock, in September 2024, the Company issued 3,135,136 shares of its common stock and received net proceeds of $10,590 and in February 2024, the Company consummated a sale of preferred stock and warrants to purchase its common stock for a gross purchase price of $9,250.

•As described in Note 4, Debt and Other Financing Arrangements, in September 2024, the Company entered into a loan facility agreement with WTI Fund X, Inc. and WTI Fund XI, Inc. (collectively “WTI” or “Lenders”) for a term loan facility of up to $15,000 (the “WTI Loan Facility”) and on September 11, 2024, the Company entered into an asset-based revolving credit facility (the “ABL Line of Credit”) with ABL OPCO LLC, as the lender, with a maximum revolving commitment amount of up to $15,000, with an additional $5,000 revolving commitment available on September 11, 2025. In connection with these transactions, the Company used its then-existing cash to repay and extinguish all borrowings outstanding under the line of credit and term loan agreement with Silicon Valley Bank, now a division of First Citizens Bank and Trust Company (“SVB”). As of March 31, 2025, the Company has borrowings of $7,500 under the WTI Loan Facility and $8,498 under the ABL Line of Credit.

Notwithstanding the above actions, the Company has experienced recurring operating losses, negative cash flows from operations since inception, and a low cash balance relative to current obligations that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the accompanying unaudited condensed consolidated financial statements are issued. The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis and accordingly, do not include any adjustments relating to the recoverability and classification of asset carrying amounts, or the amount and classification of liabilities that might result should the Company be unable to continue as a going concern.

The Company has not generated sufficient cash flows from operations to satisfy its capital requirements. There can be no assurance that the Company will generate sufficient future cash flows from operations due to potential factors, including but not limited to inflation, recession, or reduced demand for the Company’s products. If revenues decrease from current levels, the Company may be unable to further reduce costs, or such reductions may limit its ability to pursue strategic initiatives and grow revenues in the future.

There can be no assurance that the Company will be able to obtain additional financing on terms acceptable to it, if at all. Failure to secure additional funding may require the Company to modify, delay or abandon some of its planned future development, or to

9

otherwise enact further operating cost reductions, which could have a material adverse effect on its business, operating results, financial condition and ability to achieve its intended business objectives.

If the Company raises additional funds through further issuances of equity or convertible debt securities, its existing stockholders could suffer significant dilution, and any new equity securities the Company issues could have rights, preferences, and privileges superior to those of holders of its common stock. If the Company is unable to obtain adequate financing or financing on terms satisfactory to the Company when it requires it, its ability to continue to pursue its business objectives and to respond to business opportunities, challenges, or unforeseen circumstances could be significantly limited, and its business, financial condition, and results of operations could be materially adversely affected. The Company also could be required to seek funds through arrangements with partners or others that may require the Company to relinquish rights or jointly own some aspects of its technologies, products, or services that the Company would otherwise pursue on its own.

The Company maintains its cash in bank deposit accounts which, at times, exceed federally insured limits. As of March 31, 2025, substantially all of the Company’s cash was held with Silicon Valley Bank and Citibank, and exceeded federally insured limits.

Although the Company’s sales and accounts receivable are derived from sales contracts with a large number of customers, its top several customers account for a significant amount of its total sales, and make up a correspondingly large portion of its accounts receivable. The Company's largest customers by total net accounts receivable consisted of the following:

	March 31, 2025		December 31, 2024
Three largest customers by total net accounts receivable	63	%	63	%

The Company's largest customers by total net revenue consisted of the following:

	Three Months Ended March 31,
	2025		2024
Customer 1	37	%	25	%
Customer 2	14	%	20	%
Customer 3	6	%	12	%

Revisions to Previously Issued Condensed Consolidated Financial Statements and Financial Information

In connection with the preparation of its 2024 financial statements, the Company identified errors in the unaudited condensed consolidated statements of cash flows for the interim period ended March 31, 2024. Specifically, the Company’s historical proceeds from short-term borrowings and payments of short-term borrowings were overstated by the same amount with no net impact to total cash flows from financing activities in its unaudited condensed consolidated statements of cash flows for the interim period ended March 31, 2024. Additionally, the Company also identified and corrected for immaterial classification errors between cash flows from operating activities and investing activities for the interim period ended March 31, 2024.

The Company assessed the effect of the errors on prior periods under the guidance of Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin No. 99, “Materiality,” codified in ASC 250, Accounting Changes and Error Corrections (“ASC 250”). Based on its assessment, the Company determined that the errors were not material to any previously issued financial statements; however, the Company has elected to revise the Company's unaudited condensed consolidated statements of cash flows. These corrections have no impact on the Company's previously reported consolidated net income (loss), financial position, net change in cash, cash equivalents, and restricted cash, or total cash, cash equivalents, and restricted cash as previously reported on the Company's unaudited condensed consolidated statements of cash flows. The Company's unaudited condensed consolidated statements of cash flows for the interim period ended March 31, 2024, have been revised and disclosed in Note 11, Revision of Previously Issued Quarterly Information (Unaudited) below.

Recently Adopted Accounting Pronouncements

In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. The Company adopted ASU 2023-07 as of January 1, 2024 on a retrospective basis. While the adoption of this standard did not have a material impact on the Company's unaudited condensed consolidated financial statements, additional disclosures are included in Note 10.

Recently Issued Accounting Guidance

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires, among other things, additional disclosures primarily related to the income tax rate reconciliation and income taxes paid. The expanded annual disclosures are effective for our year ending December 31, 2025. The Company is currently evaluating the impact

10

that ASU 2023-09 will have on its consolidated financial statements and whether the Company will apply the standard prospectively or retrospectively.

In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses. The standard is intended to require more detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to all prior periods presented in the financial statements. The Company is currently assessing the impact this standard will have on its consolidated financial statements.

11

Note 2. Certain Balance Sheet Accounts

Restricted Cash

The Company’s restricted cash consists of cash collateral that is held by the Company’s financial institutions to secure its financing arrangements. Specifically, restricted cash that is classified within current assets in the unaudited condensed consolidated balance sheets consists of cash collateral to secure its current credit card borrowings. Cash as reported on the unaudited condensed consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted cash as shown on the unaudited condensed consolidated balance sheets and consists of the following (in thousands):

	March 31,
	2025		2024
Reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets:
Cash and cash equivalents	$	16,310	$	18,397
Restricted cash	300		—
Total cash, cash equivalents, and restricted cash	$	16,610	$	18,397

Allowance for Credit and Other Losses

The Company records its accounts receivable at sales value and maintains an allowance for its current estimate of expected credit losses from customers. Provisions for expected credit losses are estimated based on historical experience, assessment of specific risk, review of outstanding invoices, and forecasts about the future. The Company establishes specific reserves for customers in an adverse financial condition and adjusts for its expectations of changes in conditions that may impact the collectability of outstanding receivables.

Changes in the Company's allowance for credit and other losses were as follows (in thousands):

	Three Months Ended March 31,
	2025		2024
Beginning balance	$	653	$	3,322
Charges to expense	95		(388)
Charges to revenue	63		56
Write-offs	—		(2,490)
Ending balance	$	811	$	500

Write-offs for the three months ended March 31, 2024 related to a settlement agreement with a former retailer for past due receivables which had previously been charged to the provision for credit losses in a prior period. A benefit was recognized to charges to expense during the three months ended March 31, 2024, which represented a partial recovery of the past due receivables in connection with the settlement.

Inventory

Details of inventory were as follows (in thousands):

	March 31, 2025		December 31, 2024
Raw materials	$	140	$	100
Finished goods	11,673		10,423
Total inventory	$	11,813	$	10,523

12

Property and Equipment, net

Property and equipment consisted of the following (in thousands):

	March 31, 2025		December 31, 2024
Tooling and manufacturing equipment	$	2,649	$	2,618
Computer equipment	307		322
Furniture and fixtures	289		289
Software	106		106
Leasehold improvements	3		35
Total property and equipment	3,354		3,370
Less: accumulated depreciation and amortization	(3,255)		(3,268)
Property and equipment, net	$	99	$	102

Depreciation and amortization expense on property and equipment was $33 and $93 for the three months ended March 31, 2025 and March 31, 2024, respectively. For the three months ended March 31, 2025 and March 31, 2024, the Company allocated $29 and $85, respectively, of depreciation and amortization expense related to tooling and manufacturing equipment within cost of revenues on the unaudited condensed consolidated statements of operations and comprehensive income (loss). The remaining depreciation and amortization expense related to property and equipment was recorded within general and administrative expenses.

Intangible Assets, net

The carrying amounts of intangible assets consisted of the following (in thousands):

	March 31, 2025
	Gross carrying amount		Accumulated amortization		Net carrying amount
Trademarks and patents	$	705	$	(367)	$	338
Internally developed software	857		(146)		711
Total intangible assets	$	1,562	$	(513)	$	1,049

	December 31, 2024
	Gross carrying amount		Accumulated amortization		Net carrying amount
Trademarks and patents	$	677	$	(346)	$	331
Internally developed software	725		(81)		644
Total intangible assets	$	1,402	$	(427)	$	975

Amortization expense of intangible assets was $86 and $16 for the three months ended March 31, 2025 and 2024, respectively. For the three months ended March 31, 2025 and 2024, the Company recorded $65 and $0, respectively, of amortization expense related to internally developed software within cost of revenues on the unaudited condensed consolidated statements of operations and comprehensive income (loss). The remaining amortization expense related to trademarks and patents was recorded within general and administrative expenses.

As of March 31, 2025, the estimated future amortization expenses and reconciliation to total intangible assets consisted of the following (in thousands):

13

March 31, 2025	Amount
Remaining nine months of 2025	$	262
2026	347
2027	255
2028	47
2029	27
Thereafter	45
Total future amortization expenses	$	983
Trademarks and patents not yet subject to amortization	66
Total intangible assets	$	1,049

Accrued and Other Expenses

Accrued and other expenses consisted of the following (in thousands):

	March 31, 2025		December 31, 2024
Accrued payroll	$	4,042	$	3,639
Accrued sales discounts	1,495		1,773
Accrued sales returns	891		902
Accrued legal settlements	5,925		5,343
Other	4,125		4,721
Total accrued and other expenses	$	16,478	$	16,378

Changes in accrued warranty were as follows (in thousands):

	Three Months Ended March 31,
	2025		2024
Accrued warranty, beginning of period	$	291	$	782
Settlements of warranty claims during the period	(187)		(191)
Provision for warranties issued during the period	124		319
Changes in provision for pre-existing warranties	77		(142)
Accrued warranty, end of period	$	305	$	768

14

Note 3. Deferred Revenues

Deferred revenues relate to performance obligations for which payments are received from customers prior to the satisfaction of the Company’s obligations to its customers. Deferred revenues primarily consist of amounts allocated to the mobile application, unspecified upgrade rights, added features, bug fixes, and content, subscription services, and are recognized over the service period of the performance obligations, which range from 1 to 27 months.

Changes in the total deferred revenues balance were as follows (in thousands):

	Three Months Ended March 31,
	2025		2024
Beginning balance	$	1,544	$	1,302
Deferral of revenues	743		521
Recognition of deferred revenues	(702)		(543)
Ending balance	$	1,585	$	1,280

The Company recognized $574 and $477 of revenue during the three months ended March 31, 2025 and 2024, respectively, that was included in the deferred revenue balance at the beginning of the respective period. Revenue for the three months ended March 31, 2025 included a reduction of revenue of $451 relating to the correction of immaterial misstatements from previous periods. Revenue for the three months ended March 31, 2024 included $330 relating to the correction of immaterial misstatements from previous periods.

15

Note 4. Debt and Other Financing Arrangements

The Company’s indebtedness consisted of the following (in thousands):

	March 31, 2025		December 31, 2024
Term loan facility payable to WTI, net	$	5,088	$	4,819
Line of credit	8,498		6,263
Financed insurance premium	313		615
Total debt	13,899		11,697
Less: current portion	(10,053)		(7,366)
Total long-term debt, net	$	3,846	$	4,331

The carrying value of the Company’s long-term debt, net approximate its fair value.

SVB Revolver and Term Loan

On November 23, 2022, the Company entered into the Third Amended and Restated Loan and Security Agreement (as amended, the “LSA”) with Silicon Valley Bank, now a division of First Citizens Bank and Trust Company ("SVB"). The LSA provided for a $10,000 revolving line of credit (the “SVB Revolver”) and for an $8,500 term loan, which amortized with equal monthly installments of $500. On September 11, 2024, the Company terminated the LSA with SVB and used existing cash to prepay and extinguish all borrowings outstanding under the line of credit and term loan facilities with SVB.

WTI Loan Facility

On September 11, 2024 (the “Effective Date”), the Company, as guarantor, and its wholly-owned subsidiary, Owlet Baby Care, Inc., a Delaware corporation ("OBCI," and together with the Company, collectively, the "Loan Parties"), as the borrower, entered into a Loan Facility Agreement (the “Loan Facility Agreement”) with WTI Fund X, Inc. and WTI Fund XI, Inc. (collectively “WTI” for a term loan facility of up to $15,000 (the “WTI Loan Facility”).

The WTI Loan Facility consists of two tranches. The first tranche of $10,000 was available at closing and through September 30, 2024, with $2,500 of the first tranche availability extendable until December 31, 2024 (the “First Tranche Commitment”). The second tranche of $5,000 is available through August 15, 2025 (the ‘Second Tranche Commitment,” or together with the First Tranche Commitment, the “Loan Commitments”) upon achievement of (a) at least $48,600 in revenue for the period that commenced October 1, 2024 and ending June 30, 2025 (the “Second Tranche Condition Period”), (b) total cash burn during the Second Tranche Condition Period not to exceed $600 for such period, (c) receipt by the Company of at least $6,000 of net proceeds from an equity financing during a period commencing on the closing date and ending on the second tranche borrowing date, and (d) receipt by WTI of the Company’s then-current, board-approved operating and financing plan to WTI's satisfaction, as well as compliance with certain reporting conditions.

The Company initiated its first drawdown under the WTI Loan Facility of $7,500 (the “Initial Loan”) shortly after closing. WTI and the Company agreed to extend the remaining $2,500 of the First Tranche Commitment until March 31, 2025. The Company ultimately elected not to draw on the remainder of the first tranche and, as a result, 62,500 unvested shares of redeemable common stock were forfeited on March 31, 2025. Once repaid, the Company cannot reborrow from the WTI Loan Facility.

Interest on the outstanding principal amounts of any borrowing under the WTI Loan Facility accrues at a rate per annum equal to the sum of the prime rate plus 3.5%, with a floor of 12%. The interest rate on the outstanding principal amounts of any borrowing under the WTI Loan Facility for the three months ended March 31, 2025 was 12%. Commencing on November 1, 2025 through maturity on January 1, 2028, the Company is required to make monthly interest and principal payments. Loans under the WTI Loan Facility also accrue 2.5% in payment-in-kind interest (“PIK Interest”) compounded monthly, and PIK Interest payments will be due and payable upon maturity of the loans. Accrued coupon interest and accrued PIK interest are recorded within accrued and other expenses and within long-term debt, net, respectively on the unaudited condensed consolidated balance sheets. Accrued PIK interest was $104 as of March 31, 2025.

The Company has the option to prepay the outstanding loans issued under the WTI Loan Facility in whole at any time by repaying all outstanding principal and accrued interest, as well as all scheduled unpaid interest on the loan, including PIK Interest, as if the loan continued to accrue interest through its stated maturity. Provided if the Company’s fully diluted market capitalization of its common stock is greater than or equal to $250,000 for 10 consecutive Trading Days, then so long as such prepayment is made within 60 days thereafter, the redemption price will be discounted by 30% of the total amount of all scheduled but unpaid interest (but excluding any PIK Interest, which will not be discounted).

The WTI Loan Facility contains certain reporting and operational covenants that must be met by the Company to borrow funds under the Loan Commitments and not cause an event of default. Upon the occurrence of an event of default, WTI could elect to force

16

redemption of the outstanding balances under the WTI Loan Facility, requiring the Company to pay all outstanding principal and accrued interest, as well as all scheduled unpaid interest on the loan, including PIK interest. Upon the occurrence of an event of default, the Company will also be required to pay default interest on any overdue balances at a rate of 5.0%. The WTI Loan Facility and any loans and obligations issued thereunder are collateralized by substantially all of the Company’s assets, with certain exceptions as set forth in the WTI Loan Facility, and are guaranteed by Owlet, Inc. As of March 31, 2025, the Company was in compliance with all covenants under the WTI Loan Facility.

As partial consideration for the availability and funding of the WTI Loan Facility, the Company and WTI Fund X, LLC (“Fund X”) and WTI Fund XI, LLC (“Fund XI”, and together with Fund X, the “WTI Funds”) entered into a Stock Issuance Agreement (the “WTI Stock Issuance Agreement”), dated as of the Effective Date. Pursuant to the WTI Stock Issuance Agreement, the Company issued to the WTI Funds an aggregate of 750,000 shares of redeemable common stock on the Effective Date, of which 62,500 shares of the redeemable common stock have been forfeited and the remaining 125,000 of unvested redeemable common stock are subject to forfeiture in the event that the Company does not draw on the remaining portion of the outstanding Loan Commitment. To the extent the Company does exercise its option under the Loan Commitments to issue additional debt, a number of forfeitable shares will 'vest' and no longer be subject to forfeiture based on the pro rata portion of the outstanding Loan Commitments drawn against.

The shares issued to WTI pursuant to the WTI Stock Issuance Agreement contain an embedded redemption option (the “Redemption Option”) such that WTI may elect to force the Company to redeem the shares that are no longer subject to forfeiture for a price of $8.40 per share. The Redemption Option may be exercised in whole or in part, at any time, from time to time, during the period commencing on the first trading day following the fifth anniversary of the Effective Date and continuing through the date which is 10 years after the Effective Date, subject to certain acceleration provisions set forth in the WTI Stock Issuance Agreement. Because the shares are redeemable at the option of the WTI Funds, the shares are recorded in mezzanine equity on the unaudited condensed consolidated balance sheets. The redeemable common shares were initially recorded at their fair value of $7.66 per share, which was an aggregate value of $4,308. The value of the redeemable common shares was determined using a combination of the value of the Company's stock on the date of issuance and the theoretical value of a stand-alone put option valued using a Black-Scholes put option model discounted by a present value factor that considers the credit spread between an estimated Company specific discount rate and the risk-free rate of return. Because the shares are required to be redeemed at the option of WTI, based solely on the passage of time, and provided WTI did not elect to otherwise sell or transfer the shares beforehand, the carrying value of the shares will accrete to their redemption value of $8.40 per share from the issuance date through September 11, 2029, the date the Redemption Option first becomes exercisable.

The Company allocated the lender fees (including the fair value of the vested shares) and third-party debt issuance costs between the Initial Loan and the remaining, undrawn Loan Commitments. The costs allocated to the Initial Loan are accounted for as a discount and will be amortized across the term of the Initial Loan using the effective interest method. The costs allocated to the remaining, undrawn Loan Commitments are accounted for as loan commitment assets, which are being amortized to interest expense using the straight-line method over the commitment periods, due to uncertainty about the Company's intent to access the Loan Commitment. The unamortized portion of the loan commitment assets was $424 as of March 31, 2025 and is recorded within Other assets on the unaudited condensed consolidated balance sheets.

As of March 31, 2025, details of the WTI Loan Facility were as follows (in thousands):

	Amount
Principal outstanding	$	7,500
Unamortized debt issuance costs	(2,516)
Accrued PIK Interest	104
Net carrying value	$	5,088

The Company recognized $222 of interest expense related to the amortization of debt issuance costs of the WTI Loan Facility and $385 of interest expense related to the amortization of the loan commitment assets during the three months ended March 31, 2025.

ABL Line of Credit

On the Effective Date, the Company, as guarantor, and its wholly-owned subsidiary, Owlet Baby Care, Inc., a Delaware corporation (“OBCI,” and together with the Company, collectively, the “Loan Parties”), as borrower, entered into a Credit and Security Agreement (the “Credit Agreement”) with the financial institutions party thereto from time to time as lenders (collectively the “Lenders”) and ABL OPCO LLC, a Delaware limited liability company, in its capacity as administrative agent for the Lenders.

The Credit Agreement provides for an asset-based revolving credit facility (the “ABL Line of Credit”) in a maximum principal amount of up to $15,000, which amount shall increase to $20,000 on September 11, 2025 (the “Revolving Commitment”). The ABL

17

Line of Credit is collateralized by substantially all of the Company's assets. Loans and other obligations under the Credit Agreement bear interest at a rate per annum equal to the 1-month Secured Overnight Financing Rate (subject to a floor of 3.5%) plus a margin, which varies between 7.5% and 8.5% depending on the Company’s earnings before interest, taxes, depreciation and amortization (“EBITDA”), provided that the interest rate shall not exceed the maximum rate permitted under applicable law.

The ABL Line of Credit matures on September 10, 2027 (the “Maturity Date”). If for any reason the Credit Agreement is terminated or all outstanding loans and other obligations are paid in full and the ABL Line of Credit is terminated before the Maturity Date, the Company will be obligated to pay a prepayment fee equal to a percentage of the then-current Revolving Commitment, which percentage decreases on certain anniversary of the closing date.

The Credit Agreement contains representations, warranties, covenants, and events of default customary for agreements of this type. OBCI’s obligations under the Credit Agreement are: (i) fully and unconditionally guaranteed by the Company; and (ii) secured by a security interest in substantially all personal property assets of the Company, including the Company's pledge of the outstanding capital stock of the Company. Among these covenants is a liquidity covenant requiring the Company to maintain liquidity of $4,000. Liquidity is defined as the sum of (x) Undrawn Availability, as defined in the Credit Agreement, on the asset-based line of credit, plus (y) unrestricted cash and funds held in deposit accounts. In addition, if the liquidity falls below $9,000, the Company is then subject to a minimum trailing-twelve-months EBITDA covenant as defined in the Credit Agreement. As of March 31, 2025, the Company was in compliance with all covenants under the Credit Agreement.

The unamortized portion of debt issuance costs related to the Credit Agreement as of March 31, 2025 was $557 and is recorded as a loan commitment asset within other assets on the unaudited condensed consolidated balance sheets. Issuance costs are amortized straight-line over the term of the Credit Agreement and recorded within interest income (expense), net on the unaudited condensed consolidated statement of operations and comprehensive income (loss).

On March 31, 2025, there was $8,498 of outstanding borrowings, which is recorded as a current liability on the unaudited condensed consolidated balance sheet based on the Company's intent and ability to repay the outstanding borrowings in the near term. The remaining borrowing base availability under the Credit Agreement was $46 as of March 31, 2025.

Financed Insurance Premiums

In 2024, the Company renewed a number of its insurance policies and entered into several new short-term commercial premium finance agreements with First Insurance Funding totaling $941 to be paid within one year, accruing interest at a weighted average rate of 8.7%. As of March 31, 2025, the remaining principal balance on the combined financed insurance premiums was $313.

Future Aggregate Maturities

As of March 31, 2025, future aggregate maturities of the WTI Loan Facility and Financed Insurance Premium payables were as follows (in thousands):

March 31, 2025	Amount
Remaining nine months of 2025	$	801
2026	3,146
2027	3,550
2028	420
Total	$	7,917

Note 5. Commitments and Contingencies

Purchase and Other Obligations

The Company entered into a services and license agreement for cloud platform services in June 2024. The Company has a purchase obligation of $6,739 to be paid over a 48-month period beginning in June 2024 and $5,313 remains to be paid at March 31, 2025.

Litigation

The Company is involved in legal proceedings from time to time arising in the normal course of business. While any outcome related to such legal proceedings cannot be predicted with certainty, other than the matters discussed below, the Company believes that the outcome of these proceedings will not have a material impact on the Company’s financial position, results of operations, or liquidity.

In November 2021, two putative class action complaints were filed against the Company in the U.S. District Court for the Central District of California, the first captioned Butala v. Owlet, Inc., Case No. 2:21-cv-09016, and the second captioned Cherian v. Owlet,

18

Inc., Case No. 2:21-cv-09293. Both complaints alleged violations of the Securities Exchange Act of 1934 (“Exchange Act”) against the Company and certain of its officers and directors on behalf of a putative class of investors who: (a) purchased the Company’s common stock between March 31, 2021 and October 4, 2021 (“Section 10(b) Claims”); or (b) held common stock in Sandbridge Acquisition Corporation (“SBG”) as of June 1, 2021, and were eligible to vote at SBG's special meeting held on July 14, 2021 (“Section 14(a) Claims”). Both complaints allege, among other things, that the Company and certain of its officers and directors made false and/or misleading statements and failed to disclose certain information regarding the FDA’s likely classification of Smart Sock as a medical device requiring marketing authorization.

On September 8, 2023, the Court ruled that while the Butala and Cherian cases were consolidated, there would be two distinct and separate classes to represent the Section 10(b) Claims and Section 14(a) Claims, respectively, and appointed lead plaintiffs and lead counsel for each class. Amended complaints were filed for each class on November 21, 2023, and then further amended in consolidated filings on December 22, 2023. The Company filed motions to dismiss the complaints on February 9, 2024 on behalf of itself and the named officers and directors. The plaintiffs filed oppositions to the motions to dismiss on March 24, 2024, and the Company filed replies in support of the motions to dismiss on May 10, 2024. On August 5, 2024, the Court denied Owlet’s and its officers’ motions to dismiss the Section 10(b) Claims and the Section 14(a) Claims. On September 24, 2024, the Court entered a scheduling order in the case, setting trial to begin on February 17, 2026. On September 26, 2024, the Court granted Owlet’s and its officers’ motion for reconsideration regarding the Section 10(b) Claims and dismissed all claims arising out of statements made prior to the merger.

Following mediation, the parties to the Butala action reached agreements in principle to settle both the Section 10(b) Claims and the Section 14(a) Claims. The Section 10(b) Claims would be resolved for $3,500 and the Section 14(a) Claims would be resolved for $1,750. On January 31, 2025, the plaintiffs filed motions seeking preliminary approval of the settlements of the Section 10(b) Claims and Section 14(a) Claims. Those motions remain pending. In accordance with ASC 450, as these amounts have become probable and estimable, the Company recognized $5,250 of general and administrative expense in the consolidated statement of operations and comprehensive income (loss) for the year ended December 31, 2024. The related liability is recorded in accrued and other expenses on the unaudited condensed consolidated balance sheet as of March 31, 2025.

Further, on August 26, 2024 and October 3, 2024, investors filed in the U.S. District Court for the Central District of California, derivatively on behalf of the Company, complaints asserting claims for violations of Section 14(a) of the Exchange Act, as well as state law claims, including breach of fiduciary duty, unjust enrichment and waste of corporate assets. One complaint (captioned Janet Vargas, Derivatively on Behalf of Nominal Defendant Owlet, Inc., Case No. 2:24 cv-07258-FLA-PVC) asserts claims against twelve of the Company’s current or former directors and officers and six current or former directors and officers of Sandbridge Acquisition Corporation. The other (captioned Nathan Capleton, Derivatively on Behalf of Nominal Defendant Owlet, Inc., Case No. 2:24 cv-08536-JAK-MAA) asserts claims against eleven of the Company’s current or former directors. Both complaints leverage the allegations made in one of the securities class action complaints. Neither complaint specifies the damages claimed in the action.

On December 13, 2024, these two complaints were consolidated into a single action captioned Vargas v. Workman, et al., No. 2:24-cv-07258-FLA (C.D. Cal.) On February 7, 2025, the plaintiffs filed an amended consolidated complaint asserting the claims previously made in the two derivative complaints. The parties in the Vargas action reached agreements in principle to settle, and plaintiffs filed a joint Notice of Settlement with the Court on March 3, 2025. On March 6, 2025, the Court vacated deadlines in the Vargas action in light of the plaintiffs’ settlement notice, and set April 2, 2025 as the deadline for plaintiffs to file a motion for preliminary approval of the settlement. On March 31, 2025, the plaintiffs filed a joint stipulation with the Court to extend that deadline to April 9, 2025. The Court so ordered the stipulation on April 2, 2025, and the plaintiffs filed the motion for preliminary approval of the settlement on April 9, 2025.

In accordance with ASC 450, as these amounts have become probable and estimable, the Company recognized $675 of general and administrative expense in the unaudited condensed consolidated statements of operations and comprehensive income (loss) for the three months ended March 31, 2025. The related liability is recorded in accrued and other expenses on the unaudited condensed consolidated balance sheet as of March 31, 2025.

19

Indemnification

In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless, and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors’ and officers’ insurance coverage that may reduce its exposure and enables the Company to recover a portion of any future amounts paid.

20

Note 6. Stock-based Compensation

The Company has various stock compensation plans, which are more fully described in Part II, Item 8 “Financial Statements and Supplementary Data - Note 8 to the Consolidated Financial Statements - Stock-based Compensation” in its 2024 Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Under the 2021 Incentive Award Plan, the Company has the ability to grant options, stock appreciation rights, restricted stock awards (“RSAs”), restricted stock units (“RSUs”), performance stock units (“PSUs”), dividend equivalents, or other stock or cash-based awards to employees, directors, or consultants. Option awards are generally granted with an exercise price equal to the fair value of the Company’s common stock at the date of grant. Options and PSU awards generally vest over a period of four years. RSUs are subject to a four year vesting term with 25% vesting after one year and quarterly thereafter, or on a 2 year vesting term with 50% after one year and the remaining after the second year, or a 1 year vesting term with 100% after one year, depending on grant reason. RSAs generally vest over less than one year. Grants to directors typically vest after one year and, in certain circumstances, vest immediately.

Stock-based Compensation Expense

Total stock-based compensation was recognized as follows (in thousands):

	Three Months Ended March 31,
	2025		2024
General and administrative	$	779	$	1,283
Sales and marketing	455		344
Research and development	423		600
Total stock-based compensation	$	1,657	$	2,227

During the three months ended March 31, 2025, the Company capitalized $27 of stock-based compensation attributable to internally developed software. There was no stock-based compensation capitalized during the three months ended March 31, 2024.

During 2024, the Company modified certain RSU awards for 11 employees and exchanged the RSUs previously granted for RSAs that would vest within six months of the date of modification. The RSAs are valued at the market value on the date of grant. As a result of the modification, the Company recognized $43 of incremental stock-based compensation expense during the three months ended March 31, 2025. As of March 31, 2025, the Company had $2 of incremental unrecognized stock-based compensation costs related to unvested RSAs that will be recognized over a weighted-average period of 0.1 years.

As of March 31, 2025, the Company had $5,815 of unrecognized stock-based compensation costs related to unvested RSUs that will be recognized over a weighted-average period of 1.2 years; and $101 of unrecognized stock-based compensation costs related to unvested PSUs that will be recognized over a weighted-average period of 0.8 years.

21

Note 7. Common Stock Issuance, Redeemable Common Stock, Common Stock Warrants, and Convertible Preferred Stock

September 2024 Offering

On September 11, 2024, the Company entered into an underwriting agreement and issued 3,135,136 shares of its common stock at a price to the public of $3.70 per share, less underwriting discounts and commissions. The net proceeds received by the Company were $10,590. The shares were issued pursuant to the Company’s registration statement on Form S-3 (File No. 333-281556), filed by the Company with the SEC on August 14, 2024, which was declared effective on August 23, 2024. The Company provided the underwriter a discount of 7% off the offering price.

In addition to the underwriter discount, the offering expenses with third parties were $863, of which $260 in issuance costs that were unpaid as of March 31, 2025. The Company also reimbursed the underwriters for $198 in fees and expenses, including legal expenses, out-of-pocket expenses, and clearing expenses. The issuance costs associated with the September 2024 Offering were recorded as a reduction to additional paid-in capital on the unaudited condensed consolidated balance sheet.

Pursuant to the underwriting agreement, the Company also issued, as a portion of the underwriting compensation payable to the underwriter, a warrant to purchase up to 125,405 shares of common stock (which was subsequently transferred to certain affiliates of the underwriter, the “Titan Warrants”). The Titan Warrants are accounted as a nonemployee stock-based award as it represents compensation for underwriter services. The compensation cost associated with the Titan Warrants was $382, and was recorded as a direct and incremental issuance cost of the associated common stock offering that was earned upon the closing and issuance of the common stock. The Titan Warrants are classified as equity and included within additional paid-in capital on the unaudited condensed consolidated balance sheets.

The Titan Warrants are initially exercisable on March 13, 2025 at an exercise price of $4.63 and have a term of five years from such initial exercise date. None of the Titan Warrants have been exercised as of March 31, 2025.

Redeemable Common Stock

As discussed in Note 4, in September 2024 as partial consideration for the availability and funding of the WTI Loan Facility, the Company issued to the WTI Funds an aggregate of 750,000 shares of common stock. The Company also granted the WTI Funds the Redeemable Option discussed in Note 4. The vested shares are recorded in mezzanine equity on the unaudited condensed consolidated balance sheets and are being accreted to the redemption value at the date the redemption feature first becomes exercisable.

August 2024 Exchange

On August 20, 2024, holders of the Series A convertible preferred stock (“Series A Preferred Stock”) of the Company elected to convert an aggregate of 15,721 shares of Series A Preferred Stock in exchange for an aggregate of 2,291,686 shares of the Company’s common stock, all as in accordance with the terms of the Certificate of Designation relating to the Series A Preferred Stock. As of March 31, 2025, the redemption value for the remaining Series A convertible preferred stock is $11,479.

February 2024 Offering

On February 25, 2024, the Company entered into a private placement investment agreement with certain investors, pursuant to which the Company issued and sold to the investors (i) an aggregate of 9,250 shares of the Company’s Series B convertible preferred stock, par value $0.0001 per share and (ii) warrants to purchase an aggregate of 1,799,021 shares of the Company's common stock, par value $0.0001 per share (the “Series B Warrants”), for an aggregate gross purchase price of $9,250.

The Series B convertible preferred stock is convertible into common stock at the option of the holder at any time after February 29, 2024 and ranks, with respect to dividend rights, rights of redemption and rights upon a liquidation event, (i) equal to the Company’s Series A convertible preferred stock, (ii) senior to the common stock and all other classes or series of equity securities of the Company established after February 29, 2024, unless such shares or equity securities expressly provide that they rank in parity with or senior to the Series B convertible preferred stock with respect to dividend rights, rights of redemption or rights upon a liquidation event, (iii) on parity with each class or series of equity securities of the Company established after February 29, 2024, the terms of which expressly provide that it ranks on parity with the Series B convertible preferred stock with respect to dividend rights, rights of redemption and rights upon a liquidation event and (iv) junior to each class or series of equity securities of the Company established after February 29, 2024, the terms of which expressly provide that it ranks senior to the Series B convertible preferred stock with respect to dividend rights, rights of redemption and rights upon a liquidation event. Except as otherwise provided in the certificate of designation relating to the Series B convertible preferred stock or as required by law, holders of shares of Series B convertible preferred stock are entitled to vote with the holders of shares of common stock (and any other class or series that may similarly be entitled to vote with the holders of common stock) on an as-converted to common stock basis at any annual or special meeting of stockholders of the Company, and not as a separate class.

At any time from and after March 1, 2029, the holders of at least a majority of the then outstanding shares of Series B convertible preferred stock may specify a date and time or the occurrence of an event by vote or written consent that all, and not less than all, of

22

the outstanding shares of Series B convertible preferred stock will automatically be: (i) converted into shares of common stock at a conversion rate of 129.6596 per share, (ii) subject to certain exceptions and limitations, redeemed for an amount per share of Series B preferred stock equal to the liquidation preference of one thousand dollars per share, plus all accrued or declared but unpaid dividends as of the redemption date and time or (iii) a combination of the foregoing.

Subject to certain exceptions, upon the occurrence of a fundamental change, voluntary or involuntary liquidation, dissolution or winding-up of the Company, the Company will be required to pay an amount per share of Series B convertible preferred stock equal to the greater of (i) one thousand dollars per share or (ii) the consideration per share of Series B convertible preferred stock as would have been payable had all such shares been converted to common stock immediately prior to the liquidation event, plus, in each case, the aggregate amount of all declared but unpaid dividends thereon to the date of final distribution to the holders of Series B convertible preferred stock. As of March 31, 2025, the redemption value for Series B convertible preferred stock is $9,250. None of the Series B convertible preferred stock had been converted as of March 31, 2025.

Each of the Series B Warrants sold in the private placement offering is exercisable for one share of common stock at an exercise price of $7.71 per share, is immediately exercisable, and will expire on March 1, 2029. As the Series B Warrants could require cash settlement in certain scenarios, the warrants were classified as liabilities upon issuance and were initially recorded at an aggregate estimated fair value of $6,856. The total proceeds from the offering were first allocated to the liability classified warrants, based on their fair values, with the residual $2,394 allocated to the Series B convertible preferred stock. The Series B convertible stock will accrete to its redemption value, starting from the issuance date to the date at which the shares become redeemable on March 1, 2029. Accretion will be recorded as a deemed dividend. None of the Series B Warrants have been exercised as of March 31, 2025.

The Company incurred $394 of issuance costs related to the offering. Issuance costs allocated to the preferred stock of $102 were recorded as a reduction to the Series B convertible preferred stock. Issuance costs allocated to the liability classified warrants of $292 were recorded as an expense within general and administrative expenses on the unaudited condensed consolidated statements of operations and comprehensive income (loss).

February 2023 Offering

On February 17, 2023 the Company entered into private placement investment agreements with certain investors, pursuant to which the Company issued and sold to the investors (i) an aggregate of 30,000 shares of the Company’s Series A convertible preferred stock, par value $0.0001 per share and (ii) warrants to purchase an aggregate of 7,871,712 shares of the Company’s common stock, par value $0.0001 per share, (“Series A Warrants”) for an aggregate purchase price of $30,000.

The Series A convertible preferred stock is convertible into common stock at the option of the holder at any time after February 17, 2023 and ranks, with respect to dividend rights, rights of redemption and rights upon a liquidation event, (i) senior to the common stock and all other classes or series of equity securities of the Company established after February 17, 2023, unless such shares or equity securities expressly provide that they rank in parity with or senior to the Series A convertible preferred stock with respect to dividend rights, rights of redemption or rights upon a liquidation event, (ii) on parity with each class or series of equity securities of the Company established after the February 17, 2023, the terms of which expressly provide that it ranks on parity with the Series A convertible preferred stock with respect to dividend rights, rights of redemption and rights upon a liquidation event and (iii) junior to each class or series of equity securities of the Company established after February 17, 2023, the terms of which expressly provide that it ranks senior to the Series A convertible preferred stock with respect to dividend rights, rights of redemption and rights upon a liquidation event. Except as otherwise provided in the certificate of designation relating to the Series A convertible preferred stock or as required by law, holders of shares of Series A convertible preferred stock are entitled to vote with the holders of shares of common stock (and any other class or series that may similarly be entitled to vote with the holders of common stock) on an as-converted to common stock basis at any annual or special meeting of stockholders of the Company, and not as a separate class.

At any time from and after February 17, 2028, the holders of at least a majority of the then outstanding shares of Series A convertible preferred stock may specify a date and time or the occurrence of an event by vote or written consent that all, and not less than all, of the outstanding shares of Series A preferred stock will automatically be: (i) converted into shares of common stock at a conversion rate of 145.7726 per share (the "Conversion Rate"), (ii) subject to certain exceptions and limitations, redeemed for an amount per share of Series A preferred stock equal to the liquidation preference of one thousand dollars per share, plus all accrued or declared but unpaid dividends as of the redemption date and time or (iii) a combination of the foregoing.

Subject to certain exceptions, upon the occurrence of a fundamental change, voluntary or involuntary liquidation, dissolution or winding-up of the Company, the Company will be required to pay an amount per share of Series A convertible preferred stock equal to the greater of (i) one thousand dollars per share or (ii) the consideration per share of Series A convertible preferred stock as would have been payable had all such shares been converted to common stock immediately prior to the liquidation event, plus, in each case, the aggregate amount of all declared but unpaid dividends thereon to the date of final distribution to the holders of Series A convertible preferred stock.

Each of the Series A Warrants sold in the private placement offering is exercisable for one share of common stock at an exercise price of $4.66 per share, is immediately exercisable, and will expire on February 17, 2028. As the Series A Warrants could require cash settlement in certain scenarios, the warrants were classified as liabilities upon issuance and were initially recorded at an aggregate

23

estimated fair value of $26,133 The total proceeds from the offering were first allocated to the liability classified warrants, based on their fair values, with the residual $3,867 allocated to the Series A convertible preferred stock. The Series A convertible stock is accreting to its redemption value, starting from the issuance date to the date at which the shares become redeemable on February 17, 2028. Accretion will be recorded as a deemed dividend. None of the Series A Warrants have been exercised as of March 31, 2025.

SBG Common Stock Warrants

As a result of the merger completed with SBG on July 15, 2021 (the “Merger”), the Company continues to record liabilities for warrants issued by SBG prior to the Merger.

Pursuant to the SBG initial public offering, SBG sold warrants to purchase an aggregate of 821,428 shares of the Company’s common stock at a price of $161.00 per share (“SBG Public Warrants”). Following the closing of the Initial Public Offering on September 17, 2020, the Company completed the sale of warrants to purchase an aggregate of 471,428 shares of the Company’s common stock at a price of $161.00 per share in a private placement to Sandbridge Acquisition Holdings LLC (the “SBG Private Placement Warrants”). Together, the SBG Public Warrants and SBG Private Placement Warrants are referred to as the “SBG Common Stock Warrants.” The SBG Public Warrants became exercisable 12 months from the closing of the Initial Public Offering. The SBG Common Stock Warrants will expire five years after the completion of the Merger or earlier upon redemption or liquidation. None of the SBG Common Stock Warrants have been exercised as of March 31, 2025.

SVB Warrants

In March 2023, in connection with the first amendment to the LSA with SVB, the Company granted SVB a warrant to purchase 10,714 shares of the Company's common stock at a price of $5.32 per share, expiring on March 27, 2035 (the “SVB Warrants”). The SVB Warrants, which were valued at $43, are classified as equity and included within additional paid-in capital on the unaudited condensed consolidated balance sheets. None of the SVB Warrants have been exercised as of March 31, 2025.

Common Stock Warrants

The following table summarizes issuable shares of the Company’s common stock based on warrant activity for the three months ended March 31, 2025:

	December 31, 2024	Shares Issuable by New Warrants	Shares Purchased by Exercise	March 31, 2025
SBG Public Warrants	821,428	—	—	821,428
SBG Private Placement Warrants	471,428	—	—	471,428
Series A Warrants	7,871,712	—	—	7,871,712
Series B Warrants	1,799,021	—	—	1,799,021
SVB Warrants	10,714	—	—	10,714
Titan Warrants	125,405	—	—	125,405
Total	11,099,708	—	—	11,099,708

24

Note 8. Fair Value Measurements

The Company’s assets and liabilities measured and reported in the financial statements at fair value on a recurring basis were as follows (in thousands):

	March 31, 2025
	Level 1		Level 2		Level 3		Balance
Assets:
Money market funds	$	9,104	$	—	$	—	$	9,104
Total assets	$	9,104	$	—	$	—	$	9,104
Liabilities:
SBG Public Warrants	$	—	$	—	$	1	$	1
SBG Private Placement Warrants	—		—		1		1
Series A Warrants	—		—		15,263		15,263
Series B Warrants	—		—		3,391		3,391
Total liabilities	$	—	$	—	$	18,656	$	18,656
	December 31, 2024
	Level 1		Level 2		Level 3		Balance
Assets:
Money market funds	$	8,223	$	—	$	—	$	8,223
Total assets	$	8,223	$	—	$	—	$	8,223
Liabilities:
SBG Public Warrants	$	—	$	—	$	5	$	5
SBG Private Placement Warrants	—		—		2		2
Series A Warrants	—		—		20,750		20,750
Series B Warrants	—		—		4,586		4,586
Total liabilities	$	—	$	—	$	25,343	$	25,343

Money market funds are included within Level 1 of the fair value hierarchy because they are valued using quoted market prices.

The SBG Public Warrants and SBG Private Placement Warrants as of March 31, 2025 and December 31, 2024 are presented in Level 3 of the fair value hierarchy. On June 15, 2023, the Company received notice from the New York Stock Exchange (the “NYSE”) that the NYSE had halted trading in the SBG Public Warrants due to the low trading price of those warrants. On June 16, 2023, the NYSE provided written notice to the Company and publicly announced that NYSE Regulation had determined to commence proceedings to delist the SBG Public Warrants and that such warrants were no longer suitable for listing based on “abnormally low” price levels, pursuant to Section 802.01D of the NYSE Listed Company Manual. As such, these instruments are no longer valued using quoted market prices and correspondingly, the SBG Private Placement Warrants can no longer be valued based on a quoted market price of the SBG Public Warrants. The Company measured the fair value of both the SBG Public Warrants and the SBG Private Placement Warrants as of March 31, 2025 and December 31, 2024 using the Black-Scholes option pricing model with the following assumptions:

SBG Common Stock Warrants - Black-Scholes Inputs	March 31, 2025			December 31, 2024
OWLT stock price	$	3.68		$	4.45
Exercise price of warrants	$	161.00		$	161.00
Term in years	1.29			1.54
Risk-free interest rate	3.99		%	4.21		%
Volatility	90.00		%	90.00		%

The Series A Warrants are presented as Level 3 measurements, relying on unobservable inputs reflecting the Company’s own assumptions. Level 3 measurements, which are not based on quoted prices in active markets, introduce a higher degree of subjectivity and may be more sensitive to fluctuations in stock price, volatility rates, and U.S. Treasury Bond rates.

25

The Company measured the fair value of the Series A Warrants as of March 31, 2025 and December 31, 2024, using the Black-Scholes option pricing model with the following assumptions:

Series A Warrants - Black-Scholes Inputs	March 31, 2025			December 31, 2024
OWLT stock price	$	3.68		$	4.45
Exercise price of warrants	$	4.66		$	4.66
Term in years	2.88			3.13
Risk-free interest rate	3.89		%	4.28		%
Volatility	90.00		%	90.00		%

The Series B Warrants are presented as Level 3 measurements, relying on unobservable inputs reflecting the Company’s own assumptions. The Company measured the fair value of the Series B Warrants as of March 31, 2025 and December 31, 2024, using the Black-Scholes option pricing model with the following assumptions:

Series B Warrants - Black-Scholes Inputs	March 31, 2025			December 31, 2024
OWLT stock price	$	3.68		$	4.45
Exercise price of warrants	$	7.71		$	7.71
Term in years	3.91			4.16
Risk-free interest rate	3.92		%	4.33		%
Volatility	90.00		%	90.00		%

The following table presents a reconciliation of the Company’s SBG Public Warrants, SBG Private Placement Warrants, Series A Warrants, and Series B Warrants (together, the “Level 3 Warrants”) measured at fair value on a recurring basis as of March 31, 2025 (in thousands):

	Level 3 Warrants
Balance as of December 31, 2024	$	25,343
Change in fair value included within common stock warrant liability adjustment	(6,687)
Balance as of March 31, 2025	$	18,656

There were no transfers between Level 1 and Level 2 in the periods reported. The SBG Public Warrants and SBG Private Placement Warrants were transferred into Level 3 in 2023, as discussed above.

Equity-Classified Warrants

The fair value of the Titan Warrants on September 11, 2024 was $382. The Company measured the fair value of the Titan Warrants at issuance on September 11, 2024, using the Black-Scholes option pricing model with the following assumptions:

Titan Warrants - Black-Scholes Inputs	September 11, 2024
OWLT stock price	$	4.35
Exercise price of warrants	$	4.63
Term in years	5.50
Risk-free interest rate	3.47		%
Volatility	85.00		%

Mezzanine-Classified Redeemable Common Stock

As described in Note 4, the vested shares issued to WTI are contingently redeemable at the option of the holder during the put period and are recorded in mezzanine equity on the unaudited condensed consolidated balance sheets. The vested redeemable common shares were recorded at their fair value of $7.66 per share, which was an aggregate value of 4,308. The value of the redeemable common shares was determined using a combination of the value of the Company's stock on the date of issuance and the theoretical value of a stand-alone put option valued using a Black-Scholes put option model discounted by a present value factor that considers the credit

26

spread between an estimated Company specific discount rate and the risk-free rate of return. The valuation model used the following assumptions:

Redeemable Common Stock - Valuation Inputs	September 11, 2024
Common stock value per share	$	4.35
Put price	$	8.40
Term in years	5.00
Risk-free interest rate	3.42		%
Volatility	85.00		%
Credit spread	9.27		%
Present value discount	63.49		%

27

Note 9. Net Income (Loss) Per Share

Basic and diluted net income (loss) per share of common stock and redeemable common stock is presented in conformity with the two-class method required for participating securities. Under the two-class method, net income (loss) is allocated to each class of common stock and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.

The Company considers its convertible preferred stock and unvested redeemable common stock to be participating securities. Under the two-class method, the net loss attributable to common stockholders is not allocated to the convertible preferred stock as the holders of the Company’s convertible preferred stock do not have a contractual obligation to share in the Company’s losses.

The following tables present the calculation of basic and diluted net income (loss) per share (in thousands, except share and per share amounts):

	Three Months Ended March 31,
	2025		2025		2024
	Redeemable Common Stock		Common Stock		Common Stock
Numerator:
Allocation of net income attributable to common stockholders	$	79	$	2,946	$	3,274
Accretion on convertible preferred stock	—		(847)		(1,328)
Accretion on redeemable common stock	21		(21)		—
Allocation of net income to participating securities	$	(14)	$	(330)	$	(661)
Allocated net income attributable to common stockholders	$	86	$	1,748	$	1,285
Denominator:
Weighted average common shares outstanding, basic	562,500		15,383,287		8,740,059
Net income per share attributable to common stockholders, basic	$	0.15	$	0.11	$	0.15

	Three Months Ended March 31,
	2025		2025		2024
	Redeemable Common Stock		Common Stock		Common Stock
Numerator:
Allocation of net income attributable to common stockholders	$	79	$	2,946	$	3,274
Accretion on convertible preferred stock	—		(847)		(1,328)
Accretion on redeemable common stock	21		(21)		—
Allocation of net income to participating securities	—		(330)		—
Effect of dilutive securities	—		—		(6,809)
Allocated net income (loss) attributable to common stockholders	$	100	$	1,748	$	(4,863)
Denominator:
Weighted average common shares outstanding, basic	562,500		15,383,287		8,740,059
Effect of dilutive securities	125,000		0		877,766
Weighted average common shares outstanding, diluted	687,500		15,383,287		9,617,825
Net income (loss) per share attributable to common stockholders, diluted	$	0.15	$	0.11	$	(0.51)

The following table summarizes the common stock equivalents of potentially dilutive outstanding securities excluded from the computation of diluted net loss per share due to their anti-dilutive effect:

28

	March 31,
	2025	2024
Stock options	377,012	463,168
RSUs	1,450,316	1,526,327
RSAs	107,636	—
PSUs	56,391	71,428
ESPP shares committed	51,073	19,388
Common stock warrants	11,099,708	3,102,591
Preferred stock	2,872,668	5,200,802
Total	16,014,804	10,383,704

The Company’s 200,536 unvested earnout shares and 125,000 unvested shares issued to WTI described in Part II, Item 8 “Financial Statements and Supplementary Data - Note 9 to the Consolidated Financial Statements - Common Stock Issuance, Redeemable Common Stock, Common Stock Warrants, and Convertible Preferred Stock” in it Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and 107,636 unvested RSAs issued in connection to the RSU to RSA conversion that occurred during 2024 were excluded from the calculation of basic and diluted per share calculations as the vesting conditions have not yet been met as of March 31, 2025.

29

Note 10. Segments

The Company operates as a single operating segment. The Company’s Chief Operating Decision Maker ("CODM") is its Chief Executive Officer. All significant operating decisions are based upon analysis of the Company as one operating segment, which is the same as its reporting segment to allocate resources, make operating decisions, and evaluate financial performance.

The CODM considers consolidated net income (loss) to be the financial measure of segment profit and loss for monitoring budget versus actual results, perform variance analysis, and forecast future performance.

The CODM considers the impact of the significant segment expenses on net income, which are the same expenses presented on the unaudited condensed consolidated statements of operations and comprehensive income (loss), with the impact of stock-based compensation removed from the operating expense categories and presented separately when making operating decisions.

The measure of segment assets is reported on the unaudited condensed consolidated balance sheets as total assets. The CODM does not review segment assets at a level other than that presented in the Company's unaudited condensed consolidated balance sheets.

Revenue by geographic area is based on the delivery address of the customer and is summarized as follows (in thousands):

	Three Months Ended March 31,
	2025		2024
United States	$	17,333	$	12,901
United Kingdom	1,207		856
Other	2,564		993
Total revenues	$	21,104	$	14,750

Other than the United States, no individual country exceeded 10% of total revenues for the three or three months ended March 31, 2025 and March 31, 2024.

The Company’s long-lived assets are composed of property and equipment and right of use assets, net, and are summarized by geographic area as follows (in thousands):

	March 31, 2025		December 31, 2024
United States	$	134	$	167
International	74		73
Total long-lived assets, net	$	208	$	240

Note 11. Revision of Previously Issued Quarterly Information (Unaudited)

The unaudited condensed consolidated statements of cash flows for the interim period March 31, 2024 have been revised to correct for prior period errors as discussed in Note 1. Basis of Presentation. The effect on the unaudited condensed consolidated statements of cash flows for the affected period is as follows (in thousands):

30

	Three Months Ended March 31, 2024
(unaudited)	As Reported		Adjustments		As Revised
Cash flows from operating activities
Other, net	$	(680)	$	(17)	$	(697)
Net cash used in operating activities	$	(3,339)	$	(17)	$	(3,356)
Cash flows from investing activities
Purchase of intangible assets	$	(54)	$	17	$	(37)
Net cash used in investing activities	$	(54)	$	17	$	(37)
Cash flows from financing activities
Proceeds from short-term borrowings	$	28,941	$	(21,688)	$	7,253
Payments of short-term borrowings	(31,392)		21,688		(9,704)
Net cash provided by financing activities	$	5,233	$	—	$	5,233

31

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto included elsewhere in this Report and in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Form 10-K and Form 10-K/A. Certain statements we make under the following discussion and analysis constitute “forward-looking statements” under the Reform Act. See “Cautionary Note Regarding Forward-Looking Statements” in this Report. You should consider our forward-looking statements in light of the risks discussed in our unaudited condensed consolidated financial statements, related notes and other financial information appearing elsewhere in this Report, the section entitled “Risk Factors” in our Form 10–K, Form 10-K/A and this Report, and our other filings with the SEC. Note that amounts included in the following discussion and analysis are presented in thousands and may not sum due to rounding.

Overview

Our mission is to empower parents with the right information at the right time, to give them more peace of mind and help them find more joy in the journey of parenting. Our digital parenting platform aims to give parents real-time data and insights to help parents feel calmer and more confident. We believe that every parent deserves peace of mind and the opportunity to feel their well-rested best. We also believe that every child deserves to live a long, happy, and healthy life, and we are working to develop products to help facilitate that belief.

Components of Operating Results

Revenues

We recognize revenue primarily from products and the associated mobile applications. Revenues are recognized when control of goods and services is transferred to customers in an amount that reflects the consideration expected to be received by us in exchange for those goods and services. Substantially all of our revenues were derived from product sales.

Cost of Revenues

Cost of revenues consists of product costs, including contract manufacturing, shipping and handling, depreciation and amortization relating to tooling and manufacturing equipment and software, warranty replacement, fulfillment costs, warehousing, hosting and platform costs, and reserves for excess and obsolete inventory.

Operating Expenses

General and Administrative. General and administrative expenses consist primarily of salaries, benefits, stock-based compensation, and bonuses for finance and accounting, legal, human resources, operations, quality and administrative executives and employees; third-party legal, accounting, customer service, software, and other professional services; corporate travel and entertainment; depreciation and amortization of property and equipment, asset impairment charges, legal settlements, and facilities rent.

Sales and Marketing. Sales and marketing expenses consist primarily of salaries, commissions, benefits, stock-based compensation, and bonuses for sales and marketing employees and contractors; third-party marketing expenses such as social media and search engine marketing, retail marketing, email marketing, and print marketing.

Research and Development. Research and development expenses consist primarily of salaries, benefits, stock-based compensation, and bonuses for employees and contractors engaged in the design, development, maintenance, and testing of our products and platforms, including clinical testing.

Other Income (Expense)

Interest Income (Expense), Net. Interest income (expense), net consists of interest incurred on our outstanding borrowings and amortization of issuance costs. Interest income consists of interest earned on our money market account.

Common Stock Warrant Liability Adjustment. Mark to market adjustment to recognize the change in fair value of common stock warrant liabilities.

Other Income (Expense), Net. Other income (expense), net includes our net gain (loss) on foreign exchange transactions.

Income Tax Provision. Income tax provision consists primarily of U.S. federal and state income taxes related to the tax jurisdictions in which we conduct business.

Results of Operations

32

The following table sets forth our results of operations for the periods, indicated in thousands:

	Three Months Ended March 31,
	2025			2024
Revenues	$	21,104		$	14,750
Cost of revenues	9,778			8,203
Gross profit	11,326			6,547
Operating expenses:
General and administrative	7,092			6,050
Sales and marketing	4,002			3,896
Research and development	2,903			2,347
Total operating expenses	13,997			12,293
Operating loss	(2,671)			(5,746)
Other income (expense):
Interest expense, net	(991)			(161)
Common stock warrant liability adjustment	6,687			9,179
Other income (expense), net	12			2
Total other income (expense), net	5,708			9,020
Income before income tax provision	3,037			3,274
Income tax provision	(12)		—	—
Net income and comprehensive income	3,025			3,274
Accretion on convertible preferred stock	(847)			(1,328)
Allocation of net income to participating securities	(344)			(661)
Accretion on redeemable common stock	(21)			—
Allocation of net income to participating securities to redeemable common stockholders	14			—
Allocation of net income attributable to redeemable common stockholders	(79)			—
Net income attributable to redeemable common stockholders	86			—
Net income attributable to common stockholders	$	1,748		$	1,285
Net income per share attributable to common stockholders, basic	$	0.11		$	0.15
Weighted-average number of shares outstanding used to compute net income per share attributable to common stockholders, basic	15,383,287			8,740,059
Net income (loss) per share attributable to common stockholders, diluted	$	0.11		$	(0.51)
Weighted-average number of shares outstanding used to compute net income (loss) per share attributable to common stockholders, diluted	15,383,287			9,617,825
Net income per share attributable to redeemable common stockholders, basic	$	0.15		$	—
Weighted-average number of shares outstanding used to compute net income per share attributable to redeemable common stockholders, basic	562,500			—
Net income per share attributable to redeemable common stockholders, diluted	$	0.15		$	—
Weighted-average number of shares outstanding used to compute net income per share attributable to redeemable common stockholders, diluted	687,500			—

Revenues

	Three Months Ended March 31,				Change
(dollars in thousands)	2025		2024		$		%
Revenues	$	21,104	$	14,750	$	6,354	43.1	%

33

Revenues increased by $6,354, or 43.1%, from $14,750 for the three months ended March 31, 2024 to $21,104 for the three months ended March 31, 2025. The increase was primarily due to higher sales of Dream Sock and Dream Duo products. The higher sales of Dream Sock and Dream Duo products reflects an increase in consumer demand as compared to the same period in the prior year.

Cost of Revenues and Gross Profit

	Three Months Ended March 31,						Change
(dollars in thousands)	2025			2024			$		%
Cost of revenues	$	9,778		$	8,203		$	1,575	19.2	%
Gross profit	$	11,326		$	6,547		$	4,779	73.0	%
Gross margin	53.7		%	44.4		%

Cost of revenues increased by $1,575, or 19.2%, from $8,203 for the three months ended March 31, 2024 to $9,778 for the three months ended March 31, 2025. The increase was primarily due to the increase in product sales. Gross margin increased from 44.4% for the three months ended March 31, 2024 to 53.7% for the three months ended March 31, 2025 primarily due to higher revenue, favorable product mix, lower returns, improved fixed cost absorption, and lower direct product and fulfillment costs.

General and Administrative

	Three Months Ended March 31,				Change
(dollars in thousands)	2025		2024		$		%
General and administrative	$	7,092	$	6,050	$	1,042	17.2	%

General and administrative expense increased by $1,042, or 17.2%, from $6,050 for the three months ended March 31, 2024 to $7,092 for the three months ended March 31, 2025. The increase was driven primarily by litigation settlements and higher compensation expense, including accrued bonuses, the absence of a bad debt recovery, and an increase in headcount, partially offset by lower stock-based compensation expense as compared to the same period in the prior year.

Sales and Marketing

	Three Months Ended March 31,				Change
(dollars in thousands)	2025		2024		$		%
Sales and marketing	$	4,002	$	3,896	$	106	2.7	%

Sales and marketing expense increased by $106, or 2.7%, from $3,896 for the three months ended March 31, 2024 to $4,002 for the three months ended March 31, 2025. The increase was driven primarily by higher compensation expense due to accrued bonuses as compared to the same period in the prior year.

Research and Development

	Three Months Ended March 31,				Change
(dollars in thousands)	2025		2024		$		%
Research and development	$	2,903	$	2,347	$	556	23.7	%

Research and development expense increased by $556, or 23.7%, from $2,347 for the three months ended March 31, 2024 to $2,903 for the three months ended March 31, 2025. The increase was driven primarily by higher compensation expense, including accrued bonuses, an increase in headcount, and increased investment in research & development, as compared to the same period in the prior year.

34

Other Income (Expense), Net

	Three Months Ended March 31,				Change
(dollars in thousands)	2025		2024		$		%
Interest expense, net	$	(991)	$	(161)	$	(830)	515.5	%
Common stock warrant liability adjustment	$	6,687	$	9,179	$	(2,492)	(27.1	%)
Other income (expense), net	$	12	$	2	$	10	500.0	%

Interest expense increased by $830, from $161 for the three months ended March 31, 2024 to $991 for the three months ended March 31, 2025. The increase was driven primarily by interest and amortization of issuance costs related to the Company's term loan facility and asset-based revolving credit facility, which were entered into in September 2024.

For the three months ended March 31, 2025, we recognized a gain of $6,687 as compared to a gain of $9,179 for the same period in the prior year resulting from a smaller decrease in the fair value of common stock warrants outstanding. Additionally, the gain recognized for the three months ended March 31, 2025 included the decrease in fair value of the Series B Warrants that were issued in February 2024, which were not outstanding for the full period in the prior year.

Liquidity and Capital Resources

We fund our operations primarily with proceeds from issuances of our convertible preferred stock, issuances of our common stock, borrowings under our loan facilities, issuances of convertible promissory notes, and sales of our products and services. As of March 31, 2025, we had cash and cash equivalents of $16,310.

On February 17, 2023 we entered into private placement investment agreements with certain investors, pursuant to which we issued and sold to the investors (i) an aggregate of 30,000 shares of our Series A convertible preferred stock, par value $0.0001 per share and (ii) warrants to purchase an aggregate of 7,871,712 shares of our common stock, par value $0.0001 per share, (“Series A Warrants”) for an aggregate purchase price of $30,000.

The Series A convertible preferred stock is convertible into common stock at the option of the holder at any time after February 17, 2023 and ranks, with respect to dividend rights, rights of redemption and rights upon a liquidation event, (i) senior to the common stock and all other classes or series of our equity securities established after February 17, 2023, unless such shares or equity securities expressly provide that they rank in parity with or senior to the Series A convertible preferred stock with respect to dividend rights, rights of redemption or rights upon a liquidation event, (ii) on parity with each class or series of our equity securities established after February 17, 2023, the terms of which expressly provide that it ranks on parity with the Series A convertible preferred stock with respect to dividend rights, rights of redemption and rights upon a liquidation event and (iii) junior to each class or series of our equity securities established after February 17, 2023, the terms of which expressly provide that it ranks senior to the Series A convertible preferred stock with respect to dividend rights, rights of redemption and rights upon a liquidation event. On August 20, 2024, holders of the Series A Preferred Stock elected to convert an aggregate of 15,721 shares of Series A Preferred Stock in exchange for an aggregate of 2,291,686 shares of common stock. Except as otherwise provided in the certificate of designation relating to the Series A convertible preferred stock or as required by law, holders of shares of Series A convertible preferred stock are entitled to vote with the holders of shares of common stock (and any other class or series that may similarly be entitled to vote with the holders of common stock) on an as-converted to common stock basis at any annual or special meeting of our stockholders, and not as a separate class.

At any time from and after February 17, 2028, the holders of at least a majority of the then outstanding shares of Series A convertible preferred stock may specify a date and time or the occurrence of an event by vote or written consent that all, and not less than all, of the outstanding shares of Series A preferred stock will automatically be: (i) converted into shares of common stock at a conversion rate of 145.7726 per share (the "Conversion Rate"), (ii) subject to certain exceptions and limitations, redeemed for an amount per share of Series A preferred stock equal to the liquidation preference of one thousand dollars per share, plus all accrued or declared but unpaid dividends as of the redemption date and time or (iii) a combination of the foregoing.

Subject to certain exceptions, upon the occurrence of a fundamental change, voluntary or involuntary liquidation, dissolution or winding-up of the Company, we will be required to pay an amount per share of Series A convertible preferred stock equal to the greater of (i) one thousand dollars per share or (ii) the consideration per share of Series A convertible preferred stock as would have been payable had all such shares been converted to common stock immediately prior to the liquidation event, plus, in each case, the aggregate amount of all declared but unpaid dividends thereon to the date of final distribution to the holders of Series A convertible preferred stock.

35

Each of the Series A Warrants sold in the private placement offering is exercisable for one share of common stock at an exercise price of $4.66 per share, is immediately exercisable, and will expire on February 17, 2028. As the Series A Warrants could require cash settlement in certain scenarios, the warrants were classified as liabilities upon issuance and were initially recorded at an aggregate estimated fair value of $26,133 The total proceeds from the offering were first allocated to the liability classified warrants, based on their fair values, with the residual $3,867 allocated to the Series A convertible preferred stock. The Series A convertible stock is accreting to its redemption value, starting from the issuance date to the date at which the shares become redeemable on February 17, 2028. Accretion will be recorded as a deemed dividend. None of the Series A Warrants have been exercised as of March 31, 2025.

On February 25, 2024 we entered into a private placement investment agreement with certain investors, pursuant to which we issued and sold to the investors (i) an aggregate of 9,250 shares of our Series B convertible preferred stock, par value $0.0001 per share and (ii) warrants to purchase an aggregate of 1,799,021 shares of our common stock, par value $0.0001 per share (the “February 2024 Warrants”), for an aggregate gross purchase price of $9,250.

The Series B convertible preferred stock is convertible into common stock at the option of the holder at any time after February 29, 2024 and ranks, with respect to dividend rights, rights of redemption and rights upon a liquidation event, (i) equal to our Series A convertible preferred stock, (ii) senior to the common stock and all other classes or series of our equity securities established after February 29, 2024, unless such shares or equity securities expressly provide that they rank in parity with or senior to the Series B convertible preferred stock with respect to dividend rights, rights of redemption or rights upon a liquidation event, (iii) on parity with each class or series of our equity securities established after February 29, 2024, the terms of which expressly provide that it ranks on parity with the Series B convertible preferred stock with respect to dividend rights, rights of redemption and rights upon a liquidation event and (iv) junior to each class or series of our equity securities established after February 29, 2024, the terms of which expressly provide that it ranks senior to the Series B convertible preferred stock with respect to dividend rights, rights of redemption and rights upon a liquidation event. Except as otherwise provided in the certificate of designation relating to the Series B convertible preferred stock or as required by law, holders of shares of Series B convertible preferred stock are entitled to vote with the holders of shares of common stock (and any other class or series that may similarly be entitled to vote with the holders of common stock) on an as-converted to common stock basis at any annual or special meeting of our stockholders, and not as a separate class.

At any time from and after March 1, 2029, the holders of at least a majority of the then outstanding shares of Series B convertible preferred stock may specify a date and time or the occurrence of an event by vote or written consent that all, and not less than all, of the outstanding shares of Series B convertible preferred stock will automatically be: (i) converted into shares of common stock at a conversion rate of 129.6596 per share, (ii) subject to certain exceptions and limitations, redeemed for an amount per share of Series B preferred stock equal to the liquidation preference of one thousand dollars per share, plus all accrued or declared but unpaid dividends as of the redemption date and time or (iii) a combination of the foregoing.

Subject to certain exceptions, upon the occurrence of a fundamental change, voluntary or involuntary liquidation, dissolution or winding-up of the Company, we will be required to pay an amount per share of Series B convertible preferred stock equal to the greater of (i) one thousand dollars per share or (ii) the consideration per share of Series B convertible preferred stock as would have been payable had all such shares been converted to common stock immediately prior to the liquidation event, plus, in each case, the aggregate amount of all declared but unpaid dividends thereon to the date of final distribution to the holders of Series B convertible preferred stock. As of March 31, 2025, the redemption value for Series B convertible preferred stock is $9,250. None of the Series B convertible preferred stock had been converted as of March 31, 2025.

Each of the February 2024 Warrants sold in the private placement offering is exercisable for one share of common stock at an exercise price of $7.7125 per share, is immediately exercisable, and will expire on March 1, 2029. As the February 2024 Warrants could require cash settlement in certain scenarios, the February 2024 warrants were classified as liabilities upon issuance and were initially recorded at an aggregate estimated fair value of $6,856. The total proceeds from the offering were first allocated to the liability classified warrants, based on their fair values, with the residual $2,394 allocated to the Series B convertible preferred stock. The Series B convertible stock will accrete to its redemption value, starting from the issuance date to the date at which the shares become redeemable on March 1, 2029. Accretion will be recorded as a deemed dividend. None of the February 2024 Warrants have been exercised as of March 31, 2025.

We incurred $394 of issuance costs related to the offering. Issuance costs allocated to the preferred stock of $102 were recorded as a reduction to the Series B convertible preferred stock. Issuance costs allocated to the liability classified warrants of $292 were recorded as an expense within general and administrative expenses on the unaudited condensed consolidated statements of operations and comprehensive income (loss).

On September 11, 2024, we entered into the underwriting agreement and issued 3,135,136 shares of our common stock at a price to the public of $3.70 per share, less underwriting discounts and commissions. The net proceeds we received were $10,590. We provided the underwriter a discount of 7% off the offering price. In addition to the underwriter discount, the offering expenses with third parties were $863, of which $260 in issuance costs that were unpaid as of March 31, 2025. We also reimbursed the underwriters for $198 in fees and expenses, including legal expenses, out-of-pocket expenses, and clearing expenses. The issuance costs associated with the

36

September 2024 Offering were recorded as a reduction to additional paid-in capital on the unaudited condensed consolidated balance sheets.

Pursuant to the underwriting agreement, we also issued, as a portion of the underwriting compensation payable to the underwriter, a warrant to purchase up to 125,405 shares of our common stock (which was subsequently transferred to certain affiliates of the underwriter, the “Titan Warrants”). The Titan Warrants are initially exercisable on March 13, 2025 at an exercise price of $4.63 and have a term of five years from such initial exercise date. None of the Titan Warrants have been exercised as of March 31, 2025.

WTI Loan Facility

On September 11, 2024 (the “Effective Date”), we, as guarantor, and our wholly-owned subsidiary, Owlet Baby Care, Inc., a Delaware corporation (“OBCI,” and together with us, collectively, the “Loan Parties”), as the borrower, entered into a Loan Facility Agreement (the “Loan Facility Agreement”) with WTI Fund X, Inc. and WTI Fund XI, Inc. (collectively “WTI” for a term loan facility of up to $15,000 (the “WTI Loan Facility”).

The WTI Loan Facility consists of two tranches. The first tranche of $10,000 was available at closing and through September 30, 2024, with $2,500 of the first tranche availability extendable until December 31, 2024 (the “First Tranche Commitment”). We initiated our first drawdown under the WTI Loan Facility of $7,500 (the “Initial Loan”) shortly after closing. We agreed with WTI to extend the remaining $2,500 of the First Tranche Commitment to March 31, 2025. We ultimately elected not to draw on the remainder of the first tranche and, as a result, 62,500 unvested shares of redeemable common stock were forfeited on March 31, 2025. Once repaid, we cannot reborrow from the WTI Loan Facility.

The second tranche of $5,000 is available through August 15, 2025 (the “Second Tranche Commitment,” or together with the First Tranche Commitment, the “Loan Commitments”) upon achievement of (a) at least $48,600 in revenue for the period that commenced October 1, 2024 and ending June 30, 2025 (the “Second Tranche Condition Period”), (b) total cash burn during the Second Tranche Condition Period not to exceed $600 for such period, (c) receipt by us of at least $6,000 of net proceeds from an equity financing during a period commencing on the closing date and ending on the second tranche borrowing date, and (d) receipt by WTI of our then-current, board-approved operating and financing plan to WTI's satisfaction, as well as compliance with certain reporting conditions.

Interest on the outstanding principal amounts of any borrowing under the WTI Loan Facility accrues at a rate per annum equal to the sum of the prime rate plus 3.5%, with a floor of 12%. The interest rate on the outstanding principal amounts of any borrowing under the WTI Loan Facility for the three months ended March 31, 2025 was 12%. Commencing on November 1, 2025 through maturity on January 1, 2028, we are required to make monthly interest and principal payments. Loans under the WTI Loan Facility also accrue 2.5% in payment-in-kind interest (“PIK Interest”) compounded monthly, and PIK Interest payments will be due and payable upon maturity of the loans. Accrued coupon interest and accrued PIK interest are recorded within accrued and other expenses and within long-term debt, net respectively on the unaudited condensed consolidated balance sheets. Accrued PIK interest was $104 as of March 31, 2025.

We have the option to prepay the outstanding loans issued under the WTI Loan Facility in whole at any time by repaying all outstanding principal and accrued interest, as well as all scheduled unpaid interest on the loan, including PIK Interest, as if the loan continued to accrue interest through its stated maturity. Provided if our fully diluted market capitalization of our common stock is greater than or equal to $250,000 for 10 consecutive Trading Days, then so long as such prepayment is made within 60 days thereafter, the redemption price will be discounted by 30% of the total amount of all scheduled but unpaid interest (but excluding any PIK Interest, which will not be discounted).

The WTI Loan Facility contains certain reporting and operational covenants that we must meet in order to borrow funds under the Loan Commitments and not cause an event of default. Upon the occurrence of an event of default, WTI could elect to force redemption of the outstanding balances under the WTI Loan Facility, requiring us to pay all outstanding principal and accrued interest, as well as all scheduled unpaid interest on the loan, including PIK interest. Upon the occurrence of an event of default, we will also be required to pay default interest on any overdue balances at a rate of 5.0%. The WTI Loan Facility and any loans and obligations issued thereunder are collateralized by substantially all of our assets, with certain exceptions as set forth in the WTI Loan Facility, and are guaranteed by Owlet, Inc. As of March 31, 2025, we were in compliance with all covenants under the WTI Loan Facility.

As partial consideration for the availability and funding of the WTI Loan Facility, we and WTI Fund X, LLC (“Fund X”) and WTI Fund XI, LLC (“Fund XI”, and together with Fund X, the “WTI Funds”) entered into a Stock Issuance Agreement (the “WTI Stock Issuance Agreement”), dated as of the Effective Date. Pursuant to the WTI Stock Issuance Agreement, we issued to the WTI Funds an aggregate of 750,000 shares of redeemable common stock on the Effective Date, of which 62,500 shares of the redeemable common stock have been forfeited and the remaining 125,000 of unvested redeemable common stock are subject to forfeiture in the event that we do not draw on the remaining portion of the outstanding Loan Commitment. To the extent we do exercise our option under the Loan Commitments to issue additional debt, a number of forfeitable shares will 'vest' and no longer be subject to forfeiture based on the pro rata portion of the outstanding Loan Commitments drawn against.

37

The shares issued to WTI pursuant to the WTI Stock Issuance Agreement contain an embedded redemption option (the “Redemption Option”) such that WTI may elect to force us to redeem the shares that are no longer subject to forfeiture for a price of $8.40 per share. The Redemption Option may be exercised in whole or in part, at any time, from time to time, during the period commencing on the first trading day following the fifth anniversary of the Effective Date and continuing through the date which is 10 years after the Effective Date, subject to certain acceleration provisions set forth in the WTI Stock Issuance Agreement. Because the shares are redeemable at the option of the WTI Funds, the shares are recorded in mezzanine equity on the unaudited condensed consolidated balance sheets. The redeemable common shares were initially recorded at their fair value of $7.66 per share, which was an aggregate value of $4,308. The value of the redeemable common shares was determined using a combination of the value of our stock on the date of issuance and the theoretical value of a stand-alone put option valued using a Black-Scholes put option model discounted by a present value factor that considers the credit spread between an estimated Company specific discount rate and the risk-free rate of return. Because the shares are required to be redeemed at the option of WTI, based solely on the passage of time, and provided WTI did not elect to otherwise sell or transfer the shares beforehand, the carrying value of the shares will accrete to their redemption value of $8.40 per share from the issuance date through September 11, 2029, the date the Redemption Option first becomes exercisable.

We allocated the lender fees (including the fair value of the vested shares) and third-party debt issuance costs between the Initial Loan and the remaining, undrawn Loan Commitments. The costs allocated to the Initial Loan are accounted for as a discount and will be amortized across the term of the Initial Loan using the effective interest method. The costs allocated to the remaining, undrawn Loan Commitments are accounted for as loan commitment assets, which are being amortized to interest expense using the straight-line method over the commitment periods, due to uncertainty about our intent to access the Loan Commitment. The unamortized portion of the loan commitment assets was $424 as of March 31, 2025 and is recorded within Other assets on the unaudited condensed consolidated balance sheets.

We recognized $222 of interest expense related to the amortization of debt issuance costs of the WTI Loan Facility and $385 of interest expense related to the amortization of the loan commitment assets during the three months ended March 31, 2025.

ABL Line of Credit

On September 11, 2024, we, as guarantor, and our wholly-owned subsidiary, Owlet Baby Care, Inc., a Delaware corporation (“OBCI,” and together with us, collectively, the “Loan Parties”), as borrower, entered into a Credit and Security Agreement (the “Credit Agreement”) with the financial institutions party thereto from time to time as lenders (collectively the “Lenders”) and ABL OPCO LLC, a Delaware limited liability company, in its capacity as administrative agent for the Lenders.

The Credit Agreement provides for an asset-based revolving credit facility (the “ABL Line of Credit”) in a maximum principal amount of up to $15,000, which amount shall increase to $20,000 on September 11, 2025 (the “Revolving Commitment”). The ABL Line of Credit is collateralized by substantially all of our assets. Loans and other obligations under the Credit Agreement bear interest at a rate per annum equal to the 1-month Secured Overnight Financing Rate (subject to a floor of 3.5%) plus a margin, which varies between 7.5% and 8.5% depending on our earnings before interest, taxes, depreciation and amortization (“EBITDA”), provided that the interest rate shall not exceed the maximum rate permitted under applicable law.

The ABL Line of Credit matures on September 10, 2027 (the “Maturity Date”). If for any reason the Credit Agreement is terminated or all outstanding loans and other obligations are paid in full and the ABL Line of Credit is terminated before the Maturity Date, we will be obligated to pay a prepayment fee equal to a percentage of the then-current Revolving Commitment, which percentage decreases on certain anniversary of the closing date.

The Credit Agreement contains representations, warranties, covenants, and events of default customary for agreements of this type. OBCI's obligations under the Credit Agreement are: (i) fully and unconditionally guaranteed by Owlet, Inc.; and (ii) secured by a security interest in substantially all our personal property assets, including Owlet Inc.'s pledge of the outstanding capital stock of the Company. Among these covenants is a liquidity covenant requiring the Company to maintain liquidity of $4,000. Liquidity is defined as the sum of (x) Undrawn Availability (as defined in the Credit Agreement) on the asset-based line of credit, plus (y) unrestricted cash and funds held in deposit accounts. In addition, if the liquidity falls below $9,000, the Company is then subject to a minimum trailing-twelve-months EBITDA covenant as defined in the Credit Agreement. As of March 31, 2025, we were in compliance with all covenants under the Credit Agreement.

The unamortized portion of debt issuance costs related to the Credit Agreement as of March 31, 2025 was $557 and is recorded as a loan commitment asset within other assets on the unaudited condensed consolidated balance sheets. Issuance costs are amortized straight-line over the term of the Credit Agreement and recorded within interest income (expense), net on the unaudited condensed consolidated statements of operations and comprehensive income (loss)).

On March 31, 2025, there was $8,498 of outstanding borrowings, which is recorded as a current liability on the unaudited condensed consolidated balance sheets based on our intent and ability to repay the outstanding borrowings in the near term. The remaining borrowing base availability under the Credit Agreement was $46 as of March 31, 2025.

Financed Insurance Premium

38

In July 2024, we renewed our corporate directors & officers and employment liability policies and entered into several new short-term commercial premium finance agreements with First Insurance Funding totaling $941 to be paid within one year, accruing interest at a weighted average rate of 8.7%. As of March 31, 2025, the remaining principal balance on the combined financed insurance premiums was $313.

Funding Requirements and Going Concern

In accordance with ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), we have evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements.

Since inception, we have experienced recurring operating losses and generated negative cash flows from operations, resulting in an accumulated deficit of $265,170 as of March 31, 2025. During the three months ended March 31, 2025 and 2024, we had negative cash flows from operations of $5,925 and $3,356, respectively. As of March 31, 2025, we had $16,310 of cash on hand.

As we continue to address these financial conditions, management has undertaken the following actions:

•As described further in Note 7, “Common Stock Issuance, Redeemable Common Stock, Common Stock Warrants, and Convertible Preferred Stock” included in our unaudited condensed consolidated financial statements included in this Report, in September 2024, we issued 3,135,136 shares of our common stock and received net proceeds of $10,590 and in February 2024, the Company consummated a sale of preferred stock and warrants to purchase our common stock for a gross purchase price of $9,250.

•As described in Note 4, “Debt and Other Financing Arrangements” included in our unaudited condensed consolidated financial statements included in this Report, in September 2024, we entered into a loan facility agreement with WTI Fund X, Inc. and WTI Fund XI, Inc. (collectively “WTI” or “Lenders”) for a term loan facility of up to $15,000 (the “WTI Loan Facility”) and on September 11, 2024, we entered into an asset-based revolving credit facility (the “ABL Line of Credit”) with ABL OPCO LLC, as the lender, with a maximum revolving commitment amount of up to $15,000, with an additional $5,000 revolving commitment available on September 11, 2025. In connection with these transactions, we used our then-existing cash to repay and extinguish all borrowings outstanding under the line of credit and term loan agreement with Silicon Valley Bank, now a division of First Citizens Bank and Trust Company (“SVB”). As of March 31, 2025 we have borrowings of $7,500 under the WTI Loan Facility and $8,498 under the ABL Line of Credit.

Notwithstanding the above actions, we have experienced recurring operating losses, negative cash flows from operations since inception, and a low cash balance relative to current obligations which raise substantial doubt about our ability to continue as a going concern within one year after the date that the accompanying unaudited condensed consolidated financial statements are issued. The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis and accordingly, do not include any adjustments relating to the recoverability and classification of asset carrying amounts, or the amount and classification of liabilities that might result should we be unable to continue as a going concern.

We have not generated sufficient cash flows from operations to satisfy our capital requirements for the next twelve months. There can be no assurance that we will generate sufficient future cash flows from operations to fund our ongoing operations due to potential factors, including but not limited to inflation, recession, or reduced demand for our products. If revenues decrease from current levels, we may be unable to further reduce costs, or such reductions may limit our ability to pursue strategic initiatives and grow revenues in the future.

There can be no assurance that we will be able to obtain additional financing on terms acceptable to us, if at all. Failure to secure additional funding may require us to modify, delay or abandon some of our planned future development, or to otherwise enact further operating cost reductions, which could have a material adverse effect on our business, operating results, financial condition and ability to achieve our intended business objectives.

If we raise additional funds through further issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences, and privileges superior to those of holders of our common stock. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, our ability to continue to pursue our business objectives and to respond to business opportunities, challenges, or unforeseen circumstances could be significantly limited, and our business, financial condition, and results of operations could be materially adversely affected. We also could be required to seek funds through arrangements with partners or others that may require us to relinquish rights or jointly own some aspects of our technologies, products, or services that we would otherwise pursue on our own.

39

Cash Flows

The following table summarizes our cash flow (in thousands):

	Three Months Ended March 31,
	2025		2024
Net cash used in operating activities	$	(5,925)	$	(3,356)
Net cash used in investing activities	(110)		(37)
Net cash provided by financing activities	2,014		5,233
Net change in cash, cash equivalents, and restricted cash	$	(4,021)	$	1,840

Operating Activities

For the three months ended March 31, 2025, net cash used in operating activities was $5,925 as compared to net cash used in operating activities of $3,356 in the prior year. The change in operating cash flows was primarily driven by an increase in accounts receivable, which was $4,453 for the three months ended March 31, 2025 as compared to decrease in accounts receivable of $2,765 for the same period in the prior year.

Investing Activities

For the three months ended March 31, 2025, we used $110 to invest in various projects, primarily for the development of our new subscription app. For the three months ended March 31, 2024, we used substantially no cash for investing activities due to the prioritization of research and development projects that supported seeking regulatory clearances for our products.

Financing Activities

For the three months ended March 31, 2025 and 2024, net cash provided by financing activities was $2,014 and $5,233, respectively. The decrease is primarily driven by the proceeds raised by the Series B preferred stock offering in February 2024.

Critical Accounting Policies and Estimates

There have been no material changes from the critical accounting policies and estimates disclosed in our Form 10-K, other than policies disclosed in this Report.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this Item.

Item 4. Controls and Procedures.

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures (as such terms are defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to provide reasonable assurance that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our management, with the participation of our principal executive officer and principal financial officer, evaluated, as of March 31, 2025, the effectiveness of our disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective as of March 31, 2025 due to the material weaknesses in our internal control over financial reporting described below.

40

Material Weaknesses in Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13(a)-15(f) and 15(d)-15(f) under the Exchange Act. With the participation of the Chief Executive Officer and the Chief Financial Officer, management conducted an evaluation of the effectiveness of our internal control over financial reporting as of March 31, 2025 based on the guidelines established in the Internal Control—Integrated Framework (2013 framework) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on that evaluation, our management concluded that our internal control over financial reporting was not effective as of March 31, 2025 because of the material weaknesses described below.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company's annual or interim financial statements will not be prevented or detected on a timely basis.

We did not design and maintain an effective control environment commensurate with our financial reporting requirements. Specifically, we did not maintain a sufficient complement of personnel with an appropriate degree of internal controls and accounting knowledge, experience, and training commensurate with our accounting and financial reporting requirements. This material weakness contributed to the following material weaknesses:

•We did not design and maintain effective controls over the segregation of duties related to journal entries. Specifically, certain personnel have the ability to both create and post journal entries within the Company’s general ledger system. This material weakness did not result in any adjustments to the consolidated financial statements.

•We did not design and maintain effective controls over the accounting for the accuracy and existence of inventory, nor controls which verified the completeness and accuracy of accrued liabilities. Each of these material weaknesses resulted in immaterial adjustments within the year ended December 31, 2022 and the accrued liabilities material weakness resulted in immaterial adjustments within the year ended December 31, 2024, and in the interim period ended March 31,2025.

•We did not design and maintain effective controls over the accounting for debt and equity arrangements, including convertible preferred stock, warrant arrangements, and stock-based compensation modifications. Further, we did not design and maintain effective controls to verify the completeness and accuracy of sales returns and accrued sales tax. Each of these material weaknesses resulted in material adjustments to several account balances and disclosures in the consolidated financial statements as of and for the year ended December 31, 2019. The sales returns material weakness also resulted in immaterial adjustments to revenue and accrued and other expenses as of and for the year ended December 31, 2022. The convertible preferred stock and warrant arrangements material weakness and sales tax material weakness resulted in immaterial adjustments for the year ended December 31, 2024.

•We did not design and maintain effective controls related to the review of the statement of cash flows. This material weakness resulted in adjustments to various line items within the operating, investing, and financing categories of the cash flow and resulted in revisions to the previously issued consolidated statement of cash flows for the year ended December 31, 2023 and to the condensed consolidated statement of cash flows for the interim periods ended March 31, 2023, June 30, 2023, September 30, 2023, March 31, 2024, June 30, 2024, and September 30, 2024.

•We did not design and maintain effective controls over IT general controls for information systems that are relevant to the preparation of our consolidated financial statements. Specifically, we did not design and maintain (i) program change management controls to ensure that IT program and data changes affecting financial IT applications and underlying accounting records are identified, tested, authorized and implemented appropriately, (ii) user access controls to ensure appropriate segregation of duties and that adequately restrict user and privileged access to financial applications, programs, and data to appropriate Company personnel, (iii) computer operations controls to ensure that critical batch jobs are monitored, and data backups are authorized and monitored, and (iv) testing and approval controls for program development to ensure that new software development is aligned with business and IT requirements. This material weakness did not result in any adjustments to the consolidated financial statements.

Additionally, each of the material weaknesses described above could result in a misstatement of one or more account balances or disclosures that would result in a material misstatement to the interim or annual consolidated financial statements that would not be prevented or detected.

Remediation Plan

We have initiated a plan to remediate these material weaknesses. The remediation measures will be ongoing, and although not all inclusive, remediation measures include hiring additional accounting and financial reporting personnel and implementing additional policies, procedures and controls, all of which will result in future costs for the Company.

41

We have taken actions to improve our IT general controls, segregation of duties over journal entries controls, inventory controls, accrued liabilities, convertible preferred stock, warrant arrangements, sales returns and accrued sales tax controls.

During the year ended December 31, 2024, we took actions to enhance the design of the controls we believe are necessary to remediate the material weaknesses related to the accrued sales tax that we believe will remediate the material weakness. Further, we made enhancements to the design of the control over the statement of cash flows that will support the remediation of the material weakness. As we continue to make progress towards remediation of these material weaknesses, we may determine the need to make further enhancements to the design of these controls. We continue to take actions to enhance the design of the controls we believe are necessary to remediate the material weaknesses related to sales returns and the accounting for debt and equity arrangements, including convertible preferred stock and warrant arrangements. While these enhancements to the design of the controls have been implemented as of September 30, 2024, we may determine the need to make further enhancements to the design of these controls. The material weaknesses will not be considered remediated until our remediation plan has been fully implemented, the applicable controls operate for a sufficient period of time, and we have concluded, through testing, that the newly implemented and enhanced controls are operating effectively.

Notwithstanding the above, our management believes that the unaudited condensed consolidated financial statements included in this Report state fairly in all material respects our financial position, results of operations and cash flows for the periods presented.

Changes in Internal Control over Financial Reporting

As described in the remediation efforts above, there were changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the three months ended March 31, 2025 that have materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

42

PART II

Item 1. Legal Proceedings.

From time to time, we may become involved in various legal proceedings that arise in the ordinary course of business. We evaluate any claims and lawsuits with respect to their potential merits, our potential defenses and counterclaims, and the expected effect on us of defending the claims and a potential adverse result. However, the results of any litigation, investigations or other legal proceedings are inherently unpredictable and expensive. Any claims against us, whether meritorious or not, could be time consuming, result in costly litigation, damage to our reputation, and divert significant resources. If any legal proceedings were to be determined adversely to us, or we were to enter into a settlement agreement, we could be exposed to monetary damages or limits on our ability to operate our business, which could have an adverse effect on our business, financial condition and operating results. For a description of our legal proceedings, see Note 5, Commitments and Contingencies within the Notes to Condensed Consolidated Financial Statements included elsewhere in this Report, which is incorporated herein by reference.

Item 1A. Risk Factors.

In addition to the information contained in this Report, you should carefully consider the risk factors disclosed in our Form 10-K and Form 10-K/A, which risk factors are incorporated herein by reference, which could materially affect our business, financial condition or results.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

There were no unregistered sales of equity securities for the three months ended March 31, 2025.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

(a) None.

(b) None.

(c) During the three months ended March 31, 2025, no directors or "officers" (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted, modified or terminated "Rule 10b5-1 trading arrangements" and/or "non-Rule 10b5-1 trading arrangements" (each as defined in Item 408 of Regulation S-K) for the purchase or sale of securities of the Company, whether or not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act.

During the three months ended March 31, 2025, the Company did not adopt, modify or terminate a "Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K ) for the purchase or sale of securities of the Company, whether or not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act.

43

Item 6. Exhibits

Exhibit Number	Description	Form	File No.	Exhibit	Filing Date
31.1*	Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**	Certification of the Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*	Inline XBRL Instance Document-the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH*	Inline XBRL Taxonomy Extension Schema Document.
101.CAL*	Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*	Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*	Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104*	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

*Filed herewith

**Furnished herewith.

44

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Company Name
Date: May 8, 2025	By:	/s/ Kurt Workman
	Name:	Kurt Workman
	Title:	Chief Executive Officer
		(Principal Executive Officer)
Date: May 8, 2025	By:	/s/ Amanda Crawford
	Name:	Amanda Crawford
	Title:	Chief Financial Officer
		(Principal Financial Officer and Principal Accounting Officer)

45

EX-31.1

Exhibit 31.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
PURSUANT TO RULE 13a-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kurt Workman, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Owlet, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 8, 2025	By:	/s/ Kurt Workman
		Kurt Workman
		Chief Executive Officer (Principal Executive Officer)

EX-31.2

Exhibit 31.2

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
PURSUANT TO RULE 13a-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Amanda Crawford, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Owlet, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 8, 2025	By:	/s/ Amanda Crawford
		Amanda Crawford
		Chief Financial Officer (Principal Financial Officer)

EX-32.1

Exhibit 32.1

CERTIFICATIONS OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned officers of Owlet, Inc., a Delaware corporation (the “Company”), does hereby certify, to the best of such officer’s knowledge, that in connection with the Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the “Report”):

(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 8, 2025	By:	/s/ Kurt Workman
		Kurt Workman
		Chief Executive Officer (Principal Executive Officer)

Date: May 8, 2025	By:	/s/ Amanda Crawford
		Amanda Crawford
		Chief Financial Officer (Principal Financial Officer)

XML

Cover Page - shares	3 Months Ended
	Mar. 31, 2025	May 06, 2025
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2025
Document Transition Report	false
Entity File Number	001-39516
Entity Registrant Name	OWLET, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-1615012
Entity Address, Address Line One	2940 West Maple Loop Drive
Entity Address, Address Line Two	Suite 203
Entity Address, City or Town	Lehi
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84043
City Area Code	(844)
Local Phone Number	334-5330
Title of 12(b) Security	Class A Common Stock, $0.0001 par value per share
Trading Symbol	OWLT
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		16,524,690
Amendment Flag	false
Entity Central Index Key	0001816708
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31

XML

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 16,310	$ 20,245
Restricted cash	300	386
Accounts receivable, net of allowance for credit losses of $811 and $653, respectively	16,525	12,136
Inventory	11,813	10,523
Prepaid expenses and other current assets	3,467	2,823
Total current assets	48,415	46,113
Property and equipment, net	99	102
Right of use assets, net	109	138
Intangible assets, net	1,049	975
Other assets	1,725	2,187
Total assets	51,397	49,515
Current liabilities:
Accounts payable	12,708	11,281
Accrued and other expenses	16,478	16,378
Current portion of deferred revenues	1,457	1,404
Line of credit	8,498	6,263
Current portion of long-term and other debt	1,554	1,103
Total current liabilities	40,695	36,429
Long-term debt, net	3,846	4,331
Common stock warrant liabilities	18,656	25,343
Other long-term liabilities	200	226
Total liabilities	63,397	66,329
Commitments and Contingencies
Mezzanine equity:
Mezzanine equity	13,806	12,937
Stockholders’ deficit:
Common stock, $0.0001 par value, 107,142,857 shares authorized as of March 31, 2025 and December 31, 2024; 15,808,849 and 15,725,783 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively	2	2
Additional paid-in capital	239,362	238,442
Accumulated deficit	(265,170)	(268,195)
Total stockholders’ deficit	(25,806)	(29,751)
Total liabilities, mezzanine equity, and stockholders' deficit	51,397	49,515
Series A Convertible Preferred Stock
Mezzanine equity:
Mezzanine equity	5,651	5,151
Series B Convertible Preferred Stock
Mezzanine equity:
Mezzanine equity	3,800	3,452
Redeemable Common Stock
Mezzanine equity:
Mezzanine equity	$ 4,355	$ 4,334

XML

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2025	Dec. 31, 2024
Allowance for doubtful accounts	$ 811	$ 653
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	107,142,857	107,142,857
Common stock, shares issued (in shares)	15,808,849	15,725,783
Common stock, shares outstanding (in shares)	15,808,849	15,725,783
Series A Convertible Preferred Stock
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares issued (in shares)	11,479	11,479
Preferred stock, shares outstanding (in shares)	11,479	11,479
Series B Convertible Preferred Stock
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares issued (in shares)	9,250	9,250
Preferred stock, shares outstanding (in shares)	9,250	9,250
Redeemable Common Stock
Preferred stock, shares issued (in shares)	687,500	750,000
Preferred stock, shares outstanding (in shares)	687,500	750,000

XML

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Revenues	$ 21,104	$ 14,750
Cost of revenues	9,778	8,203
Gross profit	11,326	6,547
Operating expenses:
General and administrative	7,092	6,050
Sales and marketing	4,002	3,896
Research and development	2,903	2,347
Total operating expenses	13,997	12,293
Operating loss	(2,671)	(5,746)
Other income (expense):
Interest expense, net	(991)	(161)
Common stock warrant liability adjustment	6,687	9,179
Other income (expense), net	12	2
Total other income (expense), net	5,708	9,020
Income before income tax provision	3,037	3,274
Income tax provision	(12)	0
Net income and comprehensive income	3,025	3,274
Accretion on convertible preferred stock	(847)	(1,328)
Allocation of net income to participating securities	(344)	(661)
Accretion on redeemable common stock	(21)	0
Allocation of net income to participating securities to redeemable common stockholders	14	0
Allocation of net income attributable to redeemable common stockholders	(79)	0
Net income attributable to redeemable common stockholders	86	0
Net income attributable to common stockholders	1,748	1,285
Net income attributable to common stockholders	$ 1,748	$ 1,285
Net income per share attributable to common stockholders, basic (in dollars per share)	$ 0.11	$ 0.15
Weighted-average common shares outstanding, basic (in shares)	15,383,287	8,740,059
Net income per share attributable to common stockholders, diluted (in dollars per share)	$ 0.11	$ (0.51)
Weighted-average number of shares outstanding, diluted (in shares)	15,383,287	9,617,825
Redeemable Common Stock
Other income (expense):
Net income per share attributable to common stockholders, basic (in dollars per share)	$ 0.15	$ 0
Weighted-average common shares outstanding, basic (in shares)	562,500	0
Net income per share attributable to common stockholders, diluted (in dollars per share)	$ 0.15	$ 0
Weighted-average number of shares outstanding, diluted (in shares)	687,500	0

XML

Condensed Consolidated Statements of Changes in Mezzanine Equity and Stockholder's Deficit - USD ($) $ in Thousands	Total	Series A Convertible Preferred Stock	Series B Convertible Preferred Stock	Redeemable Common Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2023		28,628	0
Beginning balance at Dec. 31, 2023		$ 7,855	$ 0
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of preferred stock (in shares)			9,250
Issuance of convertible preferred stock			$ 2,394
Preferred stock issuance costs			(102)
Accretion on convertible preferred stock		$ 1,212	$ 116
Conversion of preferred stock (in shares)		(1,178)
Conversion of preferred stock		$ (332)
Ending balance (in shares) at Mar. 31, 2024		27,450	9,250
Ending balance at Mar. 31, 2024		$ 8,735	$ 2,408
Beginning balance (in shares) at Dec. 31, 2023					8,797,456
Beginning balance at Dec. 31, 2023	$ (37,531)				$ 1	$ 218,127	$ (255,659)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accretion on convertible preferred stock	(1,328)					(1,328)
Conversion of preferred stock (in shares)					171,719
Conversion of preferred stock	332					332
Issuance of common stock for restricted stock units vesting (in shares)					22,437
Issuance of common stock for restricted stock units vesting	0					0
Issuance of common stock for employee stock purchase plans (in shares)					22,791
Issuance of common stock for employee stock purchase plan	92					92
Stock-based compensation	2,227					2,227
Net income	3,274						3,274
Ending balance (in shares) at Mar. 31, 2024					9,014,403
Ending balance at Mar. 31, 2024	(32,934)				$ 1	219,450	(252,385)
Beginning balance (in shares) at Dec. 31, 2023		28,628	0
Beginning balance at Dec. 31, 2023		$ 7,855	$ 0
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of convertible preferred stock				$ 4,308
Ending balance (in shares) at Dec. 31, 2024		11,479	9,250	750,000
Ending balance at Dec. 31, 2024	12,937	$ 5,151	$ 3,452	$ 4,334
Beginning balance (in shares) at Dec. 31, 2023					8,797,456
Beginning balance at Dec. 31, 2023	(37,531)				$ 1	218,127	(255,659)
Ending balance (in shares) at Dec. 31, 2024					15,725,783
Ending balance at Dec. 31, 2024	(29,751)				$ 2	238,442	(268,195)
Increase (Decrease) in Temporary Equity [Roll Forward]
Accretion on convertible preferred stock		$ 500	$ 348
Accretion on redeemable common stock				$ 21
Ending balance (in shares) at Mar. 31, 2025		11,479	9,250	687,500
Ending balance at Mar. 31, 2025	13,806	$ 5,651	$ 3,800	$ 4,355
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accretion on convertible preferred stock	(847)					(847)
Accretion on redeemable common stock	(21)					(21)
Common stock issuance costs	7					7
Forfeiture of redeemable common stock (in shares)				(62,500)
Issuance of common stock for restricted stock units vesting (in shares)					56,149
Issuance of common stock for employee stock purchase plans (in shares)					26,917
Issuance of common stock for employee stock purchase plan	97					97
Stock-based compensation	1,684					1,684
Net income	3,025						3,025
Ending balance (in shares) at Mar. 31, 2025					15,808,849
Ending balance at Mar. 31, 2025	$ (25,806)				$ 2	$ 239,362	$ (265,170)

XML

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Cash flows from operating activities
Net income	$ 3,025	$ 3,274
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation and amortization	119	109
Stock-based compensation	1,657	2,227
Provision for credit losses	64	(388)
Common stock warrant liability adjustment	(6,687)	(9,179)
Impairment of intangible and other assets	5	9
Amortization of right of use assets	29	356
Amortization of issuance costs	659
Other adjustments, net	169	16
Changes in assets and liabilities:
Accounts receivable	(4,453)	2,765
Prepaid expenses and other assets	(619)	555
Inventory	(1,408)	(1,245)
Deferred revenue	1,520	(1,158)
Lease liabilities	(48)	(477)
Other liabilities	0	(201)
Deferred revenue	42	(22)
Other, net	1	3
Net cash used in operating activities	(5,925)	(3,356)
Cash flows from investing activities
Purchase of property and equipment	(4)	0
Purchase of intangible assets	0	(37)
Capitalized internal-use software development costs	(106)	0
Net cash used in investing activities	(110)	(37)
Cash flows from financing activities
Proceeds from issuance of preferred stock, net of $0 and $158 of paid transaction costs, respectively	0	9,092
Proceeds from short-term borrowings	13,424	7,253
Payments of short-term borrowings	(11,491)	(9,704)
Payments of long-term borrowings	0	(1,500)
Employee taxes paid related to the net share settlement of stock-based awards	(395)	(31)
Proceeds related to the issuance of common stock under stock plans	395	31
Issuance costs paid related to 2024 preferred stock and warrants	(16)	0
Other, net	97	92
Net cash provided by financing activities	2,014	5,233
Net change in cash, cash equivalents, and restricted cash	(4,021)	1,840
Cash, cash equivalents, and restricted cash at beginning of period	20,631	16,557
Cash, cash equivalents, and restricted cash at end of period	16,610	18,397
Supplemental disclosure of non-cash investing and financing activities:
Cash paid for interest	357	419
Purchases of property and equipment included in accounts payable	26	3
Purchases of intangible assets included in accounts payable	33	13
Conversion of preferred stock	0	332
Accretion on preferred stock and redeemable common stock	869	1,328
Equity issuance costs included in accounts payable and accrued liabilities	260	235
Reclassification from long-term to current debt	753	0
Stock-based compensation for software development	$ 27	$ 0

XML

Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Statement of Cash Flows [Abstract]
Payments of costs related to the issuance of preferred stock and warrants	$ 0	$ 158

XML

Basis of Presentation

3 Months Ended

Mar. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

Basis of Presentation

As used in these financial statements, unless otherwise stated or the context otherwise requires: “we,” “us,” “our,” “Owlet,” the “Company,” and similar references refer to Owlet, Inc. and its subsidiaries, “common stock” refers to our Class A common stock.

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and applicable rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. The condensed consolidated balance sheet as of December 31, 2024, included herein, was derived from the audited consolidated financial statements as of that date, but does not include all disclosures including certain notes required by U.S. GAAP on an annual reporting basis. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary for the fair statement of the Company’s financial position, results of operations, and cash flows for the interim periods presented. All dollar amounts, except per share amounts, in the notes are presented in thousands, unless otherwise specified.

Certain prior year amounts have been reclassified to conform to the current period presentation.

Risks and Uncertainties

In accordance with ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements included in this quarterly report on Form 10-Q are issued.

Since inception, the Company has experienced recurring operating losses and generated negative cash flows from operations, resulting in an accumulated deficit of $265,170 as of March 31, 2025. During the three months ended March 31, 2025 and 2024, the Company had negative cash flows from operations of $5,925 and $3,356, respectively. As of March 31, 2025, the Company had $16,310 of cash on hand.

As the Company continues to address these financial conditions, management has undertaken the following actions:

•As described further in Note 7, Common Stock Issuance, Redeemable Common Stock, Common Stock Warrants, and Convertible Preferred Stock, in September 2024, the Company issued 3,135,136 shares of its common stock and received net proceeds of $10,590 and in February 2024, the Company consummated a sale of preferred stock and warrants to purchase its common stock for a gross purchase price of $9,250.

•As described in Note 4, Debt and Other Financing Arrangements, in September 2024, the Company entered into a loan facility agreement with WTI Fund X, Inc. and WTI Fund XI, Inc. (collectively “WTI” or “Lenders”) for a term loan facility of up to $15,000 (the “WTI Loan Facility”) and on September 11, 2024, the Company entered into an asset-based revolving credit facility (the “ABL Line of Credit”) with ABL OPCO LLC, as the lender, with a maximum revolving commitment amount of up to $15,000, with an additional $5,000 revolving commitment available on September 11, 2025. In connection with these transactions, the Company used its then-existing cash to repay and extinguish all borrowings outstanding under the line of credit and term loan agreement with Silicon Valley Bank, now a division of First Citizens Bank and Trust Company (“SVB”). As of March 31, 2025, the Company has borrowings of $7,500 under the WTI Loan Facility and $8,498 under the ABL Line of Credit.

Notwithstanding the above actions, the Company has experienced recurring operating losses, negative cash flows from operations since inception, and a low cash balance relative to current obligations that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the accompanying unaudited condensed consolidated financial statements are issued. The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis and accordingly, do not include any adjustments relating to the recoverability and classification of asset carrying amounts, or the amount and classification of liabilities that might result should the Company be unable to continue as a going concern.

The Company has not generated sufficient cash flows from operations to satisfy its capital requirements. There can be no assurance that the Company will generate sufficient future cash flows from operations due to potential factors, including but not limited to inflation, recession, or reduced demand for the Company’s products. If revenues decrease from current levels, the Company may be unable to further reduce costs, or such reductions may limit its ability to pursue strategic initiatives and grow revenues in the future.

There can be no assurance that the Company will be able to obtain additional financing on terms acceptable to it, if at all. Failure to secure additional funding may require the Company to modify, delay or abandon some of its planned future development, or to

otherwise enact further operating cost reductions, which could have a material adverse effect on its business, operating results, financial condition and ability to achieve its intended business objectives.

If the Company raises additional funds through further issuances of equity or convertible debt securities, its existing stockholders could suffer significant dilution, and any new equity securities the Company issues could have rights, preferences, and privileges superior to those of holders of its common stock. If the Company is unable to obtain adequate financing or financing on terms satisfactory to the Company when it requires it, its ability to continue to pursue its business objectives and to respond to business opportunities, challenges, or unforeseen circumstances could be significantly limited, and its business, financial condition, and results of operations could be materially adversely affected. The Company also could be required to seek funds through arrangements with partners or others that may require the Company to relinquish rights or jointly own some aspects of its technologies, products, or services that the Company would otherwise pursue on its own.

The Company maintains its cash in bank deposit accounts which, at times, exceed federally insured limits. As of March 31, 2025, substantially all of the Company’s cash was held with Silicon Valley Bank and Citibank, and exceeded federally insured limits.

Although the Company’s sales and accounts receivable are derived from sales contracts with a large number of customers, its top several customers account for a significant amount of its total sales, and make up a correspondingly large portion of its accounts receivable. The Company's largest customers by total net accounts receivable consisted of the following:

	March 31, 2025		December 31, 2024
Three largest customers by total net accounts receivable	63	%	63	%

The Company's largest customers by total net revenue consisted of the following:

	Three Months Ended March 31,
	2025		2024
Customer 1	37	%	25	%
Customer 2	14	%	20	%
Customer 3	6	%	12	%

Revisions to Previously Issued Condensed Consolidated Financial Statements and Financial Information

In connection with the preparation of its 2024 financial statements, the Company identified errors in the unaudited condensed consolidated statements of cash flows for the interim period ended March 31, 2024. Specifically, the Company’s historical proceeds from short-term borrowings and payments of short-term borrowings were overstated by the same amount with no net impact to total cash flows from financing activities in its unaudited condensed consolidated statements of cash flows for the interim period ended March 31, 2024. Additionally, the Company also identified and corrected for immaterial classification errors between cash flows from operating activities and investing activities for the interim period ended March 31, 2024.

The Company assessed the effect of the errors on prior periods under the guidance of Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin No. 99, “Materiality,” codified in ASC 250, Accounting Changes and Error Corrections (“ASC 250”). Based on its assessment, the Company determined that the errors were not material to any previously issued financial statements; however, the Company has elected to revise the Company's unaudited condensed consolidated statements of cash flows. These corrections have no impact on the Company's previously reported consolidated net income (loss), financial position, net change in cash, cash equivalents, and restricted cash, or total cash, cash equivalents, and restricted cash as previously reported on the Company's unaudited condensed consolidated statements of cash flows. The Company's unaudited condensed consolidated statements of cash flows for the interim period ended March 31, 2024, have been revised and disclosed in Note 11, Revision of Previously Issued Quarterly Information (Unaudited) below.

Recently Adopted Accounting Pronouncements

In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. The Company adopted ASU 2023-07 as of January 1, 2024 on a retrospective basis. While the adoption of this standard did not have a material impact on the Company's unaudited condensed consolidated financial statements, additional disclosures are included in Note 10.

Recently Issued Accounting Guidance

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires, among other things, additional disclosures primarily related to the income tax rate reconciliation and income taxes paid. The expanded annual disclosures are effective for our year ending December 31, 2025. The Company is currently evaluating the impact

that ASU 2023-09 will have on its consolidated financial statements and whether the Company will apply the standard prospectively or retrospectively.

In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses. The standard is intended to require more detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to all prior periods presented in the financial statements. The Company is currently assessing the impact this standard will have on its consolidated financial statements.

XML

Certain Balance Sheet Accounts

3 Months Ended

Mar. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Certain Balance Sheet Accounts

Certain Balance Sheet Accounts

Restricted Cash

The Company’s restricted cash consists of cash collateral that is held by the Company’s financial institutions to secure its financing arrangements. Specifically, restricted cash that is classified within current assets in the unaudited condensed consolidated balance sheets consists of cash collateral to secure its current credit card borrowings. Cash as reported on the unaudited condensed consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted cash as shown on the unaudited condensed consolidated balance sheets and consists of the following (in thousands):

	March 31,
	2025		2024
Reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets:
Cash and cash equivalents	$	16,310	$	18,397
Restricted cash	300		—
Total cash, cash equivalents, and restricted cash	$	16,610	$	18,397

Allowance for Credit and Other Losses

The Company records its accounts receivable at sales value and maintains an allowance for its current estimate of expected credit losses from customers. Provisions for expected credit losses are estimated based on historical experience, assessment of specific risk, review of outstanding invoices, and forecasts about the future. The Company establishes specific reserves for customers in an adverse financial condition and adjusts for its expectations of changes in conditions that may impact the collectability of outstanding receivables.

Changes in the Company's allowance for credit and other losses were as follows (in thousands):

	Three Months Ended March 31,
	2025		2024
Beginning balance	$	653	$	3,322
Charges to expense	95		(388)
Charges to revenue	63		56
Write-offs	—		(2,490)
Ending balance	$	811	$	500

Write-offs for the three months ended March 31, 2024 related to a settlement agreement with a former retailer for past due receivables which had previously been charged to the provision for credit losses in a prior period. A benefit was recognized to charges to expense during the three months ended March 31, 2024, which represented a partial recovery of the past due receivables in connection with the settlement.

Inventory

Details of inventory were as follows (in thousands):

	March 31, 2025		December 31, 2024
Raw materials	$	140	$	100
Finished goods	11,673		10,423
Total inventory	$	11,813	$	10,523

Property and Equipment, net

Property and equipment consisted of the following (in thousands):

	March 31, 2025		December 31, 2024
Tooling and manufacturing equipment	$	2,649	$	2,618
Computer equipment	307		322
Furniture and fixtures	289		289
Software	106		106
Leasehold improvements	3		35
Total property and equipment	3,354		3,370
Less: accumulated depreciation and amortization	(3,255)		(3,268)
Property and equipment, net	$	99	$	102

Depreciation and amortization expense on property and equipment was $33 and $93 for the three months ended March 31, 2025 and March 31, 2024, respectively. For the three months ended March 31, 2025 and March 31, 2024, the Company allocated $29 and $85, respectively, of depreciation and amortization expense related to tooling and manufacturing equipment within cost of revenues on the unaudited condensed consolidated statements of operations and comprehensive income (loss). The remaining depreciation and amortization expense related to property and equipment was recorded within general and administrative expenses.

Intangible Assets, net

The carrying amounts of intangible assets consisted of the following (in thousands):

	March 31, 2025
	Gross carrying amount		Accumulated amortization		Net carrying amount
Trademarks and patents	$	705	$	(367)	$	338
Internally developed software	857		(146)		711
Total intangible assets	$	1,562	$	(513)	$	1,049

	December 31, 2024
	Gross carrying amount		Accumulated amortization		Net carrying amount
Trademarks and patents	$	677	$	(346)	$	331
Internally developed software	725		(81)		644
Total intangible assets	$	1,402	$	(427)	$	975

Amortization expense of intangible assets was $86 and $16 for the three months ended March 31, 2025 and 2024, respectively. For the three months ended March 31, 2025 and 2024, the Company recorded $65 and $0, respectively, of amortization expense related to internally developed software within cost of revenues on the unaudited condensed consolidated statements of operations and comprehensive income (loss). The remaining amortization expense related to trademarks and patents was recorded within general and administrative expenses.

As of March 31, 2025, the estimated future amortization expenses and reconciliation to total intangible assets consisted of the following (in thousands):

March 31, 2025	Amount
Remaining nine months of 2025	$	262
2026	347
2027	255
2028	47
2029	27
Thereafter	45
Total future amortization expenses	$	983
Trademarks and patents not yet subject to amortization	66
Total intangible assets	$	1,049

Accrued and Other Expenses

Accrued and other expenses consisted of the following (in thousands):

	March 31, 2025		December 31, 2024
Accrued payroll	$	4,042	$	3,639
Accrued sales discounts	1,495		1,773
Accrued sales returns	891		902
Accrued legal settlements	5,925		5,343
Other	4,125		4,721
Total accrued and other expenses	$	16,478	$	16,378

Changes in accrued warranty were as follows (in thousands):

	Three Months Ended March 31,
	2025		2024
Accrued warranty, beginning of period	$	291	$	782
Settlements of warranty claims during the period	(187)		(191)
Provision for warranties issued during the period	124		319
Changes in provision for pre-existing warranties	77		(142)
Accrued warranty, end of period	$	305	$	768

XML

Deferred Revenues

3 Months Ended

Mar. 31, 2025

Deferred Revenue [Abstract]

Deferred Revenues

Deferred Revenues

Deferred revenues relate to performance obligations for which payments are received from customers prior to the satisfaction of the Company’s obligations to its customers. Deferred revenues primarily consist of amounts allocated to the mobile application, unspecified upgrade rights, added features, bug fixes, and content, subscription services, and are recognized over the service period of the performance obligations, which range from 1 to 27 months.

Changes in the total deferred revenues balance were as follows (in thousands):

	Three Months Ended March 31,
	2025		2024
Beginning balance	$	1,544	$	1,302
Deferral of revenues	743		521
Recognition of deferred revenues	(702)		(543)
Ending balance	$	1,585	$	1,280

The Company recognized $574 and $477 of revenue during the three months ended March 31, 2025 and 2024, respectively, that was included in the deferred revenue balance at the beginning of the respective period. Revenue for the three months ended March 31, 2025 included a reduction of revenue of $451 relating to the correction of immaterial misstatements from previous periods. Revenue for the three months ended March 31, 2024 included $330 relating to the correction of immaterial misstatements from previous periods.

XML

Debt and Other Financing Arrangements

3 Months Ended

Mar. 31, 2025

Debt Disclosure [Abstract]

Debt and Other Financing Arrangements

Debt and Other Financing Arrangements

The Company’s indebtedness consisted of the following (in thousands):

	March 31, 2025		December 31, 2024
Term loan facility payable to WTI, net	$	5,088	$	4,819
Line of credit	8,498		6,263
Financed insurance premium	313		615
Total debt	13,899		11,697
Less: current portion	(10,053)		(7,366)
Total long-term debt, net	$	3,846	$	4,331

The carrying value of the Company’s long-term debt, net approximate its fair value.

SVB Revolver and Term Loan

On November 23, 2022, the Company entered into the Third Amended and Restated Loan and Security Agreement (as amended, the “LSA”) with Silicon Valley Bank, now a division of First Citizens Bank and Trust Company ("SVB"). The LSA provided for a $10,000 revolving line of credit (the “SVB Revolver”) and for an $8,500 term loan, which amortized with equal monthly installments of $500. On September 11, 2024, the Company terminated the LSA with SVB and used existing cash to prepay and extinguish all borrowings outstanding under the line of credit and term loan facilities with SVB.

WTI Loan Facility

On September 11, 2024 (the “Effective Date”), the Company, as guarantor, and its wholly-owned subsidiary, Owlet Baby Care, Inc., a Delaware corporation ("OBCI," and together with the Company, collectively, the "Loan Parties"), as the borrower, entered into a Loan Facility Agreement (the “Loan Facility Agreement”) with WTI Fund X, Inc. and WTI Fund XI, Inc. (collectively “WTI” for a term loan facility of up to $15,000 (the “WTI Loan Facility”).

The WTI Loan Facility consists of two tranches. The first tranche of $10,000 was available at closing and through September 30, 2024, with $2,500 of the first tranche availability extendable until December 31, 2024 (the “First Tranche Commitment”). The second tranche of $5,000 is available through August 15, 2025 (the ‘Second Tranche Commitment,” or together with the First Tranche Commitment, the “Loan Commitments”) upon achievement of (a) at least $48,600 in revenue for the period that commenced October 1, 2024 and ending June 30, 2025 (the “Second Tranche Condition Period”), (b) total cash burn during the Second Tranche Condition Period not to exceed $600 for such period, (c) receipt by the Company of at least $6,000 of net proceeds from an equity financing during a period commencing on the closing date and ending on the second tranche borrowing date, and (d) receipt by WTI of the Company’s then-current, board-approved operating and financing plan to WTI's satisfaction, as well as compliance with certain reporting conditions.

The Company initiated its first drawdown under the WTI Loan Facility of $7,500 (the “Initial Loan”) shortly after closing. WTI and the Company agreed to extend the remaining $2,500 of the First Tranche Commitment until March 31, 2025. The Company ultimately elected not to draw on the remainder of the first tranche and, as a result, 62,500 unvested shares of redeemable common stock were forfeited on March 31, 2025. Once repaid, the Company cannot reborrow from the WTI Loan Facility.

Interest on the outstanding principal amounts of any borrowing under the WTI Loan Facility accrues at a rate per annum equal to the sum of the prime rate plus 3.5%, with a floor of 12%. The interest rate on the outstanding principal amounts of any borrowing under the WTI Loan Facility for the three months ended March 31, 2025 was 12%. Commencing on November 1, 2025 through maturity on January 1, 2028, the Company is required to make monthly interest and principal payments. Loans under the WTI Loan Facility also accrue 2.5% in payment-in-kind interest (“PIK Interest”) compounded monthly, and PIK Interest payments will be due and payable upon maturity of the loans. Accrued coupon interest and accrued PIK interest are recorded within accrued and other expenses and within long-term debt, net, respectively on the unaudited condensed consolidated balance sheets. Accrued PIK interest was $104 as of March 31, 2025.

The Company has the option to prepay the outstanding loans issued under the WTI Loan Facility in whole at any time by repaying all outstanding principal and accrued interest, as well as all scheduled unpaid interest on the loan, including PIK Interest, as if the loan continued to accrue interest through its stated maturity. Provided if the Company’s fully diluted market capitalization of its common stock is greater than or equal to $250,000 for 10 consecutive Trading Days, then so long as such prepayment is made within 60 days thereafter, the redemption price will be discounted by 30% of the total amount of all scheduled but unpaid interest (but excluding any PIK Interest, which will not be discounted).

The WTI Loan Facility contains certain reporting and operational covenants that must be met by the Company to borrow funds under the Loan Commitments and not cause an event of default. Upon the occurrence of an event of default, WTI could elect to force

redemption of the outstanding balances under the WTI Loan Facility, requiring the Company to pay all outstanding principal and accrued interest, as well as all scheduled unpaid interest on the loan, including PIK interest. Upon the occurrence of an event of default, the Company will also be required to pay default interest on any overdue balances at a rate of 5.0%. The WTI Loan Facility and any loans and obligations issued thereunder are collateralized by substantially all of the Company’s assets, with certain exceptions as set forth in the WTI Loan Facility, and are guaranteed by Owlet, Inc. As of March 31, 2025, the Company was in compliance with all covenants under the WTI Loan Facility.

As partial consideration for the availability and funding of the WTI Loan Facility, the Company and WTI Fund X, LLC (“Fund X”) and WTI Fund XI, LLC (“Fund XI”, and together with Fund X, the “WTI Funds”) entered into a Stock Issuance Agreement (the “WTI Stock Issuance Agreement”), dated as of the Effective Date. Pursuant to the WTI Stock Issuance Agreement, the Company issued to the WTI Funds an aggregate of 750,000 shares of redeemable common stock on the Effective Date, of which 62,500 shares of the redeemable common stock have been forfeited and the remaining 125,000 of unvested redeemable common stock are subject to forfeiture in the event that the Company does not draw on the remaining portion of the outstanding Loan Commitment. To the extent the Company does exercise its option under the Loan Commitments to issue additional debt, a number of forfeitable shares will 'vest' and no longer be subject to forfeiture based on the pro rata portion of the outstanding Loan Commitments drawn against.

The shares issued to WTI pursuant to the WTI Stock Issuance Agreement contain an embedded redemption option (the “Redemption Option”) such that WTI may elect to force the Company to redeem the shares that are no longer subject to forfeiture for a price of $8.40 per share. The Redemption Option may be exercised in whole or in part, at any time, from time to time, during the period commencing on the first trading day following the fifth anniversary of the Effective Date and continuing through the date which is 10 years after the Effective Date, subject to certain acceleration provisions set forth in the WTI Stock Issuance Agreement. Because the shares are redeemable at the option of the WTI Funds, the shares are recorded in mezzanine equity on the unaudited condensed consolidated balance sheets. The redeemable common shares were initially recorded at their fair value of $7.66 per share, which was an aggregate value of $4,308. The value of the redeemable common shares was determined using a combination of the value of the Company's stock on the date of issuance and the theoretical value of a stand-alone put option valued using a Black-Scholes put option model discounted by a present value factor that considers the credit spread between an estimated Company specific discount rate and the risk-free rate of return. Because the shares are required to be redeemed at the option of WTI, based solely on the passage of time, and provided WTI did not elect to otherwise sell or transfer the shares beforehand, the carrying value of the shares will accrete to their redemption value of $8.40 per share from the issuance date through September 11, 2029, the date the Redemption Option first becomes exercisable.

The Company allocated the lender fees (including the fair value of the vested shares) and third-party debt issuance costs between the Initial Loan and the remaining, undrawn Loan Commitments. The costs allocated to the Initial Loan are accounted for as a discount and will be amortized across the term of the Initial Loan using the effective interest method. The costs allocated to the remaining, undrawn Loan Commitments are accounted for as loan commitment assets, which are being amortized to interest expense using the straight-line method over the commitment periods, due to uncertainty about the Company's intent to access the Loan Commitment. The unamortized portion of the loan commitment assets was $424 as of March 31, 2025 and is recorded within Other assets on the unaudited condensed consolidated balance sheets.

As of March 31, 2025, details of the WTI Loan Facility were as follows (in thousands):

	Amount
Principal outstanding	$	7,500
Unamortized debt issuance costs	(2,516)
Accrued PIK Interest	104
Net carrying value	$	5,088

The Company recognized $222 of interest expense related to the amortization of debt issuance costs of the WTI Loan Facility and $385 of interest expense related to the amortization of the loan commitment assets during the three months ended March 31, 2025.

ABL Line of Credit

On the Effective Date, the Company, as guarantor, and its wholly-owned subsidiary, Owlet Baby Care, Inc., a Delaware corporation (“OBCI,” and together with the Company, collectively, the “Loan Parties”), as borrower, entered into a Credit and Security Agreement (the “Credit Agreement”) with the financial institutions party thereto from time to time as lenders (collectively the “Lenders”) and ABL OPCO LLC, a Delaware limited liability company, in its capacity as administrative agent for the Lenders.

The Credit Agreement provides for an asset-based revolving credit facility (the “ABL Line of Credit”) in a maximum principal amount of up to $15,000, which amount shall increase to $20,000 on September 11, 2025 (the “Revolving Commitment”). The ABL

Line of Credit is collateralized by substantially all of the Company's assets. Loans and other obligations under the Credit Agreement bear interest at a rate per annum equal to the 1-month Secured Overnight Financing Rate (subject to a floor of 3.5%) plus a margin, which varies between 7.5% and 8.5% depending on the Company’s earnings before interest, taxes, depreciation and amortization (“EBITDA”), provided that the interest rate shall not exceed the maximum rate permitted under applicable law.

The ABL Line of Credit matures on September 10, 2027 (the “Maturity Date”). If for any reason the Credit Agreement is terminated or all outstanding loans and other obligations are paid in full and the ABL Line of Credit is terminated before the Maturity Date, the Company will be obligated to pay a prepayment fee equal to a percentage of the then-current Revolving Commitment, which percentage decreases on certain anniversary of the closing date.

The Credit Agreement contains representations, warranties, covenants, and events of default customary for agreements of this type. OBCI’s obligations under the Credit Agreement are: (i) fully and unconditionally guaranteed by the Company; and (ii) secured by a security interest in substantially all personal property assets of the Company, including the Company's pledge of the outstanding capital stock of the Company. Among these covenants is a liquidity covenant requiring the Company to maintain liquidity of $4,000. Liquidity is defined as the sum of (x) Undrawn Availability, as defined in the Credit Agreement, on the asset-based line of credit, plus (y) unrestricted cash and funds held in deposit accounts. In addition, if the liquidity falls below $9,000, the Company is then subject to a minimum trailing-twelve-months EBITDA covenant as defined in the Credit Agreement. As of March 31, 2025, the Company was in compliance with all covenants under the Credit Agreement.

The unamortized portion of debt issuance costs related to the Credit Agreement as of March 31, 2025 was $557 and is recorded as a loan commitment asset within other assets on the unaudited condensed consolidated balance sheets. Issuance costs are amortized straight-line over the term of the Credit Agreement and recorded within interest income (expense), net on the unaudited condensed consolidated statement of operations and comprehensive income (loss).

On March 31, 2025, there was $8,498 of outstanding borrowings, which is recorded as a current liability on the unaudited condensed consolidated balance sheet based on the Company's intent and ability to repay the outstanding borrowings in the near term. The remaining borrowing base availability under the Credit Agreement was $46 as of March 31, 2025.

Financed Insurance Premiums

In 2024, the Company renewed a number of its insurance policies and entered into several new short-term commercial premium finance agreements with First Insurance Funding totaling $941 to be paid within one year, accruing interest at a weighted average rate of 8.7%. As of March 31, 2025, the remaining principal balance on the combined financed insurance premiums was $313.

Future Aggregate Maturities

As of March 31, 2025, future aggregate maturities of the WTI Loan Facility and Financed Insurance Premium payables were as follows (in thousands):

March 31, 2025	Amount
Remaining nine months of 2025	$	801
2026	3,146
2027	3,550
2028	420
Total	$	7,917

XML

Commitments and Contingencies

3 Months Ended

Mar. 31, 2025

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Commitments and Contingencies

Purchase and Other Obligations

The Company entered into a services and license agreement for cloud platform services in June 2024. The Company has a purchase obligation of $6,739 to be paid over a 48-month period beginning in June 2024 and $5,313 remains to be paid at March 31, 2025.

Litigation

The Company is involved in legal proceedings from time to time arising in the normal course of business. While any outcome related to such legal proceedings cannot be predicted with certainty, other than the matters discussed below, the Company believes that the outcome of these proceedings will not have a material impact on the Company’s financial position, results of operations, or liquidity.

In November 2021, two putative class action complaints were filed against the Company in the U.S. District Court for the Central District of California, the first captioned Butala v. Owlet, Inc., Case No. 2:21-cv-09016, and the second captioned Cherian v. Owlet,

Inc., Case No. 2:21-cv-09293. Both complaints alleged violations of the Securities Exchange Act of 1934 (“Exchange Act”) against the Company and certain of its officers and directors on behalf of a putative class of investors who: (a) purchased the Company’s common stock between March 31, 2021 and October 4, 2021 (“Section 10(b) Claims”); or (b) held common stock in Sandbridge Acquisition Corporation (“SBG”) as of June 1, 2021, and were eligible to vote at SBG's special meeting held on July 14, 2021 (“Section 14(a) Claims”). Both complaints allege, among other things, that the Company and certain of its officers and directors made false and/or misleading statements and failed to disclose certain information regarding the FDA’s likely classification of Smart Sock as a medical device requiring marketing authorization.

On September 8, 2023, the Court ruled that while the Butala and Cherian cases were consolidated, there would be two distinct and separate classes to represent the Section 10(b) Claims and Section 14(a) Claims, respectively, and appointed lead plaintiffs and lead counsel for each class. Amended complaints were filed for each class on November 21, 2023, and then further amended in consolidated filings on December 22, 2023. The Company filed motions to dismiss the complaints on February 9, 2024 on behalf of itself and the named officers and directors. The plaintiffs filed oppositions to the motions to dismiss on March 24, 2024, and the Company filed replies in support of the motions to dismiss on May 10, 2024. On August 5, 2024, the Court denied Owlet’s and its officers’ motions to dismiss the Section 10(b) Claims and the Section 14(a) Claims. On September 24, 2024, the Court entered a scheduling order in the case, setting trial to begin on February 17, 2026. On September 26, 2024, the Court granted Owlet’s and its officers’ motion for reconsideration regarding the Section 10(b) Claims and dismissed all claims arising out of statements made prior to the merger.

Following mediation, the parties to the Butala action reached agreements in principle to settle both the Section 10(b) Claims and the Section 14(a) Claims. The Section 10(b) Claims would be resolved for $3,500 and the Section 14(a) Claims would be resolved for $1,750. On January 31, 2025, the plaintiffs filed motions seeking preliminary approval of the settlements of the Section 10(b) Claims and Section 14(a) Claims. Those motions remain pending. In accordance with ASC 450, as these amounts have become probable and estimable, the Company recognized $5,250 of general and administrative expense in the consolidated statement of operations and comprehensive income (loss) for the year ended December 31, 2024. The related liability is recorded in accrued and other expenses on the unaudited condensed consolidated balance sheet as of March 31, 2025.

Further, on August 26, 2024 and October 3, 2024, investors filed in the U.S. District Court for the Central District of California, derivatively on behalf of the Company, complaints asserting claims for violations of Section 14(a) of the Exchange Act, as well as state law claims, including breach of fiduciary duty, unjust enrichment and waste of corporate assets. One complaint (captioned Janet Vargas, Derivatively on Behalf of Nominal Defendant Owlet, Inc., Case No. 2:24 cv-07258-FLA-PVC) asserts claims against twelve of the Company’s current or former directors and officers and six current or former directors and officers of Sandbridge Acquisition Corporation. The other (captioned Nathan Capleton, Derivatively on Behalf of Nominal Defendant Owlet, Inc., Case No. 2:24 cv-08536-JAK-MAA) asserts claims against eleven of the Company’s current or former directors. Both complaints leverage the allegations made in one of the securities class action complaints. Neither complaint specifies the damages claimed in the action.

On December 13, 2024, these two complaints were consolidated into a single action captioned Vargas v. Workman, et al., No. 2:24-cv-07258-FLA (C.D. Cal.) On February 7, 2025, the plaintiffs filed an amended consolidated complaint asserting the claims previously made in the two derivative complaints. The parties in the Vargas action reached agreements in principle to settle, and plaintiffs filed a joint Notice of Settlement with the Court on March 3, 2025. On March 6, 2025, the Court vacated deadlines in the Vargas action in light of the plaintiffs’ settlement notice, and set April 2, 2025 as the deadline for plaintiffs to file a motion for preliminary approval of the settlement. On March 31, 2025, the plaintiffs filed a joint stipulation with the Court to extend that deadline to April 9, 2025. The Court so ordered the stipulation on April 2, 2025, and the plaintiffs filed the motion for preliminary approval of the settlement on April 9, 2025.

In accordance with ASC 450, as these amounts have become probable and estimable, the Company recognized $675 of general and administrative expense in the unaudited condensed consolidated statements of operations and comprehensive income (loss) for the three months ended March 31, 2025. The related liability is recorded in accrued and other expenses on the unaudited condensed consolidated balance sheet as of March 31, 2025.

Indemnification

In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless, and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors’ and officers’ insurance coverage that may reduce its exposure and enables the Company to recover a portion of any future amounts paid.

XML

Stock-based Compensation

3 Months Ended

Mar. 31, 2025

Share-Based Payment Arrangement [Abstract]

Stock-based Compensation

Stock-based Compensation

The Company has various stock compensation plans, which are more fully described in Part II, Item 8 “Financial Statements and Supplementary Data - Note 8 to the Consolidated Financial Statements - Stock-based Compensation” in its 2024 Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Under the 2021 Incentive Award Plan, the Company has the ability to grant options, stock appreciation rights, restricted stock awards (“RSAs”), restricted stock units (“RSUs”), performance stock units (“PSUs”), dividend equivalents, or other stock or cash-based awards to employees, directors, or consultants. Option awards are generally granted with an exercise price equal to the fair value of the Company’s common stock at the date of grant. Options and PSU awards generally vest over a period of four years. RSUs are subject to a four year vesting term with 25% vesting after one year and quarterly thereafter, or on a 2 year vesting term with 50% after one year and the remaining after the second year, or a 1 year vesting term with 100% after one year, depending on grant reason. RSAs generally vest over less than one year. Grants to directors typically vest after one year and, in certain circumstances, vest immediately.

Stock-based Compensation Expense

Total stock-based compensation was recognized as follows (in thousands):

	Three Months Ended March 31,
	2025		2024
General and administrative	$	779	$	1,283
Sales and marketing	455		344
Research and development	423		600
Total stock-based compensation	$	1,657	$	2,227

During the three months ended March 31, 2025, the Company capitalized $27 of stock-based compensation attributable to internally developed software. There was no stock-based compensation capitalized during the three months ended March 31, 2024.

During 2024, the Company modified certain RSU awards for 11 employees and exchanged the RSUs previously granted for RSAs that would vest within six months of the date of modification. The RSAs are valued at the market value on the date of grant. As a result of the modification, the Company recognized $43 of incremental stock-based compensation expense during the three months ended March 31, 2025. As of March 31, 2025, the Company had $2 of incremental unrecognized stock-based compensation costs related to unvested RSAs that will be recognized over a weighted-average period of 0.1 years.

As of March 31, 2025, the Company had $5,815 of unrecognized stock-based compensation costs related to unvested RSUs that will be recognized over a weighted-average period of 1.2 years; and $101 of unrecognized stock-based compensation costs related to unvested PSUs that will be recognized over a weighted-average period of 0.8 years.

XML

Common Stock Issuance, Redeemable Common Stock, Common Stock Warrants, and Convertible Preferred Stock

3 Months Ended

Mar. 31, 2025

Equity [Abstract]

Common Stock Issuance, Redeemable Common Stock, Common Stock Warrants, and Convertible Preferred Stock

Common Stock Issuance, Redeemable Common Stock, Common Stock Warrants, and Convertible Preferred Stock

September 2024 Offering

On September 11, 2024, the Company entered into an underwriting agreement and issued 3,135,136 shares of its common stock at a price to the public of $3.70 per share, less underwriting discounts and commissions. The net proceeds received by the Company were $10,590. The shares were issued pursuant to the Company’s registration statement on Form S-3 (File No. 333-281556), filed by the Company with the SEC on August 14, 2024, which was declared effective on August 23, 2024. The Company provided the underwriter a discount of 7% off the offering price.

In addition to the underwriter discount, the offering expenses with third parties were $863, of which $260 in issuance costs that were unpaid as of March 31, 2025. The Company also reimbursed the underwriters for $198 in fees and expenses, including legal expenses, out-of-pocket expenses, and clearing expenses. The issuance costs associated with the September 2024 Offering were recorded as a reduction to additional paid-in capital on the unaudited condensed consolidated balance sheet.

Pursuant to the underwriting agreement, the Company also issued, as a portion of the underwriting compensation payable to the underwriter, a warrant to purchase up to 125,405 shares of common stock (which was subsequently transferred to certain affiliates of the underwriter, the “Titan Warrants”). The Titan Warrants are accounted as a nonemployee stock-based award as it represents compensation for underwriter services. The compensation cost associated with the Titan Warrants was $382, and was recorded as a direct and incremental issuance cost of the associated common stock offering that was earned upon the closing and issuance of the common stock. The Titan Warrants are classified as equity and included within additional paid-in capital on the unaudited condensed consolidated balance sheets.

The Titan Warrants are initially exercisable on March 13, 2025 at an exercise price of $4.63 and have a term of five years from such initial exercise date. None of the Titan Warrants have been exercised as of March 31, 2025.

Redeemable Common Stock

As discussed in Note 4, in September 2024 as partial consideration for the availability and funding of the WTI Loan Facility, the Company issued to the WTI Funds an aggregate of 750,000 shares of common stock. The Company also granted the WTI Funds the Redeemable Option discussed in Note 4. The vested shares are recorded in mezzanine equity on the unaudited condensed consolidated balance sheets and are being accreted to the redemption value at the date the redemption feature first becomes exercisable.

August 2024 Exchange

On August 20, 2024, holders of the Series A convertible preferred stock (“Series A Preferred Stock”) of the Company elected to convert an aggregate of 15,721 shares of Series A Preferred Stock in exchange for an aggregate of 2,291,686 shares of the Company’s common stock, all as in accordance with the terms of the Certificate of Designation relating to the Series A Preferred Stock. As of March 31, 2025, the redemption value for the remaining Series A convertible preferred stock is $11,479.

February 2024 Offering

On February 25, 2024, the Company entered into a private placement investment agreement with certain investors, pursuant to which the Company issued and sold to the investors (i) an aggregate of 9,250 shares of the Company’s Series B convertible preferred stock, par value $0.0001 per share and (ii) warrants to purchase an aggregate of 1,799,021 shares of the Company's common stock, par value $0.0001 per share (the “Series B Warrants”), for an aggregate gross purchase price of $9,250.

The Series B convertible preferred stock is convertible into common stock at the option of the holder at any time after February 29, 2024 and ranks, with respect to dividend rights, rights of redemption and rights upon a liquidation event, (i) equal to the Company’s Series A convertible preferred stock, (ii) senior to the common stock and all other classes or series of equity securities of the Company established after February 29, 2024, unless such shares or equity securities expressly provide that they rank in parity with or senior to the Series B convertible preferred stock with respect to dividend rights, rights of redemption or rights upon a liquidation event, (iii) on parity with each class or series of equity securities of the Company established after February 29, 2024, the terms of which expressly provide that it ranks on parity with the Series B convertible preferred stock with respect to dividend rights, rights of redemption and rights upon a liquidation event and (iv) junior to each class or series of equity securities of the Company established after February 29, 2024, the terms of which expressly provide that it ranks senior to the Series B convertible preferred stock with respect to dividend rights, rights of redemption and rights upon a liquidation event. Except as otherwise provided in the certificate of designation relating to the Series B convertible preferred stock or as required by law, holders of shares of Series B convertible preferred stock are entitled to vote with the holders of shares of common stock (and any other class or series that may similarly be entitled to vote with the holders of common stock) on an as-converted to common stock basis at any annual or special meeting of stockholders of the Company, and not as a separate class.

At any time from and after March 1, 2029, the holders of at least a majority of the then outstanding shares of Series B convertible preferred stock may specify a date and time or the occurrence of an event by vote or written consent that all, and not less than all, of

the outstanding shares of Series B convertible preferred stock will automatically be: (i) converted into shares of common stock at a conversion rate of 129.6596 per share, (ii) subject to certain exceptions and limitations, redeemed for an amount per share of Series B preferred stock equal to the liquidation preference of one thousand dollars per share, plus all accrued or declared but unpaid dividends as of the redemption date and time or (iii) a combination of the foregoing.

Subject to certain exceptions, upon the occurrence of a fundamental change, voluntary or involuntary liquidation, dissolution or winding-up of the Company, the Company will be required to pay an amount per share of Series B convertible preferred stock equal to the greater of (i) one thousand dollars per share or (ii) the consideration per share of Series B convertible preferred stock as would have been payable had all such shares been converted to common stock immediately prior to the liquidation event, plus, in each case, the aggregate amount of all declared but unpaid dividends thereon to the date of final distribution to the holders of Series B convertible preferred stock. As of March 31, 2025, the redemption value for Series B convertible preferred stock is $9,250. None of the Series B convertible preferred stock had been converted as of March 31, 2025.

Each of the Series B Warrants sold in the private placement offering is exercisable for one share of common stock at an exercise price of $7.71 per share, is immediately exercisable, and will expire on March 1, 2029. As the Series B Warrants could require cash settlement in certain scenarios, the warrants were classified as liabilities upon issuance and were initially recorded at an aggregate estimated fair value of $6,856. The total proceeds from the offering were first allocated to the liability classified warrants, based on their fair values, with the residual $2,394 allocated to the Series B convertible preferred stock. The Series B convertible stock will accrete to its redemption value, starting from the issuance date to the date at which the shares become redeemable on March 1, 2029. Accretion will be recorded as a deemed dividend. None of the Series B Warrants have been exercised as of March 31, 2025.

The Company incurred $394 of issuance costs related to the offering. Issuance costs allocated to the preferred stock of $102 were recorded as a reduction to the Series B convertible preferred stock. Issuance costs allocated to the liability classified warrants of $292 were recorded as an expense within general and administrative expenses on the unaudited condensed consolidated statements of operations and comprehensive income (loss).

February 2023 Offering

On February 17, 2023 the Company entered into private placement investment agreements with certain investors, pursuant to which the Company issued and sold to the investors (i) an aggregate of 30,000 shares of the Company’s Series A convertible preferred stock, par value $0.0001 per share and (ii) warrants to purchase an aggregate of 7,871,712 shares of the Company’s common stock, par value $0.0001 per share, (“Series A Warrants”) for an aggregate purchase price of $30,000.

The Series A convertible preferred stock is convertible into common stock at the option of the holder at any time after February 17, 2023 and ranks, with respect to dividend rights, rights of redemption and rights upon a liquidation event, (i) senior to the common stock and all other classes or series of equity securities of the Company established after February 17, 2023, unless such shares or equity securities expressly provide that they rank in parity with or senior to the Series A convertible preferred stock with respect to dividend rights, rights of redemption or rights upon a liquidation event, (ii) on parity with each class or series of equity securities of the Company established after the February 17, 2023, the terms of which expressly provide that it ranks on parity with the Series A convertible preferred stock with respect to dividend rights, rights of redemption and rights upon a liquidation event and (iii) junior to each class or series of equity securities of the Company established after February 17, 2023, the terms of which expressly provide that it ranks senior to the Series A convertible preferred stock with respect to dividend rights, rights of redemption and rights upon a liquidation event. Except as otherwise provided in the certificate of designation relating to the Series A convertible preferred stock or as required by law, holders of shares of Series A convertible preferred stock are entitled to vote with the holders of shares of common stock (and any other class or series that may similarly be entitled to vote with the holders of common stock) on an as-converted to common stock basis at any annual or special meeting of stockholders of the Company, and not as a separate class.

At any time from and after February 17, 2028, the holders of at least a majority of the then outstanding shares of Series A convertible preferred stock may specify a date and time or the occurrence of an event by vote or written consent that all, and not less than all, of the outstanding shares of Series A preferred stock will automatically be: (i) converted into shares of common stock at a conversion rate of 145.7726 per share (the "Conversion Rate"), (ii) subject to certain exceptions and limitations, redeemed for an amount per share of Series A preferred stock equal to the liquidation preference of one thousand dollars per share, plus all accrued or declared but unpaid dividends as of the redemption date and time or (iii) a combination of the foregoing.

Subject to certain exceptions, upon the occurrence of a fundamental change, voluntary or involuntary liquidation, dissolution or winding-up of the Company, the Company will be required to pay an amount per share of Series A convertible preferred stock equal to the greater of (i) one thousand dollars per share or (ii) the consideration per share of Series A convertible preferred stock as would have been payable had all such shares been converted to common stock immediately prior to the liquidation event, plus, in each case, the aggregate amount of all declared but unpaid dividends thereon to the date of final distribution to the holders of Series A convertible preferred stock.

Each of the Series A Warrants sold in the private placement offering is exercisable for one share of common stock at an exercise price of $4.66 per share, is immediately exercisable, and will expire on February 17, 2028. As the Series A Warrants could require cash settlement in certain scenarios, the warrants were classified as liabilities upon issuance and were initially recorded at an aggregate

estimated fair value of $26,133 The total proceeds from the offering were first allocated to the liability classified warrants, based on their fair values, with the residual $3,867 allocated to the Series A convertible preferred stock. The Series A convertible stock is accreting to its redemption value, starting from the issuance date to the date at which the shares become redeemable on February 17, 2028. Accretion will be recorded as a deemed dividend. None of the Series A Warrants have been exercised as of March 31, 2025.

SBG Common Stock Warrants

As a result of the merger completed with SBG on July 15, 2021 (the “Merger”), the Company continues to record liabilities for warrants issued by SBG prior to the Merger.

Pursuant to the SBG initial public offering, SBG sold warrants to purchase an aggregate of 821,428 shares of the Company’s common stock at a price of $161.00 per share (“SBG Public Warrants”). Following the closing of the Initial Public Offering on September 17, 2020, the Company completed the sale of warrants to purchase an aggregate of 471,428 shares of the Company’s common stock at a price of $161.00 per share in a private placement to Sandbridge Acquisition Holdings LLC (the “SBG Private Placement Warrants”). Together, the SBG Public Warrants and SBG Private Placement Warrants are referred to as the “SBG Common Stock Warrants.” The SBG Public Warrants became exercisable 12 months from the closing of the Initial Public Offering. The SBG Common Stock Warrants will expire five years after the completion of the Merger or earlier upon redemption or liquidation. None of the SBG Common Stock Warrants have been exercised as of March 31, 2025.

SVB Warrants

In March 2023, in connection with the first amendment to the LSA with SVB, the Company granted SVB a warrant to purchase 10,714 shares of the Company's common stock at a price of $5.32 per share, expiring on March 27, 2035 (the “SVB Warrants”). The SVB Warrants, which were valued at $43, are classified as equity and included within additional paid-in capital on the unaudited condensed consolidated balance sheets. None of the SVB Warrants have been exercised as of March 31, 2025.

Common Stock Warrants

The following table summarizes issuable shares of the Company’s common stock based on warrant activity for the three months ended March 31, 2025:

	December 31, 2024	Shares Issuable by New Warrants	Shares Purchased by Exercise	March 31, 2025
SBG Public Warrants	821,428	—	—	821,428
SBG Private Placement Warrants	471,428	—	—	471,428
Series A Warrants	7,871,712	—	—	7,871,712
Series B Warrants	1,799,021	—	—	1,799,021
SVB Warrants	10,714	—	—	10,714
Titan Warrants	125,405	—	—	125,405
Total	11,099,708	—	—	11,099,708

XML

Fair Value Measurements

3 Months Ended

Mar. 31, 2025

Fair Value Disclosures [Abstract]

Fair Value Measurements

Fair Value Measurements

The Company’s assets and liabilities measured and reported in the financial statements at fair value on a recurring basis were as follows (in thousands):

	March 31, 2025
	Level 1		Level 2		Level 3		Balance
Assets:
Money market funds	$	9,104	$	—	$	—	$	9,104
Total assets	$	9,104	$	—	$	—	$	9,104
Liabilities:
SBG Public Warrants	$	—	$	—	$	1	$	1
SBG Private Placement Warrants	—		—		1		1
Series A Warrants	—		—		15,263		15,263
Series B Warrants	—		—		3,391		3,391
Total liabilities	$	—	$	—	$	18,656	$	18,656
	December 31, 2024
	Level 1		Level 2		Level 3		Balance
Assets:
Money market funds	$	8,223	$	—	$	—	$	8,223
Total assets	$	8,223	$	—	$	—	$	8,223
Liabilities:
SBG Public Warrants	$	—	$	—	$	5	$	5
SBG Private Placement Warrants	—		—		2		2
Series A Warrants	—		—		20,750		20,750
Series B Warrants	—		—		4,586		4,586
Total liabilities	$	—	$	—	$	25,343	$	25,343

Money market funds are included within Level 1 of the fair value hierarchy because they are valued using quoted market prices.

The SBG Public Warrants and SBG Private Placement Warrants as of March 31, 2025 and December 31, 2024 are presented in Level 3 of the fair value hierarchy. On June 15, 2023, the Company received notice from the New York Stock Exchange (the “NYSE”) that the NYSE had halted trading in the SBG Public Warrants due to the low trading price of those warrants. On June 16, 2023, the NYSE provided written notice to the Company and publicly announced that NYSE Regulation had determined to commence proceedings to delist the SBG Public Warrants and that such warrants were no longer suitable for listing based on “abnormally low” price levels, pursuant to Section 802.01D of the NYSE Listed Company Manual. As such, these instruments are no longer valued using quoted market prices and correspondingly, the SBG Private Placement Warrants can no longer be valued based on a quoted market price of the SBG Public Warrants. The Company measured the fair value of both the SBG Public Warrants and the SBG Private Placement Warrants as of March 31, 2025 and December 31, 2024 using the Black-Scholes option pricing model with the following assumptions:

SBG Common Stock Warrants - Black-Scholes Inputs	March 31, 2025			December 31, 2024
OWLT stock price	$	3.68		$	4.45
Exercise price of warrants	$	161.00		$	161.00
Term in years	1.29			1.54
Risk-free interest rate	3.99		%	4.21		%
Volatility	90.00		%	90.00		%

The Series A Warrants are presented as Level 3 measurements, relying on unobservable inputs reflecting the Company’s own assumptions. Level 3 measurements, which are not based on quoted prices in active markets, introduce a higher degree of subjectivity and may be more sensitive to fluctuations in stock price, volatility rates, and U.S. Treasury Bond rates.

The Company measured the fair value of the Series A Warrants as of March 31, 2025 and December 31, 2024, using the Black-Scholes option pricing model with the following assumptions:

Series A Warrants - Black-Scholes Inputs	March 31, 2025			December 31, 2024
OWLT stock price	$	3.68		$	4.45
Exercise price of warrants	$	4.66		$	4.66
Term in years	2.88			3.13
Risk-free interest rate	3.89		%	4.28		%
Volatility	90.00		%	90.00		%

The Series B Warrants are presented as Level 3 measurements, relying on unobservable inputs reflecting the Company’s own assumptions. The Company measured the fair value of the Series B Warrants as of March 31, 2025 and December 31, 2024, using the Black-Scholes option pricing model with the following assumptions:

Series B Warrants - Black-Scholes Inputs	March 31, 2025			December 31, 2024
OWLT stock price	$	3.68		$	4.45
Exercise price of warrants	$	7.71		$	7.71
Term in years	3.91			4.16
Risk-free interest rate	3.92		%	4.33		%
Volatility	90.00		%	90.00		%

The following table presents a reconciliation of the Company’s SBG Public Warrants, SBG Private Placement Warrants, Series A Warrants, and Series B Warrants (together, the “Level 3 Warrants”) measured at fair value on a recurring basis as of March 31, 2025 (in thousands):

	Level 3 Warrants
Balance as of December 31, 2024	$	25,343
Change in fair value included within common stock warrant liability adjustment	(6,687)
Balance as of March 31, 2025	$	18,656

There were no transfers between Level 1 and Level 2 in the periods reported. The SBG Public Warrants and SBG Private Placement Warrants were transferred into Level 3 in 2023, as discussed above.

Equity-Classified Warrants

The fair value of the Titan Warrants on September 11, 2024 was $382. The Company measured the fair value of the Titan Warrants at issuance on September 11, 2024, using the Black-Scholes option pricing model with the following assumptions:

Titan Warrants - Black-Scholes Inputs	September 11, 2024
OWLT stock price	$	4.35
Exercise price of warrants	$	4.63
Term in years	5.50
Risk-free interest rate	3.47		%
Volatility	85.00		%

Mezzanine-Classified Redeemable Common Stock

As described in Note 4, the vested shares issued to WTI are contingently redeemable at the option of the holder during the put period and are recorded in mezzanine equity on the unaudited condensed consolidated balance sheets. The vested redeemable common shares were recorded at their fair value of $7.66 per share, which was an aggregate value of 4,308. The value of the redeemable common shares was determined using a combination of the value of the Company's stock on the date of issuance and the theoretical value of a stand-alone put option valued using a Black-Scholes put option model discounted by a present value factor that considers the credit

spread between an estimated Company specific discount rate and the risk-free rate of return. The valuation model used the following assumptions:

Redeemable Common Stock - Valuation Inputs	September 11, 2024
Common stock value per share	$	4.35
Put price	$	8.40
Term in years	5.00
Risk-free interest rate	3.42		%
Volatility	85.00		%
Credit spread	9.27		%
Present value discount	63.49		%

XML

Net Income (Loss) Per Share

3 Months Ended

Mar. 31, 2025

Earnings Per Share [Abstract]

Net Income (Loss) Per Share

Net Income (Loss) Per Share

Basic and diluted net income (loss) per share of common stock and redeemable common stock is presented in conformity with the two-class method required for participating securities. Under the two-class method, net income (loss) is allocated to each class of common stock and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.

The Company considers its convertible preferred stock and unvested redeemable common stock to be participating securities. Under the two-class method, the net loss attributable to common stockholders is not allocated to the convertible preferred stock as the holders of the Company’s convertible preferred stock do not have a contractual obligation to share in the Company’s losses.

The following tables present the calculation of basic and diluted net income (loss) per share (in thousands, except share and per share amounts):

	Three Months Ended March 31,
	2025		2025		2024
	Redeemable Common Stock		Common Stock		Common Stock
Numerator:
Allocation of net income attributable to common stockholders	$	79	$	2,946	$	3,274
Accretion on convertible preferred stock	—		(847)		(1,328)
Accretion on redeemable common stock	21		(21)		—
Allocation of net income to participating securities	$	(14)	$	(330)	$	(661)
Allocated net income attributable to common stockholders	$	86	$	1,748	$	1,285
Denominator:
Weighted average common shares outstanding, basic	562,500		15,383,287		8,740,059
Net income per share attributable to common stockholders, basic	$	0.15	$	0.11	$	0.15

	Three Months Ended March 31,
	2025		2025		2024
	Redeemable Common Stock		Common Stock		Common Stock
Numerator:
Allocation of net income attributable to common stockholders	$	79	$	2,946	$	3,274
Accretion on convertible preferred stock	—		(847)		(1,328)
Accretion on redeemable common stock	21		(21)		—
Allocation of net income to participating securities	—		(330)		—
Effect of dilutive securities	—		—		(6,809)
Allocated net income (loss) attributable to common stockholders	$	100	$	1,748	$	(4,863)
Denominator:
Weighted average common shares outstanding, basic	562,500		15,383,287		8,740,059
Effect of dilutive securities	125,000		0		877,766
Weighted average common shares outstanding, diluted	687,500		15,383,287		9,617,825
Net income (loss) per share attributable to common stockholders, diluted	$	0.15	$	0.11	$	(0.51)

The following table summarizes the common stock equivalents of potentially dilutive outstanding securities excluded from the computation of diluted net loss per share due to their anti-dilutive effect:

	March 31,
	2025	2024
Stock options	377,012	463,168
RSUs	1,450,316	1,526,327
RSAs	107,636	—
PSUs	56,391	71,428
ESPP shares committed	51,073	19,388
Common stock warrants	11,099,708	3,102,591
Preferred stock	2,872,668	5,200,802
Total	16,014,804	10,383,704

The Company’s 200,536 unvested earnout shares and 125,000 unvested shares issued to WTI described in Part II, Item 8 “Financial Statements and Supplementary Data - Note 9 to the Consolidated Financial Statements - Common Stock Issuance, Redeemable Common Stock, Common Stock Warrants, and Convertible Preferred Stock” in it Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and 107,636 unvested RSAs issued in connection to the RSU to RSA conversion that occurred during 2024 were excluded from the calculation of basic and diluted per share calculations as the vesting conditions have not yet been met as of March 31, 2025.

XML

Segments

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Segments

Segments

The Company operates as a single operating segment. The Company’s Chief Operating Decision Maker ("CODM") is its Chief Executive Officer. All significant operating decisions are based upon analysis of the Company as one operating segment, which is the same as its reporting segment to allocate resources, make operating decisions, and evaluate financial performance.

The CODM considers consolidated net income (loss) to be the financial measure of segment profit and loss for monitoring budget versus actual results, perform variance analysis, and forecast future performance.

The CODM considers the impact of the significant segment expenses on net income, which are the same expenses presented on the unaudited condensed consolidated statements of operations and comprehensive income (loss), with the impact of stock-based compensation removed from the operating expense categories and presented separately when making operating decisions.

The measure of segment assets is reported on the unaudited condensed consolidated balance sheets as total assets. The CODM does not review segment assets at a level other than that presented in the Company's unaudited condensed consolidated balance sheets.

Revenue by geographic area is based on the delivery address of the customer and is summarized as follows (in thousands):

	Three Months Ended March 31,
	2025		2024
United States	$	17,333	$	12,901
United Kingdom	1,207		856
Other	2,564		993
Total revenues	$	21,104	$	14,750

Other than the United States, no individual country exceeded 10% of total revenues for the three or three months ended March 31, 2025 and March 31, 2024.

The Company’s long-lived assets are composed of property and equipment and right of use assets, net, and are summarized by geographic area as follows (in thousands):

	March 31, 2025		December 31, 2024
United States	$	134	$	167
International	74		73
Total long-lived assets, net	$	208	$	240

XML

Revision of Previously Issued Quarterly Information (Unaudited)

3 Months Ended

Mar. 31, 2025

Accounting Changes and Error Corrections [Abstract]

Revision of Previously Issued Quarterly Information (Unaudited)

Revision of Previously Issued Quarterly Information (Unaudited)

The unaudited condensed consolidated statements of cash flows for the interim period March 31, 2024 have been revised to correct for prior period errors as discussed in Note 1. Basis of Presentation. The effect on the unaudited condensed consolidated statements of cash flows for the affected period is as follows (in thousands):

	Three Months Ended March 31, 2024
(unaudited)	As Reported		Adjustments		As Revised
Cash flows from operating activities
Other, net	$	(680)	$	(17)	$	(697)
Net cash used in operating activities	$	(3,339)	$	(17)	$	(3,356)
Cash flows from investing activities
Purchase of intangible assets	$	(54)	$	17	$	(37)
Net cash used in investing activities	$	(54)	$	17	$	(37)
Cash flows from financing activities
Proceeds from short-term borrowings	$	28,941	$	(21,688)	$	7,253
Payments of short-term borrowings	(31,392)		21,688		(9,704)
Net cash provided by financing activities	$	5,233	$	—	$	5,233

XML

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Pay vs Performance Disclosure
Net income	$ 3,025	$ 3,274

XML

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2025
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

XML

Basis of Presentation (Policies)

3 Months Ended

Mar. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation and Principles of Consolidation

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and applicable rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. The condensed consolidated balance sheet as of December 31, 2024, included herein, was derived from the audited consolidated financial statements as of that date, but does not include all disclosures including certain notes required by U.S. GAAP on an annual reporting basis. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary for the fair statement of the Company’s financial position, results of operations, and cash flows for the interim periods presented. All dollar amounts, except per share amounts, in the notes are presented in thousands, unless otherwise specified.

Reclassification

Certain prior year amounts have been reclassified to conform to the current period presentation.

Recently Adopted Accounting Pronouncements and Recently Issued Accounting Guidance

Recently Adopted Accounting Pronouncements

In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. The Company adopted ASU 2023-07 as of January 1, 2024 on a retrospective basis. While the adoption of this standard did not have a material impact on the Company's unaudited condensed consolidated financial statements, additional disclosures are included in Note 10.

Recently Issued Accounting Guidance

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires, among other things, additional disclosures primarily related to the income tax rate reconciliation and income taxes paid. The expanded annual disclosures are effective for our year ending December 31, 2025. The Company is currently evaluating the impact

that ASU 2023-09 will have on its consolidated financial statements and whether the Company will apply the standard prospectively or retrospectively.

In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses. The standard is intended to require more detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to all prior periods presented in the financial statements. The Company is currently assessing the impact this standard will have on its consolidated financial statements.

XML

Basis of Presentation (Tables)

3 Months Ended

Mar. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedules of Concentration of Risk, by Risk Factor

The Company's largest customers by total net accounts receivable consisted of the following:

	March 31, 2025		December 31, 2024
Three largest customers by total net accounts receivable	63	%	63	%

The Company's largest customers by total net revenue consisted of the following:

	Three Months Ended March 31,
	2025		2024
Customer 1	37	%	25	%
Customer 2	14	%	20	%
Customer 3	6	%	12	%

XML

Certain Balance Sheet Accounts (Tables)

3 Months Ended

Mar. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Cash and Cash Equivalents

Cash as reported on the unaudited condensed consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted cash as shown on the unaudited condensed consolidated balance sheets and consists of the following (in thousands):

	March 31,
	2025		2024
Reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets:
Cash and cash equivalents	$	16,310	$	18,397
Restricted cash	300		—
Total cash, cash equivalents, and restricted cash	$	16,610	$	18,397

Restrictions on Cash and Cash Equivalents

Cash as reported on the unaudited condensed consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted cash as shown on the unaudited condensed consolidated balance sheets and consists of the following (in thousands):

	March 31,
	2025		2024
Reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets:
Cash and cash equivalents	$	16,310	$	18,397
Restricted cash	300		—
Total cash, cash equivalents, and restricted cash	$	16,610	$	18,397

Schedule of Allowance for Credit Losses

Changes in the Company's allowance for credit and other losses were as follows (in thousands):

	Three Months Ended March 31,
	2025		2024
Beginning balance	$	653	$	3,322
Charges to expense	95		(388)
Charges to revenue	63		56
Write-offs	—		(2,490)
Ending balance	$	811	$	500

Schedule of Inventory

Details of inventory were as follows (in thousands):

	March 31, 2025		December 31, 2024
Raw materials	$	140	$	100
Finished goods	11,673		10,423
Total inventory	$	11,813	$	10,523

Schedule of Property and Equipment

Property and equipment consisted of the following (in thousands):

	March 31, 2025		December 31, 2024
Tooling and manufacturing equipment	$	2,649	$	2,618
Computer equipment	307		322
Furniture and fixtures	289		289
Software	106		106
Leasehold improvements	3		35
Total property and equipment	3,354		3,370
Less: accumulated depreciation and amortization	(3,255)		(3,268)
Property and equipment, net	$	99	$	102

Schedule of Finite-Lived Intangible Assets

The carrying amounts of intangible assets consisted of the following (in thousands):

	March 31, 2025
	Gross carrying amount		Accumulated amortization		Net carrying amount
Trademarks and patents	$	705	$	(367)	$	338
Internally developed software	857		(146)		711
Total intangible assets	$	1,562	$	(513)	$	1,049

	December 31, 2024
	Gross carrying amount		Accumulated amortization		Net carrying amount
Trademarks and patents	$	677	$	(346)	$	331
Internally developed software	725		(81)		644
Total intangible assets	$	1,402	$	(427)	$	975

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense

As of March 31, 2025, the estimated future amortization expenses and reconciliation to total intangible assets consisted of the following (in thousands):

March 31, 2025	Amount
Remaining nine months of 2025	$	262
2026	347
2027	255
2028	47
2029	27
Thereafter	45
Total future amortization expenses	$	983
Trademarks and patents not yet subject to amortization	66
Total intangible assets	$	1,049

Schedule of Accrued and Other Expenses

Accrued and other expenses consisted of the following (in thousands):

	March 31, 2025		December 31, 2024
Accrued payroll	$	4,042	$	3,639
Accrued sales discounts	1,495		1,773
Accrued sales returns	891		902
Accrued legal settlements	5,925		5,343
Other	4,125		4,721
Total accrued and other expenses	$	16,478	$	16,378

Schedule of Accrued Warranty

Changes in accrued warranty were as follows (in thousands):

	Three Months Ended March 31,
	2025		2024
Accrued warranty, beginning of period	$	291	$	782
Settlements of warranty claims during the period	(187)		(191)
Provision for warranties issued during the period	124		319
Changes in provision for pre-existing warranties	77		(142)
Accrued warranty, end of period	$	305	$	768

XML

Deferred Revenues (Tables)

3 Months Ended

Mar. 31, 2025

Deferred Revenue [Abstract]

Summary of Changes in the Total Deferred Revenues Balance

Changes in the total deferred revenues balance were as follows (in thousands):

	Three Months Ended March 31,
	2025		2024
Beginning balance	$	1,544	$	1,302
Deferral of revenues	743		521
Recognition of deferred revenues	(702)		(543)
Ending balance	$	1,585	$	1,280

XML

Debt and Other Financing Arrangements (Tables)

3 Months Ended

Mar. 31, 2025

Debt Disclosure [Abstract]

Summary of the Company's Long-term Indebtedness

The Company’s indebtedness consisted of the following (in thousands):

	March 31, 2025		December 31, 2024
Term loan facility payable to WTI, net	$	5,088	$	4,819
Line of credit	8,498		6,263
Financed insurance premium	313		615
Total debt	13,899		11,697
Less: current portion	(10,053)		(7,366)
Total long-term debt, net	$	3,846	$	4,331

Schedule of WTI Loan Facility

As of March 31, 2025, details of the WTI Loan Facility were as follows (in thousands):

	Amount
Principal outstanding	$	7,500
Unamortized debt issuance costs	(2,516)
Accrued PIK Interest	104
Net carrying value	$	5,088

Summary of Future Aggregate Maturities of Notes Payable

As of March 31, 2025, future aggregate maturities of the WTI Loan Facility and Financed Insurance Premium payables were as follows (in thousands):

March 31, 2025	Amount
Remaining nine months of 2025	$	801
2026	3,146
2027	3,550
2028	420
Total	$	7,917

XML

Stock-based Compensation (Tables)

3 Months Ended

Mar. 31, 2025

Share-Based Payment Arrangement [Abstract]

Schedule of Stock-based Compensation Expense

Total stock-based compensation was recognized as follows (in thousands):

	Three Months Ended March 31,
	2025		2024
General and administrative	$	779	$	1,283
Sales and marketing	455		344
Research and development	423		600
Total stock-based compensation	$	1,657	$	2,227

XML

Common Stock Issuance, Redeemable Common Stock, Common Stock Warrants, and Convertible Preferred Stock (Tables)

3 Months Ended

Mar. 31, 2025

Equity [Abstract]

Schedule of Warrant Activity

The following table summarizes issuable shares of the Company’s common stock based on warrant activity for the three months ended March 31, 2025:

	December 31, 2024	Shares Issuable by New Warrants	Shares Purchased by Exercise	March 31, 2025
SBG Public Warrants	821,428	—	—	821,428
SBG Private Placement Warrants	471,428	—	—	471,428
Series A Warrants	7,871,712	—	—	7,871,712
Series B Warrants	1,799,021	—	—	1,799,021
SVB Warrants	10,714	—	—	10,714
Titan Warrants	125,405	—	—	125,405
Total	11,099,708	—	—	11,099,708

XML

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2025

Fair Value Disclosures [Abstract]

Summary of Assets and Liabilities Fair Value Measurement

The Company’s assets and liabilities measured and reported in the financial statements at fair value on a recurring basis were as follows (in thousands):

	March 31, 2025
	Level 1		Level 2		Level 3		Balance
Assets:
Money market funds	$	9,104	$	—	$	—	$	9,104
Total assets	$	9,104	$	—	$	—	$	9,104
Liabilities:
SBG Public Warrants	$	—	$	—	$	1	$	1
SBG Private Placement Warrants	—		—		1		1
Series A Warrants	—		—		15,263		15,263
Series B Warrants	—		—		3,391		3,391
Total liabilities	$	—	$	—	$	18,656	$	18,656
	December 31, 2024
	Level 1		Level 2		Level 3		Balance
Assets:
Money market funds	$	8,223	$	—	$	—	$	8,223
Total assets	$	8,223	$	—	$	—	$	8,223
Liabilities:
SBG Public Warrants	$	—	$	—	$	5	$	5
SBG Private Placement Warrants	—		—		2		2
Series A Warrants	—		—		20,750		20,750
Series B Warrants	—		—		4,586		4,586
Total liabilities	$	—	$	—	$	25,343	$	25,343

Schedule of Black-Scholes Option Pricing Model Assumptions

The Company measured the fair value of both the SBG Public Warrants and the SBG Private Placement Warrants as of March 31, 2025 and December 31, 2024 using the Black-Scholes option pricing model with the following assumptions:

SBG Common Stock Warrants - Black-Scholes Inputs	March 31, 2025			December 31, 2024
OWLT stock price	$	3.68		$	4.45
Exercise price of warrants	$	161.00		$	161.00
Term in years	1.29			1.54
Risk-free interest rate	3.99		%	4.21		%
Volatility	90.00		%	90.00		%

The Company measured the fair value of the Series A Warrants as of March 31, 2025 and December 31, 2024, using the Black-Scholes option pricing model with the following assumptions:

Series A Warrants - Black-Scholes Inputs	March 31, 2025			December 31, 2024
OWLT stock price	$	3.68		$	4.45
Exercise price of warrants	$	4.66		$	4.66
Term in years	2.88			3.13
Risk-free interest rate	3.89		%	4.28		%
Volatility	90.00		%	90.00		%

The Series B Warrants are presented as Level 3 measurements, relying on unobservable inputs reflecting the Company’s own assumptions. The Company measured the fair value of the Series B Warrants as of March 31, 2025 and December 31, 2024, using the Black-Scholes option pricing model with the following assumptions:

Series B Warrants - Black-Scholes Inputs	March 31, 2025			December 31, 2024
OWLT stock price	$	3.68		$	4.45
Exercise price of warrants	$	7.71		$	7.71
Term in years	3.91			4.16
Risk-free interest rate	3.92		%	4.33		%
Volatility	90.00		%	90.00		%

The Company measured the fair value of the Titan Warrants at issuance on September 11, 2024, using the Black-Scholes option pricing model with the following assumptions:

Titan Warrants - Black-Scholes Inputs	September 11, 2024
OWLT stock price	$	4.35
Exercise price of warrants	$	4.63
Term in years	5.50
Risk-free interest rate	3.47		%
Volatility	85.00		%

The valuation model used the following assumptions:

Redeemable Common Stock - Valuation Inputs	September 11, 2024
Common stock value per share	$	4.35
Put price	$	8.40
Term in years	5.00
Risk-free interest rate	3.42		%
Volatility	85.00		%
Credit spread	9.27		%
Present value discount	63.49		%

Reconciliation of Preferred Stock Warrant Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level 3)

The following table presents a reconciliation of the Company’s SBG Public Warrants, SBG Private Placement Warrants, Series A Warrants, and Series B Warrants (together, the “Level 3 Warrants”) measured at fair value on a recurring basis as of March 31, 2025 (in thousands):

	Level 3 Warrants
Balance as of December 31, 2024	$	25,343
Change in fair value included within common stock warrant liability adjustment	(6,687)
Balance as of March 31, 2025	$	18,656

XML

Net Income (Loss) Per Share (Tables)

3 Months Ended

Mar. 31, 2025

Earnings Per Share [Abstract]

Summary of Net Loss Attributable to Common Stockholders

The following tables present the calculation of basic and diluted net income (loss) per share (in thousands, except share and per share amounts):

	Three Months Ended March 31,
	2025		2025		2024
	Redeemable Common Stock		Common Stock		Common Stock
Numerator:
Allocation of net income attributable to common stockholders	$	79	$	2,946	$	3,274
Accretion on convertible preferred stock	—		(847)		(1,328)
Accretion on redeemable common stock	21		(21)		—
Allocation of net income to participating securities	$	(14)	$	(330)	$	(661)
Allocated net income attributable to common stockholders	$	86	$	1,748	$	1,285
Denominator:
Weighted average common shares outstanding, basic	562,500		15,383,287		8,740,059
Net income per share attributable to common stockholders, basic	$	0.15	$	0.11	$	0.15

	Three Months Ended March 31,
	2025		2025		2024
	Redeemable Common Stock		Common Stock		Common Stock
Numerator:
Allocation of net income attributable to common stockholders	$	79	$	2,946	$	3,274
Accretion on convertible preferred stock	—		(847)		(1,328)
Accretion on redeemable common stock	21		(21)		—
Allocation of net income to participating securities	—		(330)		—
Effect of dilutive securities	—		—		(6,809)
Allocated net income (loss) attributable to common stockholders	$	100	$	1,748	$	(4,863)
Denominator:
Weighted average common shares outstanding, basic	562,500		15,383,287		8,740,059
Effect of dilutive securities	125,000		0		877,766
Weighted average common shares outstanding, diluted	687,500		15,383,287		9,617,825
Net income (loss) per share attributable to common stockholders, diluted	$	0.15	$	0.11	$	(0.51)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following table summarizes the common stock equivalents of potentially dilutive outstanding securities excluded from the computation of diluted net loss per share due to their anti-dilutive effect:

	March 31,
	2025	2024
Stock options	377,012	463,168
RSUs	1,450,316	1,526,327
RSAs	107,636	—
PSUs	56,391	71,428
ESPP shares committed	51,073	19,388
Common stock warrants	11,099,708	3,102,591
Preferred stock	2,872,668	5,200,802
Total	16,014,804	10,383,704

XML

Segments (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Revenue by Geographic Areas

Revenue by geographic area is based on the delivery address of the customer and is summarized as follows (in thousands):

	Three Months Ended March 31,
	2025		2024
United States	$	17,333	$	12,901
United Kingdom	1,207		856
Other	2,564		993
Total revenues	$	21,104	$	14,750

Schedule of Long-Lived Assets by Geographical Area

The Company’s long-lived assets are composed of property and equipment and right of use assets, net, and are summarized by geographic area as follows (in thousands):

	March 31, 2025		December 31, 2024
United States	$	134	$	167
International	74		73
Total long-lived assets, net	$	208	$	240

XML

Revision of Previously Issued Quarterly Information (Unaudited) (Tables)

3 Months Ended

Mar. 31, 2025

Accounting Changes and Error Corrections [Abstract]

Schedule of Error Corrections and Prior Period Adjustments

The effect on the unaudited condensed consolidated statements of cash flows for the affected period is as follows (in thousands):

	Three Months Ended March 31, 2024
(unaudited)	As Reported		Adjustments		As Revised
Cash flows from operating activities
Other, net	$	(680)	$	(17)	$	(697)
Net cash used in operating activities	$	(3,339)	$	(17)	$	(3,356)
Cash flows from investing activities
Purchase of intangible assets	$	(54)	$	17	$	(37)
Net cash used in investing activities	$	(54)	$	17	$	(37)
Cash flows from financing activities
Proceeds from short-term borrowings	$	28,941	$	(21,688)	$	7,253
Payments of short-term borrowings	(31,392)		21,688		(9,704)
Net cash provided by financing activities	$	5,233	$	—	$	5,233

XML

Basis of Presentation - Additional Information (Details)				1 Months Ended		3 Months Ended
	Sep. 11, 2024 USD ($)	Feb. 25, 2024 USD ($) $ / shares	Jul. 07, 2023	Sep. 30, 2024 USD ($)	Feb. 29, 2024 USD ($)	Mar. 31, 2025 USD ($) $ / shares shares	Mar. 31, 2024 USD ($)	Sep. 11, 2025 USD ($)	Dec. 31, 2024 USD ($) $ / shares shares
Subsidiary, Sale of Stock [Line Items]
Stock split ratio, common stock			0.071
Common stock, shares authorized (in shares) | shares						107,142,857			107,142,857
Common stock, par value (in dollars per share) | $ / shares						$ 0.0001			$ 0.0001
Accumulated Deficit						$ 265,170,000			$ 268,195,000
Net cash used in operating activities						(5,925,000)	$ (3,356,000)
Financed insurance premiums						13,899,000			11,697,000
Cash and cash equivalents						16,310,000	$ 18,397,000		20,245,000
WTI Loan Facility | Term Loan
Subsidiary, Sale of Stock [Line Items]
Term loan facility	$ 15,000,000
Financed insurance premiums						5,088,000			4,819,000
WTI Loan Facility | Term Loan | First Tranche Commitment
Subsidiary, Sale of Stock [Line Items]
Term loan facility	10,000,000
Proceeds from long-term borrowings						7,500,000
ABL Line of Credit | Line of Credit
Subsidiary, Sale of Stock [Line Items]
Financed insurance premiums						$ 8,498,000			$ 6,263,000
ABL Line of Credit | Line of Credit | Revolving Credit Facility
Subsidiary, Sale of Stock [Line Items]
Maximum borrowing capacity	15,000,000
ABL Line of Credit | Line of Credit | Revolving Credit Facility | Forecast
Subsidiary, Sale of Stock [Line Items]
Maximum borrowing capacity								$ 20,000,000
Additional maximum borrowing capacity								$ 5,000,000
September 2024 Offering
Subsidiary, Sale of Stock [Line Items]
Proceeds received from issuance of common stock				$ 10,590,000
Consideration received	$ 10,590,000
Series B Convertible Preferred Stock | Private Placement
Subsidiary, Sale of Stock [Line Items]
Common stock, par value (in dollars per share) | $ / shares		$ 0.0001
Proceeds from issuance of preferred stock, net of $0 and $158 of paid transaction costs, respectively		$ 9,250,000			$ 9,250,000

XML

Basis of Presentation - Schedule of Customer Concentration Risk (Details) - Customer Concentration Risk	3 Months Ended		12 Months Ended
	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024
Three Largest Customers | Accounts Receivable
Concentration Risk [Line Items]
Concentration risk percentage	63.00%		63.00%
Customer 1 | Revenue from Contract with Customer Benchmark
Concentration Risk [Line Items]
Concentration risk percentage	37.00%	25.00%
Customer 2 | Revenue from Contract with Customer Benchmark
Concentration Risk [Line Items]
Concentration risk percentage	14.00%	20.00%
Customer 3 | Revenue from Contract with Customer Benchmark
Concentration Risk [Line Items]
Concentration risk percentage	6.00%	12.00%

XML

Certain Balance Sheet Accounts - Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2025	Dec. 31, 2024	Mar. 31, 2024	Dec. 31, 2023
Reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets:
Cash and cash equivalents	$ 16,310	$ 20,245	$ 18,397
Restricted cash	300		0
Total cash, cash equivalents, and restricted cash	$ 16,610	$ 20,631	$ 18,397	$ 16,557

XML

Certain Balance Sheet Accounts - Schedule of Allowance for Credit Losses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Beginning balance	$ 653	$ 3,322
Charges to expense	95	(388)
Charges to revenue	63	56
Write-offs	0	(2,490)
Ending balance	$ 811	$ 500

XML

Certain Balance Sheet Accounts - Schedule of Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2025	Dec. 31, 2024
Inventory [Line Items]
Inventory	$ 11,813	$ 10,523
Raw materials
Inventory [Line Items]
Inventory	140	100
Finished goods
Inventory [Line Items]
Inventory	$ 11,673	$ 10,423

XML

Certain Balance Sheet Accounts - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2025	Dec. 31, 2024
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 3,354	$ 3,370
Less: accumulated depreciation and amortization	(3,255)	(3,268)
Property and equipment, net	99	102
Tooling and manufacturing equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	2,649	2,618
Computer equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	307	322
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Total property and equipment	289	289
Software
Property, Plant and Equipment [Line Items]
Total property and equipment	106	106
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 3	$ 35

XML

Certain Balance Sheet Accounts - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Property, Plant and Equipment [Line Items]
Amortization of intangible assets	$ 86	$ 16
Capitalized computer software, amortization	65	0
Tooling and manufacturing equipment
Property, Plant and Equipment [Line Items]
Depreciation and amortization expense	29	85
Property and Equipment
Property, Plant and Equipment [Line Items]
Depreciation and amortization expense	$ 33	$ 93

XML

Certain Balance Sheet Accounts - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2025	Dec. 31, 2024
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 1,562	$ 1,402
Accumulated amortization	(513)	(427)
Net carrying amount	1,049	975
Trademarks and patents
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	705	677
Accumulated amortization	(367)	(346)
Net carrying amount	338	331
Internally developed software
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	857	725
Accumulated amortization	(146)	(81)
Net carrying amount	$ 711	$ 644

XML

Certain Balance Sheet Accounts - Schedule of Intangible Assets, Future Amortization Expense (Details) - USD ($) $ in Thousands	Mar. 31, 2025	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Remaining nine months of 2025	$ 262
2026	347
2027	255
2028	47
2029	27
Thereafter	45
Total future amortization expenses	983
Trademarks and patents not yet subject to amortization	66
Net carrying amount	$ 1,049	$ 975

XML

Certain Balance Sheet Accounts - Schedule of Accrued and Other Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2025	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued payroll	$ 4,042	$ 3,639
Accrued sales discounts	1,495	1,773
Accrued sales returns	891	902
Accrued legal settlements	5,925	5,343
Other	4,125	4,721
Accrued and other expenses	$ 16,478	$ 16,378

XML

Certain Balance Sheet Accounts - Summary of Changes In Accrued Warranty (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Movement in Standard Product Warranty Accrual [Roll Forward]
Accrued warranty, beginning of period	$ 291	$ 782
Settlements of warranty claims during the period	(187)	(191)
Provision for warranties issued during the period	124	319
Changes in provision for pre-existing warranties	77	(142)
Accrued warranty, end of period	$ 305	$ 768

XML

Deferred Revenues - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Recognition of deferred revenues	$ 574	$ 477
Recognition of deferred revenues related to correction of immaterial misstatements	$ 451	$ 330
Minimum
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Service period of the performance obligations	1 month
Maximum
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Service period of the performance obligations	27 months

XML

Deferred Revenues- Summary of Changes in the Total Deferred Revenues Balance (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Contract With Customer, Liability [Roll Forward]
Beginning balance	$ 1,544	$ 1,302
Deferral of revenues	743	521
Recognition of deferred revenues	(702)	(543)
Ending balance	$ 1,585	$ 1,280

XML

Debt and Other Financing Arrangements - Summary of the Company's Long-term Indebtedness (Details) - USD ($) $ in Thousands	Mar. 31, 2025	Dec. 31, 2024
Line of Credit Facility [Line Items]
Total debt	$ 13,899	$ 11,697
Less: current portion	(10,053)	(7,366)
Total long-term debt, net	3,846	4,331
WTI Loan Facility | Term Loan
Line of Credit Facility [Line Items]
Total debt	5,088	4,819
ABL Line of Credit | Line of Credit
Line of Credit Facility [Line Items]
Total debt	8,498	6,263
Financed insurance premium | Financed insurance premium
Line of Credit Facility [Line Items]
Total debt	$ 313	$ 615

XML

Debt and Other Financing Arrangements - SVB Revolver and Term Loan (Details) - USD ($)	Mar. 31, 2025	Nov. 23, 2022
LSA
Debt Instrument [Line Items]
Total debt		$ 8,500,000
Monthly installments		$ 500,000
Line of Credit | SVB Revolver | Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 10,000,000

XML

Debt and Other Financing Arrangements - WTI Loan Facility (Details) - USD ($)		1 Months Ended	3 Months Ended	9 Months Ended	11 Months Ended	60 Months Ended
	Sep. 11, 2024	Sep. 30, 2024	Mar. 31, 2025	Jun. 30, 2025	Aug. 15, 2025	Sep. 11, 2029
Debt Instrument [Line Items]
Accrued PIK Interest			$ 104,000
Default interest on overdue balance, percentage	0.050
Unamortized debt issuance cost			424,000
Amortization of issuance costs			659,000
Interest expense			$ 385,000
Redeemable Common Stock
Debt Instrument [Line Items]
Shares forfeited during the period (in shares)			62,500
Stock issued during period, price per share (in dollars per share)	$ 7.66
Private Placement
Debt Instrument [Line Items]
Sale of stock, shares issued in transaction (in shares)	750,000	750,000
Private Placement | Minimum
Debt Instrument [Line Items]
Put option, exercise period	5 years
Private Placement | Maximum
Debt Instrument [Line Items]
Put option, exercise period	10 years
Private Placement - Shares Subject to Vesting
Debt Instrument [Line Items]
Number of unvested shares (in shares)	125,000
Forecast | Redeemable Common Stock
Debt Instrument [Line Items]
Accretion to redemption value, per share (in dollars per share)						$ 8.40
Term Loan | WTI Loan Facility
Debt Instrument [Line Items]
Term loan facility	$ 15,000,000
Interest rate			12.00%
Payment-in-kind interest, percentage	0.025
Accrued PIK Interest			$ 104,000
Payment of interest, market capitalization threshold	$ 250,000,000
Threshold consecutive trading days	10 days
Prepayment term (in days)	60 days
Prepayment discount	0.30
Amortization of issuance costs			222,000
Term Loan | WTI Loan Facility | Base Rate
Debt Instrument [Line Items]
Interest rate	3.50%
Term Loan | WTI Loan Facility | Floor Rate
Debt Instrument [Line Items]
Interest rate	12.00%
Term Loan | WTI Loan Facility | Forecast
Debt Instrument [Line Items]
Minimum revenue requirement				$ 48,600,000
Total cash burn, maximum					$ 600,000
Net proceeds from equity financing, minimum					$ 6,000,000
Term Loan | WTI Loan Facility | First Tranche Commitment
Debt Instrument [Line Items]
Term loan facility	$ 10,000,000
Proceeds from long-term borrowings			$ 7,500,000
Remaining borrowing capacity		$ 2,500,000
Term Loan | WTI Loan Facility | First Tranche Commitment Extension
Debt Instrument [Line Items]
Term loan facility	2,500,000
Term Loan | WTI Loan Facility | Second Tranche Commitment
Debt Instrument [Line Items]
Term loan facility	$ 5,000,000

XML

Debt and Other Financing Arrangements - WTI Loan Facility - Schedule of Outstanding Debt (Details) $ in Thousands	Mar. 31, 2025 USD ($)
Debt Instrument [Line Items]
Accrued PIK Interest	$ 104
Term Loan | WTI Loan Facility
Debt Instrument [Line Items]
Principal outstanding	7,500
Unamortized debt issuance costs	(2,516)
Accrued PIK Interest	104
Total debt	$ 5,088

XML

Debt and Other Financing Arrangements - ABL Line of Credit (Details) - USD ($) $ in Thousands	Sep. 11, 2024	Sep. 11, 2025	Mar. 31, 2025
Line of Credit Facility [Line Items]
Unamortized debt issuance cost			$ 424
Revolving Credit Facility | ABL Line of Credit | Line of Credit
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 15,000
Interest rate	3.50%
Liquidity threshold			4,000
Unrestricted cash balance			9,000
Unamortized debt issuance cost			557
Remaining borrowing capacity			$ 46
Revolving Credit Facility | ABL Line of Credit | Line of Credit | Minimum
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate	7.50%
Revolving Credit Facility | ABL Line of Credit | Line of Credit | Maximum
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate	8.50%
Revolving Credit Facility | ABL Line of Credit | Line of Credit | Forecast
Line of Credit Facility [Line Items]
Maximum borrowing capacity		$ 20,000

XML

Debt and Other Financing Arrangements - Financed Insurance Premiums (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Mar. 31, 2025
Debt Instrument [Line Items]
Financed insurance premiums	$ 11,697	$ 13,899
First Insurance Funding
Debt Instrument [Line Items]
Financed insurance liability to be paid	$ 941
Financed insurance premium accrued interest rate	8.70%
Financed insurance premium | Financed insurance premium
Debt Instrument [Line Items]
Financed insurance premiums	$ 615	$ 313

XML

Debt and Other Financing Arrangements - Summary of Future Aggregate Maturities of Notes Payable (Details) $ in Thousands	Mar. 31, 2025 USD ($)
Debt Disclosure [Abstract]
Remaining nine months of 2025	$ 801
2026	3,146
2027	3,550
2028	420
Total	$ 7,917

XML

Commitments and Contingencies - Narrative (Details) $ in Thousands		1 Months Ended	3 Months Ended	12 Months Ended
	Jun. 30, 2024 USD ($)	Nov. 30, 2021 claim	Mar. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Dec. 13, 2024 complaint	Oct. 03, 2024 director_officer	Aug. 26, 2024 director_officer	Sep. 08, 2023 class
Cloud Platform Services
Loss Contingencies [Line Items]
Purchase obligation	$ 6,739		$ 5,313
Purchase obligation period	48 months
Butala v. Owlet, Inc. and Cherian v. Owlet, Inc. | Pending Litigation
Loss Contingencies [Line Items]
Number of new claims filed | claim		2
Number of distinct and separate classes | class								2
Settlement accrual				$ 5,250
Janet Vargas, Derivatively on Behalf of Nominal Defendant Owlet, Inc. | Pending Litigation
Loss Contingencies [Line Items]
Settlement accrual			$ 675
Number of directors or officers included in complaints | director_officer							12
Number of complaints consolidated | complaint					2
Janet Vargas, Derivatively on Behalf of Nominal Defendant Owlet, Inc. | Pending Litigation | Sandbridge Acquisition Corporation
Loss Contingencies [Line Items]
Number of directors or officers included in complaints | director_officer							6
Nathan Capleton, Derivatively on Behalf of Nominal Defendant Owlet, Inc. | Pending Litigation
Loss Contingencies [Line Items]
Number of directors or officers included in complaints | director_officer						11
Butala v. Owlet, Inc. and Cherian v. Owlet, Inc. - Section 10(b) | Pending Litigation
Loss Contingencies [Line Items]
Litigation settlement, amount awarded to other party				3,500
Butala v. Owlet, Inc. and Cherian v. Owlet, Inc. - Section 14(a) | Pending Litigation
Loss Contingencies [Line Items]
Litigation settlement, amount awarded to other party				$ 1,750

XML

Stock-based Compensation - Additional Information (Details)	3 Months Ended		12 Months Ended
	Mar. 31, 2025 USD ($)	Mar. 31, 2024 USD ($)	Dec. 31, 2024 employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incremental stock-based compensation expense	$ 43,000
Software
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation capitalized	$ 27,000	$ 0
PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Unrecognized stock-based compensation costs related to unvested RSUs	$ 101,000
Unrecognized share-based compensation cost, period for recognition	9 months 18 days
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Number of employees effected by modification | employee			11
Unrecognized stock-based compensation costs related to unvested RSUs	$ 5,815,000
Unrecognized share-based compensation cost, period for recognition	1 year 2 months 12 days
RSAs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Modified RSAs vesting period			6 months
Unrecognized stock-based compensation costs related to unvested RSUs	$ 2,000
Unrecognized share-based compensation cost, period for recognition	1 month 6 days
Restricted Stock Units (RSUs), Four Year Vesting Term
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Restricted Stock Units (RSUs), Four Year Vesting Term | Share-Based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Award vesting rights, percentage	25.00%
Restricted Stock Units (RSUs), Two Year Vesting Term
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	2 years
Restricted Stock Units (RSUs), Two Year Vesting Term | Share-Based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Award vesting rights, percentage	50.00%
Restricted Stock Units (RSUs), One Year Vesting Term
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Award vesting rights, percentage	100.00%

XML

Stock-based Compensation - Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 1,657	$ 2,227
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	779	1,283
Sales and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	455	344
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 423	$ 600

XML

Common Stock Issuance, Redeemable Common Stock, Common Stock Warrants, and Convertible Preferred Stock - Additional Information (Details) $ / shares in Units, $ in Thousands						1 Months Ended		3 Months Ended
	Sep. 13, 2024 USD ($)	Sep. 11, 2024 USD ($) $ / shares shares	Aug. 20, 2024 shares	Feb. 25, 2024 USD ($) $ / shares shares	Sep. 17, 2020 $ / shares shares	Sep. 30, 2024 shares	Feb. 29, 2024 USD ($)	Mar. 31, 2025 USD ($) $ / shares shares	Mar. 31, 2024 USD ($)	Mar. 13, 2025 $ / shares	Dec. 31, 2024 $ / shares shares	Mar. 31, 2023 USD ($) $ / shares shares
Subsidiary or Equity Method Investee [Line Items]
Offering expenses | $								$ 16	$ 0
Warrants outstanding								11,099,708			11,099,708
Warrants exercised (in shares)								0
Common stock, shares issued (in shares)								15,808,849			15,725,783
Common stock, par value (in dollars per share) | $ / shares								$ 0.0001			$ 0.0001
Net proceeds from issuance of preferred stock and warrants | $								$ 0	9,092
General and administrative | $								7,092	$ 6,050
Period for warrants to become exercisable after IPO					12 months
Series A Convertible Preferred Stock
Subsidiary or Equity Method Investee [Line Items]
Redemption value | $								$ 11,479
Preferred stock, shares issued (in shares)								11,479			11,479
Preferred stock, par value (in dollars per share) | $ / shares								$ 0.0001			$ 0.0001
Conversion of stock, shares converted (in shares)			15,721
Series B Convertible Preferred Stock
Subsidiary or Equity Method Investee [Line Items]
Warrants exercised (in shares)								0
Redemption value | $								$ 9,250
Preferred stock, shares issued (in shares)								9,250			9,250
Preferred stock, par value (in dollars per share) | $ / shares								$ 0.0001			$ 0.0001
Common Class A
Subsidiary or Equity Method Investee [Line Items]
Shares issued upon conversion (in shares)			2,291,686
Titan Warrants
Subsidiary or Equity Method Investee [Line Items]
Warrants outstanding								125,405			125,405
Issuance cost | $		$ 382
Exercise price of warrant (in dollars per share) | $ / shares										$ 4.63
Warrants expiration period								5 years
Warrants exercised (in shares)								0
Public Warrant
Subsidiary or Equity Method Investee [Line Items]
Warrants exercised (in shares)								0
Private Placement Warrants
Subsidiary or Equity Method Investee [Line Items]
Sale of number of warrants (in shares)					471,428
SBG Public Warrants
Subsidiary or Equity Method Investee [Line Items]
Warrants outstanding								821,428			821,428
Warrants expiration period								5 years
Warrants exercised (in shares)								0
SVB Warrants
Subsidiary or Equity Method Investee [Line Items]
Warrants outstanding								10,714			10,714
Exercise price of warrant (in dollars per share) | $ / shares												$ 5.32
Warrants exercised (in shares)								0
Number of securities called by warrants (in shares)												10,714
Value of warrants | $												$ 43
September 2024 Offering
Subsidiary or Equity Method Investee [Line Items]
Sale of stock, shares issued in transaction (in shares)		3,135,136
Sale of stock, price per share (in dollars per share) | $ / shares		$ 3.70
Consideration received | $		$ 10,590
Offering price discount to underwriter		0.07
Offering expenses | $								$ 863
Unpaid issuance costs | $								$ 260
Reimbursement to underwriter of stock issuance costs | $	$ 198
Private Placement
Subsidiary or Equity Method Investee [Line Items]
Sale of stock, shares issued in transaction (in shares)		750,000				750,000
Preferred stock issuance costs | $				$ 102
Private Placement | Series B Convertible Preferred Stock
Subsidiary or Equity Method Investee [Line Items]
Exercise price of warrant (in dollars per share) | $ / shares				$ 7.71
Warrants exercised (in shares)								0
Preferred stock, shares issued (in shares)				9,250
Preferred stock, par value (in dollars per share) | $ / shares				$ 0.0001
Common stock, shares issued (in shares)				1,799,021
Common stock, par value (in dollars per share) | $ / shares				$ 0.0001
Proceeds from issuance of preferred stock, net of $0 and $158 of paid transaction costs, respectively | $				$ 9,250			$ 9,250
Convertible preferred stock, conversion ratio				129.6596
Liquidation preference | $				$ 1
Number of securities called by each warrant (in shares)				1
Aggregate estimated fair value of warrants | $				$ 6,856
Net proceeds from issuance of preferred stock and warrants | $				2,394
Accrued stock issuance costs | $				394
General and administrative | $				$ 292
Initial Public Offering | Public Shares
Subsidiary or Equity Method Investee [Line Items]
Units issued (in shares)					821,428
Initial Public Offering | Public Warrant
Subsidiary or Equity Method Investee [Line Items]
Exercise price of warrant (in dollars per share) | $ / shares					$ 161.00

XML

Common Stock Issuance, Redeemable Common Stock, Common Stock Warrants, and Convertible Preferred Stock - February Offerings (Details) $ / shares in Units, $ in Thousands		3 Months Ended
	Feb. 17, 2023 USD ($) $ / shares shares	Mar. 31, 2025 USD ($) $ / shares shares	Mar. 31, 2024 USD ($)	Dec. 31, 2024 $ / shares shares
Class of Warrant or Right [Line Items]
Common stock, shares issued (in shares)		15,808,849		15,725,783
Common stock, par value (in dollars per share) | $ / shares		$ 0.0001		$ 0.0001
Net proceeds from issuance of preferred stock and warrants | $		$ 0	$ 9,092
Warrants exercised (in shares)		0
General and administrative | $		$ 7,092	$ 6,050
February 2023 Warrants
Class of Warrant or Right [Line Items]
Common stock, shares issued (in shares)	7,871,712
Common stock, par value (in dollars per share) | $ / shares	$ 0.0001
Proceeds from issuance of preferred stock | $	$ 30,000
Number of securities called by each warrant (in shares)	1
Exercise price of warrant (in dollars per share) | $ / shares	$ 4.66
Aggregate estimated fair value of warrants | $	$ 26,133
Net proceeds from issuance of preferred stock and warrants | $	$ 3,867
Warrants exercised (in shares)		0
Series A Convertible Preferred Stock
Class of Warrant or Right [Line Items]
Preferred stock, shares issued (in shares)		11,479		11,479
Preferred stock, par value (in dollars per share) | $ / shares		$ 0.0001		$ 0.0001
Series A Convertible Preferred Stock | February 2023 Warrants
Class of Warrant or Right [Line Items]
Preferred stock, shares issued (in shares)	30,000
Preferred stock, par value (in dollars per share) | $ / shares	$ 0.0001
Convertible preferred stock, conversion ratio	145.7726
Liquidation preference | $	$ 1

XML

Common Stock Issuance, Redeemable Common Stock, Common Stock Warrants, and Convertible Preferred Stock - Summary of Warrant Activity (Details)	3 Months Ended
	Mar. 31, 2025 shares
Schedule of Warrant Activity [Roll Forward]
Warrants outstanding, beginning balance (in shares)	11,099,708
Shares Issuable by New Warrants (in shares)	0
Share Purchased by Exercise (in shares)	0
Warrants outstanding, ending balance (in shares)	11,099,708
SBG Public Warrants
Schedule of Warrant Activity [Roll Forward]
Warrants outstanding, beginning balance (in shares)	821,428
Shares Issuable by New Warrants (in shares)	0
Share Purchased by Exercise (in shares)	0
Warrants outstanding, ending balance (in shares)	821,428
SBG Private Placement Warrants
Schedule of Warrant Activity [Roll Forward]
Warrants outstanding, beginning balance (in shares)	471,428
Shares Issuable by New Warrants (in shares)	0
Share Purchased by Exercise (in shares)	0
Warrants outstanding, ending balance (in shares)	471,428
Series A Warrants
Schedule of Warrant Activity [Roll Forward]
Warrants outstanding, beginning balance (in shares)	7,871,712
Shares Issuable by New Warrants (in shares)	0
Share Purchased by Exercise (in shares)	0
Warrants outstanding, ending balance (in shares)	7,871,712
Series B Warrants
Schedule of Warrant Activity [Roll Forward]
Warrants outstanding, beginning balance (in shares)	1,799,021
Shares Issuable by New Warrants (in shares)	0
Share Purchased by Exercise (in shares)	0
Warrants outstanding, ending balance (in shares)	1,799,021
SVB Warrants
Schedule of Warrant Activity [Roll Forward]
Warrants outstanding, beginning balance (in shares)	10,714
Shares Issuable by New Warrants (in shares)	0
Share Purchased by Exercise (in shares)	0
Warrants outstanding, ending balance (in shares)	10,714
Titan Warrants
Schedule of Warrant Activity [Roll Forward]
Warrants outstanding, beginning balance (in shares)	125,405
Shares Issuable by New Warrants (in shares)	0
Share Purchased by Exercise (in shares)	0
Warrants outstanding, ending balance (in shares)	125,405

XML

Fair Value Measurements - Summary of Assets and Liabilities Fair Value Measurement (Details) - USD ($) $ in Thousands	Mar. 31, 2025	Dec. 31, 2024
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	$ 9,104	$ 8,223
Total liabilities	18,656	25,343
SBG Public Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	1	5
SBG Private Placement Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	1	2
Series A Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	15,263	20,750
Series B Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	3,391	4,586
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	9,104	8,223
Total liabilities	0	0
Level 1 | SBG Public Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	0	0
Level 1 | SBG Private Placement Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	0	0
Level 1 | Series A Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	0	0
Level 1 | Series B Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	0	0
Total liabilities	0	0
Level 2 | SBG Public Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	0	0
Level 2 | SBG Private Placement Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	0	0
Level 2 | Series A Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	0	0
Level 2 | Series B Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	0	0
Total liabilities	18,656	25,343
Level 3 | SBG Public Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	1	5
Level 3 | SBG Private Placement Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	1	2
Level 3 | Series A Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	15,263	20,750
Level 3 | Series B Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	3,391	4,586
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	9,104	8,223
Money market funds | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	9,104	8,223
Money market funds | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	0	0
Money market funds | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	$ 0	$ 0

XML

Fair Value Measurements - Schedule of Black-Scholes Option Pricing Model Assumptions (Details) $ in Thousands	Mar. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Sep. 11, 2024 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of warrants	$ 18,656	$ 25,343
SBG Public Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants expiration period	5 years
Fair value of warrants	$ 1	5
Series A Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of warrants	15,263	20,750
Series B Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of warrants	$ 3,391	$ 4,586
Titan Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants expiration period	5 years
Fair value of warrants			$ 382
OWLT stock price (in dollars per share) | Redeemable Common Stock
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Temporary equity, measurement input			4.35
OWLT stock price (in dollars per share) | SBG Public Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement input	3.68	4.45
OWLT stock price (in dollars per share) | Series A Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement input	3.68	4.45
OWLT stock price (in dollars per share) | Series B Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement input	3.68	4.45
OWLT stock price (in dollars per share) | Titan Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement input			4.35
Put price | Redeemable Common Stock
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Temporary equity, measurement input			8.40
Exercise price (in dollars per share) | SBG Public Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement input	161.00	161.00
Exercise price (in dollars per share) | Series A Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement input	4.66	4.66
Exercise price (in dollars per share) | Series B Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement input	7.71	7.71
Exercise price (in dollars per share) | Titan Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement input			4.63
Term in years | Redeemable Common Stock
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Temporary equity, term			5 years
Term in years | SBG Public Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants expiration period	1 year 3 months 14 days	1 year 6 months 14 days
Term in years | Series A Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants expiration period	2 years 10 months 17 days	3 years 1 month 17 days
Term in years | Series B Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants expiration period	3 years 10 months 28 days	4 years 1 month 28 days
Term in years | Titan Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants expiration period			5 years 6 months
Risk-free interest rate | Redeemable Common Stock
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Temporary equity, measurement input			0.0342
Risk-free interest rate | SBG Public Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement input	0.0399	0.0421
Risk-free interest rate | Series A Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement input	0.0389	0.0428
Risk-free interest rate | Series B Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement input	0.0392	0.0433
Risk-free interest rate | Titan Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement input			0.0347
Volatility | Redeemable Common Stock
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Temporary equity, measurement input			0.8500
Volatility | SBG Public Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement input	0.9000	0.9000
Volatility | Series A Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement input	0.9000	0.9000
Volatility | Series B Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement input	0.9000	0.9000
Volatility | Titan Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement input			0.8500
Credit spread | Redeemable Common Stock
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Temporary equity, measurement input			0.0927
Present value discount | Redeemable Common Stock
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Temporary equity, measurement input			0.6349

XML

Fair Value Measurements - Reconciliation of Preferred Stock Warrant Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level 3) (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2025 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 25,343
Change in fair value included within common stock warrant liability adjustment	(6,687)
Ending Balance	$ 18,656

XML

Fair Value Measurements - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	2 Months Ended	12 Months Ended
	Sep. 11, 2024	Dec. 31, 2024	Mar. 31, 2025
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of warrants		$ 25,343	$ 18,656
Titan Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of warrants	$ 382
Redeemable Common Stock
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Stock issued during period, price per share (in dollars per share)	$ 7.66
Issuance of convertible preferred stock	$ 4,308	$ 4,308

XML

Net Income (Loss) Per Share - Summary of Computation of Net Loss Attributable To Common Stockholders (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Numerator:
Net income	$ 3,025	$ 3,274
Allocation of net income attributable to redeemable common stockholders	79	0
Net income attributable to common stockholders	1,748	1,285
Net income attributable to common stockholders	$ 1,748	$ 1,285
Denominator:
Weighted-average common shares used in computed net loss per share attributable to common stockholders, basic (in shares)	15,383,287	8,740,059
Weighted-average common shares outstanding, diluted (in shares)	15,383,287	9,617,825
Net income per share attributable to common stockholders, basic (in dollars per share)	$ 0.11	$ 0.15
Net income (loss) per share attributable to common stockholders, diluted (in dollars per share)	$ 0.11	$ (0.51)
Redeemable Common Stock
Numerator:
Net income	$ 79
Accretion on convertible preferred stock	0
Accretion on redeemable common stock	21
Allocation of net income attributable to redeemable common stockholders	(14)
Allocation of net income to participating securities	0
Effect of dilutive securities	0
Net income attributable to common stockholders	86
Net income attributable to common stockholders	$ 100
Denominator:
Weighted-average common shares used in computed net loss per share attributable to common stockholders, basic (in shares)	562,500
Effect of dilutive securities (in shares)	125,000
Weighted-average common shares outstanding, diluted (in shares)	687,500
Net income per share attributable to common stockholders, basic (in dollars per share)	$ 0.15
Net income (loss) per share attributable to common stockholders, diluted (in dollars per share)	$ 0.15
Non-Redeemable Common Stock
Numerator:
Net income	$ 2,946	$ 3,274
Accretion on convertible preferred stock	(847)	(1,328)
Accretion on redeemable common stock	(21)	0
Allocation of net income attributable to redeemable common stockholders	(330)	(661)
Allocation of net income to participating securities	(330)	0
Effect of dilutive securities	0	(6,809)
Net income attributable to common stockholders	1,748	1,285
Net income attributable to common stockholders	$ 1,748	$ (4,863)
Denominator:
Weighted-average common shares used in computed net loss per share attributable to common stockholders, basic (in shares)	15,383,287	8,740,059
Effect of dilutive securities (in shares)	0	877,766
Weighted-average common shares outstanding, diluted (in shares)	15,383,287	9,617,825
Net income per share attributable to common stockholders, basic (in dollars per share)	$ 0.11	$ 0.15
Net income (loss) per share attributable to common stockholders, diluted (in dollars per share)	$ 0.11	$ (0.51)

XML

Net Income (Loss) Per Share - Antidilutive Securities Excluded from Computation of EPS (Details) - shares	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive common stock equivalents have been excluded from the computation of diluted net loss per share	16,014,804	10,383,704
Shares subject to vesting (in shares)	200,536
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive common stock equivalents have been excluded from the computation of diluted net loss per share	377,012	463,168
RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive common stock equivalents have been excluded from the computation of diluted net loss per share	1,450,316	1,526,327
RSAs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive common stock equivalents have been excluded from the computation of diluted net loss per share	107,636	0
PSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive common stock equivalents have been excluded from the computation of diluted net loss per share	56,391	71,428
ESPP shares committed
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive common stock equivalents have been excluded from the computation of diluted net loss per share	51,073	19,388
Common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive common stock equivalents have been excluded from the computation of diluted net loss per share	11,099,708	3,102,591
Preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive common stock equivalents have been excluded from the computation of diluted net loss per share	2,872,668	5,200,802
WTI Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive common stock equivalents have been excluded from the computation of diluted net loss per share	125,000
Converted Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive common stock equivalents have been excluded from the computation of diluted net loss per share	107,636

XML

Segments - Additional Information (Details)	3 Months Ended
	Mar. 31, 2025 segment
Segment Reporting [Abstract]
Number of operating segments	1

XML

Segments - Revenue by Geographic Areas (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 21,104	$ 14,750
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	17,333	12,901
United Kingdom
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	1,207	856
Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 2,564	$ 993

XML

Segments - Schedule of Long-Lived Assets by Geographical Area (Details) - USD ($) $ in Thousands	Mar. 31, 2025	Dec. 31, 2024
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets, net	$ 208	$ 240
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets, net	134	167
Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets, net	$ 74	$ 73

XML

Revision of Previously Issued Quarterly Information (Unaudited) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Other, net		$ (697)
Net cash used in operating activities	$ (5,925)	(3,356)
Purchase of intangible assets	0	(37)
Net cash used in investing activities	(110)	(37)
Proceeds from short-term borrowings	13,424	7,253
Proceeds from short-term borrowings	(11,491)	(9,704)
Net cash provided by financing activities	$ 2,014	5,233
As Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Other, net		(680)
Net cash used in operating activities		(3,339)
Purchase of intangible assets		(54)
Net cash used in investing activities		(54)
Proceeds from short-term borrowings		28,941
Proceeds from short-term borrowings		(31,392)
Net cash provided by financing activities		5,233
Adjustments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Other, net		(17)
Net cash used in operating activities		(17)
Purchase of intangible assets		17
Net cash used in investing activities		17
Proceeds from short-term borrowings		(21,688)
Proceeds from short-term borrowings		21,688
Net cash provided by financing activities		$ 0